Carrel name: keyword-hsct-cord Creating study carrel named keyword-hsct-cord Initializing database file: cache/cord-005446-jr3yj4o2.json key: cord-005446-jr3yj4o2 authors: Forrest, D L; Thompson, K; Dorcas, V G; Couban, S H; Pierce, R title: Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study date: 2003-06-10 journal: Bone Marrow Transplant DOI: 10.1038/sj.bmt.1704087 sha: doc_id: 5446 cord_uid: jr3yj4o2 file: cache/cord-000121-duwfxeyt.json key: cord-000121-duwfxeyt authors: Dzieciątkowski, Tomasz; Przybylski, Maciej; Torosian, Tigran; Tomaszewska, Agnieszka; Łuczak, Mirosław title: Prevalence of human herpesvirus 6 antibodies and DNA in allogeneic stem cell transplant patients: two-year single centre experience date: 2008-05-30 journal: Arch Immunol Ther Exp (Warsz) DOI: 10.1007/s00005-008-0021-6 sha: doc_id: 121 cord_uid: duwfxeyt file: cache/cord-010130-28bt3x25.json key: cord-010130-28bt3x25 authors: Crocchiolo, R.; Bramanti, S.; Vai, A.; Sarina, B.; Mineri, R.; Casari, E.; Tordato, F.; Mauro, E.; Timofeeva, I.; Lugli, E.; Mavilio, D.; Carlo‐Stella, C.; Santoro, A.; Castagna, L. title: Infections after T‐replete haploidentical transplantation and high‐dose cyclophosphamide as graft‐versus‐host disease prophylaxis date: 2015-03-26 journal: Transpl Infect Dis DOI: 10.1111/tid.12365 sha: doc_id: 10130 cord_uid: 28bt3x25 file: cache/cord-005448-5fznfp5p.json key: cord-005448-5fznfp5p authors: Holtan, S G; Hogan, W J; Elliott, M A; Ansell, S M; Inwards, D J; Porrata, L F; Johnston, P B; Micallef, I N; Lacy, M Q; Gastineau, D A; Litzow, M R title: CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies date: 2010-03-08 journal: Bone Marrow Transplant DOI: 10.1038/bmt.2010.49 sha: doc_id: 5448 cord_uid: 5fznfp5p file: cache/cord-006492-pc1vayyl.json key: cord-006492-pc1vayyl authors: Ono, Shintaro; Okano, Tsubasa; Hoshino, Akihiro; Yanagimachi, Masakatsu; Hamamoto, Kazuko; Nakazawa, Yozo; Imamura, Toshihiko; Onuma, Masaei; Niizuma, Hidetaka; Sasahara, Yoji; Tsujimoto, Hiroshi; Wada, Taizo; Kunisaki, Reiko; Takagi, Masatoshi; Imai, Kohsuke; Morio, Tomohiro; Kanegane, Hirokazu title: Hematopoietic Stem Cell Transplantation for XIAP Deficiency in Japan date: 2016-11-04 journal: J Clin Immunol DOI: 10.1007/s10875-016-0348-4 sha: doc_id: 6492 cord_uid: pc1vayyl file: cache/cord-007791-nzjm6zyq.json key: cord-007791-nzjm6zyq authors: Carreras, Enric; Cooke, Kenneth R. title: Noninfectious Pulmonary Complications date: 2018-09-12 journal: The EBMT Handbook DOI: 10.1007/978-3-030-02278-5_52 sha: doc_id: 7791 cord_uid: nzjm6zyq file: cache/cord-015922-5wwy0m2k.json key: cord-015922-5wwy0m2k authors: Marty, Francisco M.; Baden, Lindsey R. title: Infection in the Hematopoietic Stem Cell Transplant Recipient date: 2008 journal: Hematopoietic Stem Cell Transplantation DOI: 10.1007/978-1-59745-438-4_19 sha: doc_id: 15922 cord_uid: 5wwy0m2k file: cache/cord-018319-tylkbh4h.json key: cord-018319-tylkbh4h authors: Chemaly, Roy F.; Rathod, Dhanesh B.; Couch, Robert title: Respiratory Viruses date: 2011-01-04 journal: Principles and Practice of Cancer Infectious Diseases DOI: 10.1007/978-1-60761-644-3_32 sha: doc_id: 18319 cord_uid: tylkbh4h file: cache/cord-006856-b1w25ob5.json key: cord-006856-b1w25ob5 authors: nan title: 19th Meeting of the Austrian Society of Transplantation, Transfusion, and Genetics, October 26–28, 2005 date: 2005 journal: Eur Surg DOI: 10.1007/s10353-005-0216-6 sha: doc_id: 6856 cord_uid: b1w25ob5 file: cache/cord-005482-v5iayczy.json key: cord-005482-v5iayczy authors: nan title: Publication Only date: 2016-03-21 journal: Bone Marrow Transplant DOI: 10.1038/bmt.2016.56 sha: doc_id: 5482 cord_uid: v5iayczy file: cache/cord-003866-3gwbc7z9.json key: cord-003866-3gwbc7z9 authors: Zecha, Judith A. E. M.; Raber-Durlacher, Judith E.; Laheij, Alexa M. G. A.; Westermann, Anneke M.; Epstein, Joel B.; de Lange, Jan; Smeele, Ludi E. title: The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy date: 2019-06-20 journal: Support Care Cancer DOI: 10.1007/s00520-019-04925-8 sha: doc_id: 3866 cord_uid: 3gwbc7z9 file: cache/cord-018906-03nynqtq.json key: cord-018906-03nynqtq authors: Moulton, Bart; Barker, Alan F. title: Pulmonary Complications date: 2014-11-25 journal: Blood and Marrow Transplant Handbook DOI: 10.1007/978-3-319-13832-9_22 sha: doc_id: 18906 cord_uid: 03nynqtq file: cache/cord-261827-uprv8a2k.json key: cord-261827-uprv8a2k authors: Brodszki, Nicholas; Turkiewicz, Dominik; Toporski, Jacek; Truedsson, Lennart; Dykes, Josefina title: Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions date: 2016-01-15 journal: Orphanet J Rare Dis DOI: 10.1186/s13023-016-0385-3 sha: doc_id: 261827 cord_uid: uprv8a2k file: cache/cord-017302-xez0zso3.json key: cord-017302-xez0zso3 authors: Stephens, R. Scott title: ICU Complications of Hematopoietic Stem Cell Transplant, Including Graft vs Host Disease date: 2019-07-24 journal: Evidence-Based Critical Care DOI: 10.1007/978-3-030-26710-0_80 sha: doc_id: 17302 cord_uid: xez0zso3 file: cache/cord-279638-jr1mbh7s.json key: cord-279638-jr1mbh7s authors: Calore, Elisabetta; Marson, Piero; Pillon, Marta; Tumino, Manuela; Tison, Tiziana; Mainardi, Chiara; De Silvestro, Giustina; Rossin, Sara; Franceschetto, Genny; Carraro, Elisa; Pescarin, Matilde; Varotto, Stefania; Destro, Roberta; Gazzola, Maria Vittoria; Basso, Giuseppe; Messina, Chiara title: Treatment of Acute Graft-versus-Host Disease in Childhood with Extracorporeal Photochemotherapy/Photopheresis: The Padova Experience date: 2015-07-14 journal: Biol Blood Marrow Transplant DOI: 10.1016/j.bbmt.2015.07.007 sha: doc_id: 279638 cord_uid: jr1mbh7s file: cache/cord-018339-tyrlpl94.json key: cord-018339-tyrlpl94 authors: Dsouza, Kevin; Pywell, Cameron; Thannickal, Victor J. title: Late Noninfectious Pulmonary Complications in Hematopoietic Stem Cell Transplantation date: 2019-07-09 journal: Oncologic Critical Care DOI: 10.1007/978-3-319-74588-6_51 sha: doc_id: 18339 cord_uid: tyrlpl94 file: cache/cord-266359-uf1ao1x1.json key: cord-266359-uf1ao1x1 authors: Hakki, Morgan; Rattray, Rogan M.; Press, Richard D. title: The clinical impact of coronavirus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients date: 2015-04-15 journal: J Clin Virol DOI: 10.1016/j.jcv.2015.04.012 sha: doc_id: 266359 cord_uid: uf1ao1x1 file: cache/cord-007788-09t52zix.json key: cord-007788-09t52zix authors: Wallhult, Elisabeth; Quinn, Barry title: Early and Acute Complications and the Principles of HSCT Nursing Care date: 2017-11-22 journal: The European Blood and Marrow Transplantation Textbook for Nurses DOI: 10.1007/978-3-319-50026-3_9 sha: doc_id: 7788 cord_uid: 09t52zix file: cache/cord-018302-lmly43rd.json key: cord-018302-lmly43rd authors: Renaud, Christian; Englund, Janet title: Respiratory Syncytial Virus and Human Metapneumovirus Infection in Transplant Recipients date: 2016-02-15 journal: Transplant Infections DOI: 10.1007/978-3-319-28797-3_31 sha: doc_id: 18302 cord_uid: lmly43rd file: cache/cord-018209-v2crgj5w.json key: cord-018209-v2crgj5w authors: Pastores, Stephen M.; Dulu, Alina O.; DeSouza, Shilpa A. title: What Has Been Learned from Postmortem Studies? date: 2010-08-19 journal: Pulmonary Involvement in Patients with Hematological Malignancies DOI: 10.1007/978-3-642-15742-4_20 sha: doc_id: 18209 cord_uid: v2crgj5w file: cache/cord-030921-wydk9p93.json key: cord-030921-wydk9p93 authors: Even-Or, Ehud; NaserEddin, Adeeb; Dinur Schejter, Yael; Shadur, Bella; Zaidman, Irina; Stepensky, Polina title: Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases date: 2020-08-27 journal: Bone Marrow Transplant DOI: 10.1038/s41409-020-01040-9 sha: doc_id: 30921 cord_uid: wydk9p93 file: cache/cord-281026-2avisuge.json key: cord-281026-2avisuge authors: Versluys, A.Birgitta; Rossen, John W.A.; van Ewijk, Bart; Schuurman, Rob; Bierings, Marc B.; Boelens, Jaap J. title: Strong Association between Respiratory Viral Infection Early after Hematopoietic Stem Cell Transplantation and the Development of Life-Threatening Acute and Chronic Alloimmune Lung Syndromes date: 2010-01-06 journal: Biol Blood Marrow Transplant DOI: 10.1016/j.bbmt.2009.12.534 sha: doc_id: 281026 cord_uid: 2avisuge file: cache/cord-322606-cx6eh0ff.json key: cord-322606-cx6eh0ff authors: Donadieu, J; Michel, G; Merlin, E; Bordigoni, P; Monteux, B; Beaupain, B; Leverger, G; Laporte, J P; Hermine, O; Buzyn, A; Bertrand, Y; Casanova, J L; Leblanc, T; Gluckman, E; Fischer, A; Stephan, J L title: Hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: experience of the French neutropenia registry date: 2005-09-05 journal: Bone Marrow Transplant DOI: 10.1038/sj.bmt.1705141 sha: doc_id: 322606 cord_uid: cx6eh0ff file: cache/cord-018243-hyvu9nuq.json key: cord-018243-hyvu9nuq authors: Salman, Huda; Cooke, Kenneth R.; Lazarus, Hillard M. title: Fibrosing Alveolitis in Hematologic Malignancy Patients Undergoing Hematopoietic Cell Transplantation date: 2010-08-19 journal: Pulmonary Involvement in Patients with Hematological Malignancies DOI: 10.1007/978-3-642-15742-4_42 sha: doc_id: 18243 cord_uid: hyvu9nuq file: cache/cord-276952-nkaow79h.json key: cord-276952-nkaow79h authors: Sim, Starling A.; Leung, Vivian K.Y.; Ritchie, David; Slavin, Monica A.; Sullivan, Sheena G.; Teh, Benjamin W. title: Viral Respiratory Tract Infections in Allogeneic Hematopoietic Stem Cell Transplantation Recipients in the Era of Molecular Testing date: 2018-03-09 journal: Biol Blood Marrow Transplant DOI: 10.1016/j.bbmt.2018.03.004 sha: doc_id: 276952 cord_uid: nkaow79h file: cache/cord-280763-4bnv2t3f.json key: cord-280763-4bnv2t3f authors: Piñana, José Luis; Pérez, Ariadna; Montoro, Juan; Giménez, Estela; Gómez, María Dolores; Lorenzo, Ignacio; Madrid, Silvia; González, Eva María; Vinuesa, Víctor; Hernández-Boluda, Juan Carlos; Salavert, Miguel; Sanz, Guillermo; Solano, Carlos; Sanz, Jaime; Navarro, David title: Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study date: 2019-06-01 journal: Clin Infect Dis DOI: 10.1093/cid/ciy792 sha: doc_id: 280763 cord_uid: 4bnv2t3f file: cache/cord-254183-98o0dssj.json key: cord-254183-98o0dssj authors: Waggoner, Jesse J.; Soda, Elizabeth A.; Deresinski, Stan title: Rare and Emerging Viral Infections in Transplant Recipients date: 2013-10-15 journal: Clin Infect Dis DOI: 10.1093/cid/cit456 sha: doc_id: 254183 cord_uid: 98o0dssj file: cache/cord-259625-8lripsf7.json key: cord-259625-8lripsf7 authors: Piñana, José Luis; Gómez, María Dolores; Montoro, Juan; Lorenzo, Ignacio; Pérez, Ariadna; Giménez, Estela; González‐Barberá, Eva María; Carretero, Carlos; Guerreiro, Manuel; Salavert, Miguel; Sanz, Guillermo; Hernández‐Boluda, Juan Carlos; Borrás, Rafael; Sanz, Jaime; Solano, Carlos; Navarro, David title: Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients date: 2019-09-03 journal: Transpl Infect Dis DOI: 10.1111/tid.13158 sha: doc_id: 259625 cord_uid: 8lripsf7 file: cache/cord-272835-6nx4f8ss.json key: cord-272835-6nx4f8ss authors: Paulsen, Grant C.; Danziger-Isakov, Lara title: Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation date: 2017-12-31 journal: Clinics in Chest Medicine DOI: 10.1016/j.ccm.2017.07.012 sha: doc_id: 272835 cord_uid: 6nx4f8ss file: cache/cord-015389-vwgai4k9.json key: cord-015389-vwgai4k9 authors: nan title: Publication only date: 2009-03-25 journal: Bone Marrow Transplant DOI: 10.1038/bmt.2009.50 sha: doc_id: 15389 cord_uid: vwgai4k9 file: cache/cord-017883-6a4fkd5v.json key: cord-017883-6a4fkd5v authors: Dutta, Ankhi; Flores, Ricardo title: Infection Prevention in Pediatric Oncology and Hematopoietic Stem Cell Transplant Recipients date: 2018-07-16 journal: Healthcare-Associated Infections in Children DOI: 10.1007/978-3-319-98122-2_16 sha: doc_id: 17883 cord_uid: 6a4fkd5v file: cache/cord-268843-zml9lbve.json key: cord-268843-zml9lbve authors: Cuvelier, Geoffrey D.E.; Rubin, Tamar S.; Junker, Anne; Sinha, Roona; Rosenberg, Alan M.; Wall, Donna A.; Schroeder, Marlis L. title: Clinical presentation, immunologic features, and hematopoietic stem cell transplant outcomes for IKBKB immune deficiency date: 2018-10-31 journal: Clin Immunol DOI: 10.1016/j.clim.2018.10.019 sha: doc_id: 268843 cord_uid: zml9lbve file: cache/cord-014712-5u4e00q6.json key: cord-014712-5u4e00q6 authors: nan title: Selected Abstracts from the 100th J Project Meeting, Antalya, Turkey, March 12-14, 2014 date: 2014-08-02 journal: J Clin Immunol DOI: 10.1007/s10875-014-0065-9 sha: doc_id: 14712 cord_uid: 5u4e00q6 file: cache/cord-292645-5nplyyai.json key: cord-292645-5nplyyai authors: Hawkinson, Dana; Hinthorn, Daniel; Danziger-Isakov, Lara title: Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults date: 2013-10-22 journal: Curr Infect Dis Rep DOI: 10.1007/s11908-013-0370-0 sha: doc_id: 292645 cord_uid: 5nplyyai file: cache/cord-291966-5jm5c2lj.json key: cord-291966-5jm5c2lj authors: Abandeh, Foad I.; Lustberg, Mark; Devine, Steven; Elder, Pat; Andritsos, Leslie; Martin, Stanley I. title: Outcomes of Hematopoietic Stem Cell Transplant Recipients with Rhinovirus Infection: A Matched, Case-Control Study date: 2013-07-22 journal: Bone Marrow Transplantation DOI: 10.1038/bmt.2013.100 sha: doc_id: 291966 cord_uid: 5jm5c2lj file: cache/cord-016932-bej10xbf.json key: cord-016932-bej10xbf authors: Lum, Lawrence G.; Bollard, Catherine M. title: Specific Adoptive T-Cell Therapy for Viral and Fungal Infections date: 2018-06-19 journal: Management of Infections in the Immunocompromised Host DOI: 10.1007/978-3-319-77674-3_20 sha: doc_id: 16932 cord_uid: bej10xbf file: cache/cord-339931-e2ylkonb.json key: cord-339931-e2ylkonb authors: Mo, Xiao-Dong; Zhang, Xiao-Hui; Xu, Lan-Ping; Wang, Yu; Yan, Chen-Hua; Chen, Huan; Chen, Yu-Hong; Han, Wei; Wang, Feng-Rong; Wang, Jing-Zhi; Liu, Kai-Yan; Huang, Xiao-Jun title: Treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: the role of corticosteroids date: 2018-03-12 journal: Ann Hematol DOI: 10.1007/s00277-018-3290-0 sha: doc_id: 339931 cord_uid: e2ylkonb file: cache/cord-283141-dh8j7lyl.json key: cord-283141-dh8j7lyl authors: Haskologlu, Sule; Kostel Bal, Sevgi; Islamoglu, Candan; Aytekin, Caner; Guner, Sukru; Sevinc, Selin; Keles, Sevgi; Kendirli, Tanil; Ceylaner, Serdar; Dogu, Figen; Ikinciogullari, Aydan title: Clinical, immunological features and follow up of 20 patients with dedicator of cytokinesis 8 (DOCK8) deficiency date: 2020-03-11 journal: Pediatr Allergy Immunol DOI: 10.1111/pai.13236 sha: doc_id: 283141 cord_uid: dh8j7lyl file: cache/cord-322822-z0ehfrg0.json key: cord-322822-z0ehfrg0 authors: Barton, Todd D.; Blumberg, Emily A. title: Viral Pneumonias Other Than Cytomegalovirus in Transplant Recipients date: 2005-11-01 journal: Clin Chest Med DOI: 10.1016/j.ccm.2005.06.004 sha: doc_id: 322822 cord_uid: z0ehfrg0 file: cache/cord-005487-vac061r8.json key: cord-005487-vac061r8 authors: nan title: Physicians Abstracts: EBMT 2010 date: 2010-04-07 journal: Bone Marrow Transplant DOI: 10.1038/bmt.2010.40 sha: doc_id: 5487 cord_uid: vac061r8 file: cache/cord-294906-1m4h116m.json key: cord-294906-1m4h116m authors: Jarmoliński, Tomasz; Matkowska‐Kocjan, Agnieszka; Rosa, Monika; Olejnik, Igor; Gorczyńska, Ewa; Kałwak, Krzysztof; Ussowicz, Marek title: SARS‐CoV‐2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation – a case report date: 2020-09-18 journal: Pediatr Transplant DOI: 10.1111/petr.13875 sha: doc_id: 294906 cord_uid: 1m4h116m file: cache/cord-347761-wgodcsav.json key: cord-347761-wgodcsav authors: Cant, Andrew; Cole, Theresa title: Infections in the Immunocompromised date: 2009-10-24 journal: Hot Topics in Infection and Immunity in Children VI DOI: 10.1007/978-1-4419-0981-7_1 sha: doc_id: 347761 cord_uid: wgodcsav file: cache/cord-004675-n8mlxe7p.json key: cord-004675-n8mlxe7p authors: nan title: 2019 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference date: 2019-02-26 journal: J Clin Immunol DOI: 10.1007/s10875-019-00597-5 sha: doc_id: 4675 cord_uid: n8mlxe7p file: cache/cord-348130-t9tysvr8.json key: cord-348130-t9tysvr8 authors: Cho, Sung-Yeon; Lee, Hyeon-Jeong; Lee, Dong-Gun title: Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea date: 2018-02-27 journal: Korean J Intern Med DOI: 10.3904/kjim.2018.036 sha: doc_id: 348130 cord_uid: t9tysvr8 file: cache/cord-294150-eq2vkm4i.json key: cord-294150-eq2vkm4i authors: Lee, Yoon‐Kyoung; Huh, Rimm; Kim, Jihyun; Ahn, Kangmo; Sung, Ki Woong; Cho, Joongbum title: Late‐onset noninfectious interstitial lung disease following autologous haematopoietic stem cell transplantation in paediatric patients date: 2016-04-12 journal: Respirology DOI: 10.1111/resp.12787 sha: doc_id: 294150 cord_uid: eq2vkm4i file: cache/cord-014976-546zaoxn.json key: cord-014976-546zaoxn authors: nan title: Publication only date: 2006-03-08 journal: Bone Marrow Transplant DOI: 10.1038/sj.bmt.1705327 sha: doc_id: 14976 cord_uid: 546zaoxn file: cache/cord-005478-5iu38pr6.json key: cord-005478-5iu38pr6 authors: nan title: The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Oral Session date: 2019-07-03 journal: Bone Marrow Transplant DOI: 10.1038/s41409-019-0562-9 sha: doc_id: 5478 cord_uid: 5iu38pr6 file: cache/cord-313474-1gux1gsi.json key: cord-313474-1gux1gsi authors: nan title: Physicians Abstracts date: 2015-03-20 journal: Bone Marrow Transplant DOI: 10.1038/bmt.2015.27 sha: doc_id: 313474 cord_uid: 1gux1gsi file: cache/cord-005480-yg7salqt.json key: cord-005480-yg7salqt authors: nan title: Oral Sessions and Working Party date: 2008-03-26 journal: Bone Marrow Transplant DOI: 10.1038/bmt.2008.30 sha: doc_id: 5480 cord_uid: yg7salqt file: cache/cord-006466-e1phpqes.json key: cord-006466-e1phpqes authors: nan title: 2018 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference date: 2018-04-23 journal: J Clin Immunol DOI: 10.1007/s10875-018-0485-z sha: doc_id: 6466 cord_uid: e1phpqes file: cache/cord-024651-578c9ut5.json key: cord-024651-578c9ut5 authors: nan title: 2020 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference date: 2020-05-11 journal: J Clin Immunol DOI: 10.1007/s10875-020-00764-z sha: doc_id: 24651 cord_uid: 578c9ut5 file: cache/cord-009997-oecpqf1j.json key: cord-009997-oecpqf1j authors: nan title: 2018 ASPHO ABSTRACTS date: 2018-03-31 journal: Pediatr Blood Cancer DOI: 10.1002/pbc.27057 sha: doc_id: 9997 cord_uid: oecpqf1j file: cache/cord-005460-ezrn8cva.json key: cord-005460-ezrn8cva authors: nan title: Physicians – Poster Session date: 2017-07-28 journal: Bone Marrow Transplant DOI: 10.1038/bmt.2017.134 sha: doc_id: 5460 cord_uid: ezrn8cva file: cache/cord-005453-4057qib7.json key: cord-005453-4057qib7 authors: nan title: The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session date: 2019-07-03 journal: Bone Marrow Transplant DOI: 10.1038/s41409-019-0559-4 sha: doc_id: 5453 cord_uid: 4057qib7 Reading metadata file and updating bibliogrpahics === updating bibliographic database Building study carrel named keyword-hsct-cord === file2bib.sh === id: cord-005448-5fznfp5p author: Holtan, S G title: CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies date: 2010-03-08 pages: extension: .txt txt: ./txt/cord-005448-5fznfp5p.txt cache: ./cache/cord-005448-5fznfp5p.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-005448-5fznfp5p.txt' === file2bib.sh === id: cord-007791-nzjm6zyq author: Carreras, Enric title: Noninfectious Pulmonary Complications date: 2018-09-12 pages: extension: .txt txt: ./txt/cord-007791-nzjm6zyq.txt cache: ./cache/cord-007791-nzjm6zyq.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-007791-nzjm6zyq.txt' === file2bib.sh === id: cord-294906-1m4h116m author: Jarmoliński, Tomasz title: SARS‐CoV‐2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation – a case report date: 2020-09-18 pages: extension: .txt txt: ./txt/cord-294906-1m4h116m.txt cache: ./cache/cord-294906-1m4h116m.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-294906-1m4h116m.txt' === file2bib.sh === id: cord-000121-duwfxeyt author: Dzieciątkowski, Tomasz title: Prevalence of human herpesvirus 6 antibodies and DNA in allogeneic stem cell transplant patients: two-year single centre experience date: 2008-05-30 pages: extension: .txt txt: ./txt/cord-000121-duwfxeyt.txt cache: ./cache/cord-000121-duwfxeyt.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-000121-duwfxeyt.txt' === file2bib.sh === id: cord-030921-wydk9p93 author: Even-Or, Ehud title: Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases date: 2020-08-27 pages: extension: .txt txt: ./txt/cord-030921-wydk9p93.txt cache: ./cache/cord-030921-wydk9p93.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-030921-wydk9p93.txt' === file2bib.sh === id: cord-018906-03nynqtq author: Moulton, Bart title: Pulmonary Complications date: 2014-11-25 pages: extension: .txt txt: ./txt/cord-018906-03nynqtq.txt cache: ./cache/cord-018906-03nynqtq.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-018906-03nynqtq.txt' === file2bib.sh === id: cord-006492-pc1vayyl author: Ono, Shintaro title: Hematopoietic Stem Cell Transplantation for XIAP Deficiency in Japan date: 2016-11-04 pages: extension: .txt txt: ./txt/cord-006492-pc1vayyl.txt cache: ./cache/cord-006492-pc1vayyl.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-006492-pc1vayyl.txt' === file2bib.sh === id: cord-276952-nkaow79h author: Sim, Starling A. title: Viral Respiratory Tract Infections in Allogeneic Hematopoietic Stem Cell Transplantation Recipients in the Era of Molecular Testing date: 2018-03-09 pages: extension: .txt txt: ./txt/cord-276952-nkaow79h.txt cache: ./cache/cord-276952-nkaow79h.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-276952-nkaow79h.txt' === file2bib.sh === id: cord-322606-cx6eh0ff author: Donadieu, J title: Hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: experience of the French neutropenia registry date: 2005-09-05 pages: extension: .txt txt: ./txt/cord-322606-cx6eh0ff.txt cache: ./cache/cord-322606-cx6eh0ff.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-322606-cx6eh0ff.txt' === file2bib.sh === id: cord-283141-dh8j7lyl author: Haskologlu, Sule title: Clinical, immunological features and follow up of 20 patients with dedicator of cytokinesis 8 (DOCK8) deficiency date: 2020-03-11 pages: extension: .txt txt: ./txt/cord-283141-dh8j7lyl.txt cache: ./cache/cord-283141-dh8j7lyl.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-283141-dh8j7lyl.txt' === file2bib.sh === id: cord-291966-5jm5c2lj author: Abandeh, Foad I. title: Outcomes of Hematopoietic Stem Cell Transplant Recipients with Rhinovirus Infection: A Matched, Case-Control Study date: 2013-07-22 pages: extension: .txt txt: ./txt/cord-291966-5jm5c2lj.txt cache: ./cache/cord-291966-5jm5c2lj.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-291966-5jm5c2lj.txt' === file2bib.sh === id: cord-266359-uf1ao1x1 author: Hakki, Morgan title: The clinical impact of coronavirus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients date: 2015-04-15 pages: extension: .txt txt: ./txt/cord-266359-uf1ao1x1.txt cache: ./cache/cord-266359-uf1ao1x1.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-266359-uf1ao1x1.txt' === file2bib.sh === id: cord-292645-5nplyyai author: Hawkinson, Dana title: Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults date: 2013-10-22 pages: extension: .txt txt: ./txt/cord-292645-5nplyyai.txt cache: ./cache/cord-292645-5nplyyai.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-292645-5nplyyai.txt' === file2bib.sh === id: cord-010130-28bt3x25 author: Crocchiolo, R. title: Infections after T‐replete haploidentical transplantation and high‐dose cyclophosphamide as graft‐versus‐host disease prophylaxis date: 2015-03-26 pages: extension: .txt txt: ./txt/cord-010130-28bt3x25.txt cache: ./cache/cord-010130-28bt3x25.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-010130-28bt3x25.txt' === file2bib.sh === id: cord-254183-98o0dssj author: Waggoner, Jesse J. title: Rare and Emerging Viral Infections in Transplant Recipients date: 2013-10-15 pages: extension: .txt txt: ./txt/cord-254183-98o0dssj.txt cache: ./cache/cord-254183-98o0dssj.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-254183-98o0dssj.txt' === file2bib.sh === id: cord-294150-eq2vkm4i author: Lee, Yoon‐Kyoung title: Late‐onset noninfectious interstitial lung disease following autologous haematopoietic stem cell transplantation in paediatric patients date: 2016-04-12 pages: extension: .txt txt: ./txt/cord-294150-eq2vkm4i.txt cache: ./cache/cord-294150-eq2vkm4i.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-294150-eq2vkm4i.txt' === file2bib.sh === id: cord-261827-uprv8a2k author: Brodszki, Nicholas title: Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions date: 2016-01-15 pages: extension: .txt txt: ./txt/cord-261827-uprv8a2k.txt cache: ./cache/cord-261827-uprv8a2k.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-261827-uprv8a2k.txt' === file2bib.sh === id: cord-018339-tyrlpl94 author: Dsouza, Kevin title: Late Noninfectious Pulmonary Complications in Hematopoietic Stem Cell Transplantation date: 2019-07-09 pages: extension: .txt txt: ./txt/cord-018339-tyrlpl94.txt cache: ./cache/cord-018339-tyrlpl94.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-018339-tyrlpl94.txt' === file2bib.sh === id: cord-280763-4bnv2t3f author: Piñana, José Luis title: Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study date: 2019-06-01 pages: extension: .txt txt: ./txt/cord-280763-4bnv2t3f.txt cache: ./cache/cord-280763-4bnv2t3f.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-280763-4bnv2t3f.txt' === file2bib.sh === id: cord-259625-8lripsf7 author: Piñana, José Luis title: Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients date: 2019-09-03 pages: extension: .txt txt: ./txt/cord-259625-8lripsf7.txt cache: ./cache/cord-259625-8lripsf7.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-259625-8lripsf7.txt' === file2bib.sh === id: cord-281026-2avisuge author: Versluys, A.Birgitta title: Strong Association between Respiratory Viral Infection Early after Hematopoietic Stem Cell Transplantation and the Development of Life-Threatening Acute and Chronic Alloimmune Lung Syndromes date: 2010-01-06 pages: extension: .txt txt: ./txt/cord-281026-2avisuge.txt cache: ./cache/cord-281026-2avisuge.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-281026-2avisuge.txt' === file2bib.sh === id: cord-003866-3gwbc7z9 author: Zecha, Judith A. E. M. title: The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy date: 2019-06-20 pages: extension: .txt txt: ./txt/cord-003866-3gwbc7z9.txt cache: ./cache/cord-003866-3gwbc7z9.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-003866-3gwbc7z9.txt' === file2bib.sh === id: cord-279638-jr1mbh7s author: Calore, Elisabetta title: Treatment of Acute Graft-versus-Host Disease in Childhood with Extracorporeal Photochemotherapy/Photopheresis: The Padova Experience date: 2015-07-14 pages: extension: .txt txt: ./txt/cord-279638-jr1mbh7s.txt cache: ./cache/cord-279638-jr1mbh7s.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-279638-jr1mbh7s.txt' === file2bib.sh === id: cord-018209-v2crgj5w author: Pastores, Stephen M. title: What Has Been Learned from Postmortem Studies? date: 2010-08-19 pages: extension: .txt txt: ./txt/cord-018209-v2crgj5w.txt cache: ./cache/cord-018209-v2crgj5w.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-018209-v2crgj5w.txt' === file2bib.sh === id: cord-005446-jr3yj4o2 author: Forrest, D L title: Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study date: 2003-06-10 pages: extension: .txt txt: ./txt/cord-005446-jr3yj4o2.txt cache: ./cache/cord-005446-jr3yj4o2.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-005446-jr3yj4o2.txt' === file2bib.sh === id: cord-339931-e2ylkonb author: Mo, Xiao-Dong title: Treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: the role of corticosteroids date: 2018-03-12 pages: extension: .txt txt: ./txt/cord-339931-e2ylkonb.txt cache: ./cache/cord-339931-e2ylkonb.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-339931-e2ylkonb.txt' === file2bib.sh === id: cord-268843-zml9lbve author: Cuvelier, Geoffrey D.E. title: Clinical presentation, immunologic features, and hematopoietic stem cell transplant outcomes for IKBKB immune deficiency date: 2018-10-31 pages: extension: .txt txt: ./txt/cord-268843-zml9lbve.txt cache: ./cache/cord-268843-zml9lbve.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-268843-zml9lbve.txt' === file2bib.sh === id: cord-347761-wgodcsav author: Cant, Andrew title: Infections in the Immunocompromised date: 2009-10-24 pages: extension: .txt txt: ./txt/cord-347761-wgodcsav.txt cache: ./cache/cord-347761-wgodcsav.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-347761-wgodcsav.txt' === file2bib.sh === id: cord-017302-xez0zso3 author: Stephens, R. Scott title: ICU Complications of Hematopoietic Stem Cell Transplant, Including Graft vs Host Disease date: 2019-07-24 pages: extension: .txt txt: ./txt/cord-017302-xez0zso3.txt cache: ./cache/cord-017302-xez0zso3.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-017302-xez0zso3.txt' === file2bib.sh === id: cord-018243-hyvu9nuq author: Salman, Huda title: Fibrosing Alveolitis in Hematologic Malignancy Patients Undergoing Hematopoietic Cell Transplantation date: 2010-08-19 pages: extension: .txt txt: ./txt/cord-018243-hyvu9nuq.txt cache: ./cache/cord-018243-hyvu9nuq.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-018243-hyvu9nuq.txt' === file2bib.sh === id: cord-017883-6a4fkd5v author: Dutta, Ankhi title: Infection Prevention in Pediatric Oncology and Hematopoietic Stem Cell Transplant Recipients date: 2018-07-16 pages: extension: .txt txt: ./txt/cord-017883-6a4fkd5v.txt cache: ./cache/cord-017883-6a4fkd5v.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-017883-6a4fkd5v.txt' === file2bib.sh === id: cord-018319-tylkbh4h author: Chemaly, Roy F. title: Respiratory Viruses date: 2011-01-04 pages: extension: .txt txt: ./txt/cord-018319-tylkbh4h.txt cache: ./cache/cord-018319-tylkbh4h.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-018319-tylkbh4h.txt' === file2bib.sh === id: cord-016932-bej10xbf author: Lum, Lawrence G. title: Specific Adoptive T-Cell Therapy for Viral and Fungal Infections date: 2018-06-19 pages: extension: .txt txt: ./txt/cord-016932-bej10xbf.txt cache: ./cache/cord-016932-bej10xbf.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-016932-bej10xbf.txt' === file2bib.sh === id: cord-322822-z0ehfrg0 author: Barton, Todd D. title: Viral Pneumonias Other Than Cytomegalovirus in Transplant Recipients date: 2005-11-01 pages: extension: .txt txt: ./txt/cord-322822-z0ehfrg0.txt cache: ./cache/cord-322822-z0ehfrg0.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 3 resourceName b'cord-322822-z0ehfrg0.txt' === file2bib.sh === id: cord-272835-6nx4f8ss author: Paulsen, Grant C. title: Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation date: 2017-12-31 pages: extension: .txt txt: ./txt/cord-272835-6nx4f8ss.txt cache: ./cache/cord-272835-6nx4f8ss.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-272835-6nx4f8ss.txt' === file2bib.sh === id: cord-348130-t9tysvr8 author: Cho, Sung-Yeon title: Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea date: 2018-02-27 pages: extension: .txt txt: ./txt/cord-348130-t9tysvr8.txt cache: ./cache/cord-348130-t9tysvr8.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-348130-t9tysvr8.txt' === file2bib.sh === id: cord-015922-5wwy0m2k author: Marty, Francisco M. title: Infection in the Hematopoietic Stem Cell Transplant Recipient date: 2008 pages: extension: .txt txt: ./txt/cord-015922-5wwy0m2k.txt cache: ./cache/cord-015922-5wwy0m2k.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-015922-5wwy0m2k.txt' === file2bib.sh === id: cord-018302-lmly43rd author: Renaud, Christian title: Respiratory Syncytial Virus and Human Metapneumovirus Infection in Transplant Recipients date: 2016-02-15 pages: extension: .txt txt: ./txt/cord-018302-lmly43rd.txt cache: ./cache/cord-018302-lmly43rd.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 2 resourceName b'cord-018302-lmly43rd.txt' === file2bib.sh === id: cord-007788-09t52zix author: Wallhult, Elisabeth title: Early and Acute Complications and the Principles of HSCT Nursing Care date: 2017-11-22 pages: extension: .txt txt: ./txt/cord-007788-09t52zix.txt cache: ./cache/cord-007788-09t52zix.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-007788-09t52zix.txt' === file2bib.sh === id: cord-015389-vwgai4k9 author: nan title: Publication only date: 2009-03-25 pages: extension: .txt txt: ./txt/cord-015389-vwgai4k9.txt cache: ./cache/cord-015389-vwgai4k9.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-015389-vwgai4k9.txt' === file2bib.sh === id: cord-005482-v5iayczy author: nan title: Publication Only date: 2016-03-21 pages: extension: .txt txt: ./txt/cord-005482-v5iayczy.txt cache: ./cache/cord-005482-v5iayczy.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 9 resourceName b'cord-005482-v5iayczy.txt' === file2bib.sh === id: cord-006856-b1w25ob5 author: nan title: 19th Meeting of the Austrian Society of Transplantation, Transfusion, and Genetics, October 26–28, 2005 date: 2005 pages: extension: .txt txt: ./txt/cord-006856-b1w25ob5.txt cache: ./cache/cord-006856-b1w25ob5.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-006856-b1w25ob5.txt' === file2bib.sh === id: cord-014712-5u4e00q6 author: nan title: Selected Abstracts from the 100th J Project Meeting, Antalya, Turkey, March 12-14, 2014 date: 2014-08-02 pages: extension: .txt txt: ./txt/cord-014712-5u4e00q6.txt cache: ./cache/cord-014712-5u4e00q6.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 4 resourceName b'cord-014712-5u4e00q6.txt' === file2bib.sh === id: cord-313474-1gux1gsi author: nan title: Physicians Abstracts date: 2015-03-20 pages: extension: .txt txt: ./txt/cord-313474-1gux1gsi.txt cache: ./cache/cord-313474-1gux1gsi.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 7 resourceName b'cord-313474-1gux1gsi.txt' === file2bib.sh === id: cord-014976-546zaoxn author: nan title: Publication only date: 2006-03-08 pages: extension: .txt txt: ./txt/cord-014976-546zaoxn.txt cache: ./cache/cord-014976-546zaoxn.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 6 resourceName b'cord-014976-546zaoxn.txt' === file2bib.sh === id: cord-005487-vac061r8 author: nan title: Physicians Abstracts: EBMT 2010 date: 2010-04-07 pages: extension: .txt txt: ./txt/cord-005487-vac061r8.txt cache: ./cache/cord-005487-vac061r8.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 6 resourceName b'cord-005487-vac061r8.txt' === file2bib.sh === id: cord-005478-5iu38pr6 author: nan title: The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Oral Session date: 2019-07-03 pages: extension: .txt txt: ./txt/cord-005478-5iu38pr6.txt cache: ./cache/cord-005478-5iu38pr6.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 6 resourceName b'cord-005478-5iu38pr6.txt' === file2bib.sh === id: cord-005480-yg7salqt author: nan title: Oral Sessions and Working Party date: 2008-03-26 pages: extension: .txt txt: ./txt/cord-005480-yg7salqt.txt cache: ./cache/cord-005480-yg7salqt.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 8 resourceName b'cord-005480-yg7salqt.txt' === file2bib.sh === id: cord-004675-n8mlxe7p author: nan title: 2019 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference date: 2019-02-26 pages: extension: .txt txt: ./txt/cord-004675-n8mlxe7p.txt cache: ./cache/cord-004675-n8mlxe7p.txt Content-Encoding ISO-8859-1 Content-Type text/plain; charset=ISO-8859-1 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 6 resourceName b'cord-004675-n8mlxe7p.txt' === file2bib.sh === id: cord-024651-578c9ut5 author: nan title: 2020 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference date: 2020-05-11 pages: extension: .txt txt: ./txt/cord-024651-578c9ut5.txt cache: ./cache/cord-024651-578c9ut5.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 6 resourceName b'cord-024651-578c9ut5.txt' === file2bib.sh === id: cord-006466-e1phpqes author: nan title: 2018 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference date: 2018-04-23 pages: extension: .txt txt: ./txt/cord-006466-e1phpqes.txt cache: ./cache/cord-006466-e1phpqes.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 7 resourceName b'cord-006466-e1phpqes.txt' === file2bib.sh === id: cord-009997-oecpqf1j author: nan title: 2018 ASPHO ABSTRACTS date: 2018-03-31 pages: extension: .txt txt: ./txt/cord-009997-oecpqf1j.txt cache: ./cache/cord-009997-oecpqf1j.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 14 resourceName b'cord-009997-oecpqf1j.txt' === file2bib.sh === id: cord-005460-ezrn8cva author: nan title: Physicians – Poster Session date: 2017-07-28 pages: extension: .txt txt: ./txt/cord-005460-ezrn8cva.txt cache: ./cache/cord-005460-ezrn8cva.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 20 resourceName b'cord-005460-ezrn8cva.txt' === file2bib.sh === id: cord-005453-4057qib7 author: nan title: The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session date: 2019-07-03 pages: extension: .txt txt: ./txt/cord-005453-4057qib7.txt cache: ./cache/cord-005453-4057qib7.txt Content-Encoding UTF-8 Content-Type text/plain; charset=UTF-8 X-Parsed-By ['org.apache.tika.parser.DefaultParser', 'org.apache.tika.parser.csv.TextAndCSVParser'] X-TIKA:content_handler ToTextContentHandler X-TIKA:embedded_depth 0 X-TIKA:parse_time_millis 22 resourceName b'cord-005453-4057qib7.txt' Que is empty; done keyword-hsct-cord === reduce.pl bib === id = cord-005446-jr3yj4o2 author = Forrest, D L title = Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study date = 2003-06-10 pages = extension = .txt mime = text/plain words = 4931 sentences = 278 flesch = 46 summary = title: Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study We evaluated 40 patients undergoing high-dose chemo/ radiotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) (allogeneic (22) , autologous (18) ) to determine the safety and feasibility of administering low molecular weight heparin (LMWH) as hepatic veno-occlusive disease (VOD) prophylaxis. We evaluated 40 patients undergoing high-dose chemo/ radiotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) (allogeneic (22) , autologous (18) ) to determine the safety and feasibility of administering low molecular weight heparin (LMWH) as hepatic veno-occlusive disease (VOD) prophylaxis. Daily patient evaluation while receiving dalteparin included patient weight, oxygen saturation, liver size, presence of right upper quadrant (RUQ) abdominal pain, ascites or pleural effusions, complete blood count (CBC), serum creatinine, assessment of bleeding and GVHD; adverse events, grading of RRT and the number of red cell and platelet transfusions were recorded; liver function tests (bilirubin, AST, ALT, alkaline phosphatase), INR, PTT and fibrinogen were measured twice weekly. cache = ./cache/cord-005446-jr3yj4o2.txt txt = ./txt/cord-005446-jr3yj4o2.txt === reduce.pl bib === id = cord-000121-duwfxeyt author = Dzieciątkowski, Tomasz title = Prevalence of human herpesvirus 6 antibodies and DNA in allogeneic stem cell transplant patients: two-year single centre experience date = 2008-05-30 pages = extension = .txt mime = text/plain words = 2549 sentences = 137 flesch = 49 summary = title: Prevalence of human herpesvirus 6 antibodies and DNA in allogeneic stem cell transplant patients: two-year single centre experience INTRODUCTION: Human herpesvirus 6 (HHV-6) has been recognized as a potentially significant pathogen in hemopoietic stem cell transplant (HSCT) recipients. In a recent study we summarized retrospective results of the determination of HHV infection status in allogeneic stem cell transplant recipients. As infections with HHV-6 are rarely accompanied by clinical symptoms, our first aim was to compare HHV-6 infection status, measured as viral DNA presence in the blood in the post-transplantation period and patients' anti-HHV-6 serological status by detection of IgG and IgM antibodies. In the two patients who had a single HHV-6-positive blood sample, viral DNA was detected at a later time. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients cache = ./cache/cord-000121-duwfxeyt.txt txt = ./txt/cord-000121-duwfxeyt.txt === reduce.pl bib === id = cord-010130-28bt3x25 author = Crocchiolo, R. title = Infections after T‐replete haploidentical transplantation and high‐dose cyclophosphamide as graft‐versus‐host disease prophylaxis date = 2015-03-26 pages = extension = .txt mime = text/plain words = 3519 sentences = 175 flesch = 46 summary = RESULTS: After a median follow‐up of 23 months, cumulative incidence of viral infections was 70% (95% confidence interval [CI] 59–81) at 100 days and 77% (95% CI 67–87) at 1 year; 35 of 65 patients at risk had CMV reactivation (54%) and the rate of polyomavirus‐virus‐associated cystitis was 19% (13/70). In the present analysis, we described infectious complications after unmanipulated, T-cell replete haplo-HSCT using post-transplant Cy in 70 consecutive patients and found, aside from a high incidence of viral infections/reactivations, especially in the early posttransplant period, a quite low incidence of late bacterial infections, together with a very low incidence of IFIs after day +180 (2 events in the overall 11 observed). In conclusion, the present single-center data on 70 consecutive patients receiving T-cell replete haplo-HSCT with post-transplant Cy confirm a high rate of viral infections before day +100 and a lower incidence of infections afterward, suggesting a satisfactory although non-optimal immune reconstitution after this type of transplantation. cache = ./cache/cord-010130-28bt3x25.txt txt = ./txt/cord-010130-28bt3x25.txt === reduce.pl bib === id = cord-005448-5fznfp5p author = Holtan, S G title = CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies date = 2010-03-08 pages = extension = .txt mime = text/plain words = 2589 sentences = 120 flesch = 39 summary = title: CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies The combination of fludarabine and melphalan as a reduced-intensity conditioning (RIC) regimen extends allogeneic hematopoietic SCT (HSCT) as a therapeutic option for elderly or frail patients with relapsed, refractory or other high-risk hematologic malignancies. Factors analyzed for association with survival included demographic and disease factors (age at transplant, sex, lymphoid vs myeloid disease, karyotype and blast percentage in those with MDS and leukemia, disease status at transplant, previous HSCT, and previous chemotherapy for solid tumors), donor/graft factors (CD34 þ cell dose, graft source, related vs unrelated graft, degree of HLA match, CMV serostatus and ABO match), and post transplant factors (time to neutrophil, lymphocyte and platelet engraftment, day þ 100 chimerism status, development of and severity of acute GVHD, development of and severity of chronic GVHD). cache = ./cache/cord-005448-5fznfp5p.txt txt = ./txt/cord-005448-5fznfp5p.txt === reduce.pl bib === id = cord-006492-pc1vayyl author = Ono, Shintaro title = Hematopoietic Stem Cell Transplantation for XIAP Deficiency in Japan date = 2016-11-04 pages = extension = .txt mime = text/plain words = 3178 sentences = 170 flesch = 45 summary = BACKGROUND: X-linked inhibitor of apoptosis protein (XIAP) deficiency is a rare immunodeficiency that is characterized by recurrent hemophagocytic lymphohistiocytosis (HLH) and splenomegaly and sometimes associated with refractory inflammatory bowel disease (IBD). Although hematopoietic stem cell transplantation (HSCT) is the only curative therapy, the outcomes of HSCT for XIAP deficiency remain unsatisfactory compared with those for SLAM-associated protein deficiency and familial HLH. CONCLUSION: The RIC regimen and HLH control might be important factors for successful HSCT outcomes, with improved IBD, in patients with XIAP deficiency. The transplantations were performed in different institutions, but all conditioning regimens were RIC, except that for patient 1, who was given an intermediate intensity regimen, but died of HLH and acute respiratory distress syndrome on day 27 post-HSCT, in which virus infection or reactivation might not be involved. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAMassociated protein deficiency/X-linked lymphoproliferative Disease type 1 cache = ./cache/cord-006492-pc1vayyl.txt txt = ./txt/cord-006492-pc1vayyl.txt === reduce.pl bib === id = cord-007791-nzjm6zyq author = Carreras, Enric title = Noninfectious Pulmonary Complications date = 2018-09-12 pages = extension = .txt mime = text/plain words = 2611 sentences = 185 flesch = 46 summary = These distinct but related pathways of inflammation culminate in the recruitment of immune cells to the lung leading to tissue damage and dysfunction (Cooke and Yanik 2016) Incidence -The strict methodology required to establish IPS diagnosis and the increased use of RIC have reduced its incidence of 20% to 25% observed 20 years ago (at that time IPS was called idiopathic pneumonia) -This reduction runs in parallel of the improvement in the diagnostic methodologies to detect infectious pathogens. A recent prospective study showed that among 198 patients included after day +100, the cumulative incidence of LONIPC is 20%, and that of BOS is 11% at 3 years among allo-HSCT recipients (Bergeron et al. Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation cache = ./cache/cord-007791-nzjm6zyq.txt txt = ./txt/cord-007791-nzjm6zyq.txt === reduce.pl bib === id = cord-015922-5wwy0m2k author = Marty, Francisco M. title = Infection in the Hematopoietic Stem Cell Transplant Recipient date = 2008 pages = extension = .txt mime = text/plain words = 10254 sentences = 489 flesch = 33 summary = Other prophylactic strategies commonly utilized in HSCT patients include acyclovir to prevent herpes simplex virus (HSV) and VZV reactivation, fluoroquinolones [5] to prevent gram-negative sepsis and fluconazole to prevent yeast infection. It has been suggested that EBV viral load surveillance in peripheral blood be carried out in high risk patients (those with primary EBV infection, anti-T cell antibody therapy for GVHD, HLA-mismatched or T cell-depleted HSCT recipients), with decreased immunosuppression +/− antiviral therapy (acyclovir or ganciclovir) carried out in the setting of high viral loads [1, 4, 41, 42] . Infliximab use in patients with severe graftversus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study cache = ./cache/cord-015922-5wwy0m2k.txt txt = ./txt/cord-015922-5wwy0m2k.txt === reduce.pl bib === id = cord-018319-tylkbh4h author = Chemaly, Roy F. title = Respiratory Viruses date = 2011-01-04 pages = extension = .txt mime = text/plain words = 8852 sentences = 467 flesch = 37 summary = Historically, the most common causes of respiratory infections in cancer patients were thought to be opportunistic bacteria and fungi, but newer diagnostic methods have revealed that respiratory viruses can cause serious morbidity and mortality in such patients, including leukemia patients and hematopoietic stem cell transplant (HSCT) recipients. Many viruses are known to cause respiratory tract infections, but the most common in hospitalized cancer patients are influenza viruses, respiratory syncytial virus (RSV), and parainfluenza viruses (PIV) [1, 2] . Although the combination of ribavirin and intravenous immunoglobulin (IVIG) or palivizumab has not been evaluated in a randomized trial, it is sometimes used in severely ill patients with RSV pneumonia, especially HSCT recipients, given that they have high mortality rates from this infection [3, 11, 14] . However, because other viruses can produce the same syndrome and influenza infection can produce other respiratory syndromes, a confirmatory test detecting the virus or viral antigens in nasal washes, throat swabs, respiratory tract secretions, or bronchoalveolar lavage specimens is needed in sporadic cases and in immunocompromised patients. cache = ./cache/cord-018319-tylkbh4h.txt txt = ./txt/cord-018319-tylkbh4h.txt === reduce.pl bib === id = cord-006856-b1w25ob5 author = nan title = 19th Meeting of the Austrian Society of Transplantation, Transfusion, and Genetics, October 26–28, 2005 date = 2005 pages = extension = .txt mime = text/plain words = 29625 sentences = 1983 flesch = 52 summary = Egr-1 and hypoxia-inducible factor-1 (HIF-1) gene expression was examined in left ventricular biopsies of explanted failing hearts in 28 ICM and 42 DCM patients, as well as in 12 donor grafts before reperfusion (control), at 10, 30, 60 minutes after reperfusion, and at 1, 2, 3, 4, 6, 12 posttransplant weeks, using real-time RT-PCR. The risk of transplant-related mortality (TRM) due to graft-versushost disease (GvHD) is higher in male recipients of female stem cells compared with female patients receiving a graft from a female donor. We therefore analyzed a single-center cohort of 72 high-risk patients transplanted with a related or unrelated stem cell graft after nonmyeloablative conditioning for outcome (acute and chronic GvHD, TRM, relapse, and survival). Four patients between the age of 34 and 44 years underwent allogeneic peripheral blood stem cell (PBSC) transplantation (SCT) from HLA-identical sibling or unrelated donors at our institution. cache = ./cache/cord-006856-b1w25ob5.txt txt = ./txt/cord-006856-b1w25ob5.txt === reduce.pl bib === id = cord-005482-v5iayczy author = nan title = Publication Only date = 2016-03-21 pages = extension = .txt mime = text/plain words = 27400 sentences = 1715 flesch = 54 summary = Material (or patients) and methods: Case Report 23-year-old male patient who underwent allogeneic hematopoietic stem cell tranplantation sixteen months ago, admitted to bone marrow transplantation clinic for shortness of breath. Material (or patients) and methods: Data sets of 436 consecutive patients who underwent allogeneic HSCT at a single center (University of Rostock) from 1998 to 10/2015 were analysed regarding their early mortality rates (d+30, d+60 Introduction: Mobilization and collection of CD34-positive stem cells for subsequent high-dose chemotherapy constitutes a standard approach in myeloma patients achieving a good remission after induction chemotherapy. Outcomes of high grade gastrointestinal gvhd post-hsct in children Material (or patients) and methods: This is a retrospective analysis of 28 pediatric patients presented with a clinical diagnosis of stage 3 and 4 acute GVHD of the GIS who were selected from allogeneic hematopoetic stem cell transplantation (HSCT) performed. cache = ./cache/cord-005482-v5iayczy.txt txt = ./txt/cord-005482-v5iayczy.txt === reduce.pl bib === id = cord-003866-3gwbc7z9 author = Zecha, Judith A. E. M. title = The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy date = 2019-06-20 pages = extension = .txt mime = text/plain words = 6120 sentences = 332 flesch = 29 summary = [38] MRSA was detected in the oral cavity following HSCT, especially during OM peak severity HSCT CT chemotherapy, CONS coagulase-negative staphylococci, HSCT hematopoietic stem cell transplantation, MRSA methicillin-resistant staphylococcus spp., OM oral mucositis When pattern recognition receptors (PRRs) expressed by cells of the innate immune system within the mucosa (e.g., macrophages, neutrophils, and dendritic cells) are exposed to CRAMPS, this results in the release of cytokines that act locally, and also may have distant effects by activating intracellular and intercellular signaling loops [64] . [70] Treatment of dental pathologies and reducing oral microbial load resulted in shorter duration of OM HSCT Khan and Wingard [54] Presence of oropharyngeal mucositis is an independent risk factor for bacteremia in neutropenic patients HSCT, non-Hodgkin lymphoma, leukemia Head and neck cancer FN febrile neutropenia, HSCT hematopoietic stem cell transplantation infrequent conversion of chronic dental disease to an acute state during CT and conclude that there is no need for the treatment of "asymptomatic" chronic dental infections prior to CT or conditioning therapy for HSCT [62, 108] . cache = ./cache/cord-003866-3gwbc7z9.txt txt = ./txt/cord-003866-3gwbc7z9.txt === reduce.pl bib === id = cord-018906-03nynqtq author = Moulton, Bart title = Pulmonary Complications date = 2014-11-25 pages = extension = .txt mime = text/plain words = 2864 sentences = 217 flesch = 45 summary = After hematopoietic stem cell transplant (HSCT), up to 60 % of patients develop pulmonary complications. In spite of antibacterial, antiviral, and antifungal prophylaxis, reduced host defenses render the HSCT patient vulnerable to pulmonary and other infections in the early weeks and even months post-transplantation. This chapter suggests an integrative approach followed by a description of the most common pulmonary syndromes seen in HSCT patients, including diffuse alveolar hemorrhage (DAH), idiopathic pneumonia syndrome (IPS), bronchiolitis obliterans syndrome (BOS), and cryptogenic organizing pneumonia (COP). Two-year mortality after hematopoietic stem cell transplant (HSCT) has been estimated using a pre-transplantation assessment of mortality (PAM) score which incorporates spirometry and diffusing capacity variables in combination with the presence of renal and hepatic dysfunction, conditioning regimen, and disease risk. Diffuse alveolar hemorrhage (DAH) is a subset of pulmonary hemorrhage that can develop in up to 5 % of all post-HSCT recipients with mortality rates ranging between 50 and 80 % based on the two largest case series. cache = ./cache/cord-018906-03nynqtq.txt txt = ./txt/cord-018906-03nynqtq.txt === reduce.pl bib === id = cord-261827-uprv8a2k author = Brodszki, Nicholas title = Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions date = 2016-01-15 pages = extension = .txt mime = text/plain words = 4395 sentences = 228 flesch = 54 summary = title: Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment available for severe combined immunodeficiency (SCID); although, there is a high incidence of severe infections and an increased risk of graft-versus host-disease (GvHD) with HSCT. Haploidentical HSCT protocols utilizing extensively ex vivo T-cell depleted grafts (CliniMACs system) have proven efficient in preventing GvHD, but cause a delay in early T-cell recovery that increases the risk of viral infections. Here, we present a novel approach for treating SCID that combines selective depletion of GvHD-inducing alpha/beta (α/β) T-cells from the haploidentical HSCT graft with a subsequent donor lymphocyte infusion (DLI) enriched for CD45RO+ memory T-cells. Unselected donor lymphocyte infusions (DLIs), which are frequently used as a "tool" to boost anti-viral immunity post-transplant, harbor a significant risk of inducing severe GvHD in the haploidentical setting [6, 7] . cache = ./cache/cord-261827-uprv8a2k.txt txt = ./txt/cord-261827-uprv8a2k.txt === reduce.pl bib === id = cord-017302-xez0zso3 author = Stephens, R. Scott title = ICU Complications of Hematopoietic Stem Cell Transplant, Including Graft vs Host Disease date = 2019-07-24 pages = extension = .txt mime = text/plain words = 5226 sentences = 289 flesch = 33 summary = Hematopoietic stem cell transplant (HSCT) has become an essential therapeutic modality in the treatment of malignant and non-malignant hematologic disease. Allogeneic transplants are associated with more morbidity and mortality than autologous transplants, and are further categorized based on conditioning regimen (myeloablative [MA] vs non-myeloablative [NMA]), donor-recipient relation (related vs unrelated), HLA matching (full match vs haploidentical vs mismatched), and stem cell source (bone marrow, peripheral blood, umbilical cord blood). Refinement of transplant techniques over the last 2 decades has dramatically decreased transplant-related mortality, but approximately 15% of HSCT patients require critical care [10] and earlier ICU admission has been associated with improved survival rates [11, 12] . Outcomes of stem cell transplant patients with acute respiratory failure requiring mechanical ventilation in the United States Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease cache = ./cache/cord-017302-xez0zso3.txt txt = ./txt/cord-017302-xez0zso3.txt === reduce.pl bib === id = cord-279638-jr1mbh7s author = Calore, Elisabetta title = Treatment of Acute Graft-versus-Host Disease in Childhood with Extracorporeal Photochemotherapy/Photopheresis: The Padova Experience date = 2015-07-14 pages = extension = .txt mime = text/plain words = 5592 sentences = 279 flesch = 57 summary = Acute graft-versus-host disease (aGVHD) is the major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Update on the mechanism of action and on clinical efficacy of extracorporeal photopheresis in the treatment of acute and chronic graft versus host disease in children Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies Role of extracorporeal photopheresis (ECP) in treatment of steroid-refractory acute graft-versus-host disease Extracorporeal Photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients cache = ./cache/cord-279638-jr1mbh7s.txt txt = ./txt/cord-279638-jr1mbh7s.txt === reduce.pl bib === id = cord-266359-uf1ao1x1 author = Hakki, Morgan title = The clinical impact of coronavirus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients date = 2015-04-15 pages = extension = .txt mime = text/plain words = 3261 sentences = 157 flesch = 38 summary = BACKGROUND: Compared to other respiratory viruses, relatively little is known about the clinical impact of coronavirus (CoV) infection after hematopoietic stem cell transplant (HSCT) or in patients with hematologic malignancies. CONCLUSIONS: CoV is frequently detected in HSCT and hematologic malignancy patients in whom suspicion for a respiratory viral infection exists, but is less likely to progress to lower respiratory tract disease than most other respiratory viruses. The clinical significance of respiratory viruses such as influenza, respiratory syncytial virus (RSV), parainfluenza viruses (PIVs), human metapneumovirus (hMPV), rhinovirus (RhV), and adenovirus (AdV) in patients with hematologic malignancies or recipients of autologous or allogeneic hematopoietic stem cell transplant (HSCT) is well described [1] [2] [3] [4] [5] [6] [7] [8] . In conclusion, we found that CoV is detected frequently in patients with hematologic malignancies and HSCT recipients in whom suspicion for a respiratory viral infection exists, but is associated with less LRTD than other respiratory viruses except RhV/EnV. cache = ./cache/cord-266359-uf1ao1x1.txt txt = ./txt/cord-266359-uf1ao1x1.txt === reduce.pl bib === id = cord-018339-tyrlpl94 author = Dsouza, Kevin title = Late Noninfectious Pulmonary Complications in Hematopoietic Stem Cell Transplantation date = 2019-07-09 pages = extension = .txt mime = text/plain words = 5734 sentences = 316 flesch = 30 summary = A recent prospective study to evaluate the epidemiology of late non onset noninfectious complications after allogenic stem cell transplant reported a cumulative incidence of BOS 36 months posttransplant at 10.7% [9] . In a study of 9550 patients of post-allogenic HCST recipients, HLA disparity, female-to-male HSCT, and peripheral blood stem cell transplant (PBSCT) were associated with an increased risk of developing OP. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants Concurrent treatment with a tumor necrosis factor-alpha inhibitor and veno-venous extracorporeal membrane oxygenation in a post-hematopoietic stem cell transplant patient with idiopathic pneumonia syndrome: a case report Incidence, clinical features, and risk factors of idiopathic pneumonia syndrome following hematopoietic stem cell transplantation in children Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation cache = ./cache/cord-018339-tyrlpl94.txt txt = ./txt/cord-018339-tyrlpl94.txt === reduce.pl bib === id = cord-007788-09t52zix author = Wallhult, Elisabeth title = Early and Acute Complications and the Principles of HSCT Nursing Care date = 2017-11-22 pages = extension = .txt mime = text/plain words = 13962 sentences = 766 flesch = 46 summary = Some other relatively rare complications are also covered here: haemorrhagic cystitis (HC), endothelial damage (ED) syndromes including engraftment syndrome (ES), idiopathic pneumonia syndrome (IPS), diffuse alveolar haemorrhage (DAH), transplant-associated microangiopathy (TAM) and sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). Oral damage may be a hallmark of graft versus host disease (GvHD) in patients following allogeneic stem cell transplantation, and the presence of lichenoid hyperkeratotic plaques (diagnostic sign), gingivitis, mucositis, erythema, pain, xerostomia and ulcers may indicate GvHD. The increased risk of infections in patients undergoing haematopoietic stem cell transplantation (HSCT) is well known, and infection is a leading cause of morbidity and mortality. Differential diagnoses will need to be excluded by assessing risk factors, symptoms and lab tests since liver dysfunction can also be seen in sepsis, viral infection, graft versus host disease (GvHD) and iron overload and as a side effect from many of the drugs used in the HSCT setting. cache = ./cache/cord-007788-09t52zix.txt txt = ./txt/cord-007788-09t52zix.txt === reduce.pl bib === id = cord-018302-lmly43rd author = Renaud, Christian title = Respiratory Syncytial Virus and Human Metapneumovirus Infection in Transplant Recipients date = 2016-02-15 pages = extension = .txt mime = text/plain words = 10500 sentences = 459 flesch = 30 summary = Respiratory viral infections due to respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) cause infections in immunocompromised transplant patients ranging from mild upper respiratory infections to severe lower respiratory tract disease with respiratory failure. Surveillance studies of respiratory viruses from transplant centers have established the high frequency and the signifi cant clinical impact of respiratory viral infections in HSCT recipients overall [ 8 -15 , 46 , 47 ] as well as the relative importance of RSV in terms of morbidity and mortality (Table 31 -2 ). A retrospective MDACC study of confi rmed RSV infections in 280 allogeneic HSCT recipients from 1996 to 2009 utilized multivariable logistic regression to demonstrate that lack of ribavirin aerosol therapy at the upper respiratory tract disease stage was an important risk factor associated with RSV LRTI and all-cause mortality [ 99 ] . cache = ./cache/cord-018302-lmly43rd.txt txt = ./txt/cord-018302-lmly43rd.txt === reduce.pl bib === id = cord-018209-v2crgj5w author = Pastores, Stephen M. title = What Has Been Learned from Postmortem Studies? date = 2010-08-19 pages = extension = .txt mime = text/plain words = 5270 sentences = 327 flesch = 31 summary = Infectious and noninfectious pulmonary complications occur in 30-60% of patients with hematological malignancy and recipients of hematopoietic stem cell transplantation (HSCT) and are associated with signifi cant morbidity and mortality [1] . This chapter will review the infectious and noninfectious pulmonary findings that have been described at autopsy in patients with hematological malignancies, including blood and bone marrow transplant recipients. Table 20 .1 lists the infectious and non-infectious pulmonary disorders reported in autopsy studies of patients with hematologic malignancy, including HSCT recipients. Several autopsy series have reported diagnostic discrepancies between premortem clinical diagnosis and postmortem autopsy findings ranging from 5% to 64% in patients with hematologic malignancy and HSCT recipients (Table 20. Infectious and noninfectious pulmonary diseases are commonly found on postmortem autopsy studies in patients with hematological malignancy and HSCT recipients. Major diagnostic discrepancies between clinical premortem diagnoses and postmortem autopsy findings have been reported in patients with hematologic malignancy. cache = ./cache/cord-018209-v2crgj5w.txt txt = ./txt/cord-018209-v2crgj5w.txt === reduce.pl bib === id = cord-030921-wydk9p93 author = Even-Or, Ehud title = Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases date = 2020-08-27 pages = extension = .txt mime = text/plain words = 3715 sentences = 182 flesch = 43 summary = We report our experience with nine pediatric patients with nonmalignant diseases who were transplanted from a haploidentical donor with PT-Cy. From 2015 to 2019, nine children with nonmalignant diseases underwent haploidentical HSCT with PT-Cy, two as a second transplant and seven as primary grafts after upfront serotherapy and busulfan-based myeloablative conditioning. Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for children with a variety of genetic nonmalignant disorders including osteopetrosis, bone marrow failure, and immune deficiencies [1] [2] [3] . Haploidentical HSCT is a readily available alternative option for patients who do not have a matched donor, but engraftment failure, high rates of graft-versus-host disease (GvHD), delayed immune reconstitution and other posttransplant complications are of significant concern. recently reported 27 haploidentical HSCT with PT-Cy for pediatric nonmalignant diseases using a busulfan-based myeloablative conditioning regimen with upfront alemtuzumab showing a high engraftment rate (24 of 27 patients engrafted) and a 2 years overall survival rate of 77.7% [6] . cache = ./cache/cord-030921-wydk9p93.txt txt = ./txt/cord-030921-wydk9p93.txt === reduce.pl bib === id = cord-281026-2avisuge author = Versluys, A.Birgitta title = Strong Association between Respiratory Viral Infection Early after Hematopoietic Stem Cell Transplantation and the Development of Life-Threatening Acute and Chronic Alloimmune Lung Syndromes date = 2010-01-06 pages = extension = .txt mime = text/plain words = 5971 sentences = 316 flesch = 49 summary = title: Strong Association between Respiratory Viral Infection Early after Hematopoietic Stem Cell Transplantation and the Development of Life-Threatening Acute and Chronic Alloimmune Lung Syndromes Alloimmune lung syndromes (allo-LS), including idiopathic pneumonia syndrome, bronchiolitis obliterans syndrome, and bronchiolitis obliterans organizing pneumonia, are severe complications after hematopoietic stem cell transplantation (HSCT). Multivariate analysis showed that respiratory viral infection early after HSCT is an important predictor for the development of allo-LS (P <.0001). To analyze risk factors for outcomes, we considered variables associated with the recipient (age at transplantation, sex, CMV serology, RV positivity, single/multiple viruses), the disease (malignant vs nonmalignant), the donor/transplantation technique (cell source, HLA disparity, donor relationship, conditioning regimen), HSCT complications (allo-LS, acute GVHD [aGVHD], CMV and adenovirus plasma DNA positivity, venoocclusive disease), and relapse. Prospective study of respiratory viral infections in pediatric hemopoietic stem cell transplantation patients cache = ./cache/cord-281026-2avisuge.txt txt = ./txt/cord-281026-2avisuge.txt === reduce.pl bib === id = cord-322606-cx6eh0ff author = Donadieu, J title = Hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: experience of the French neutropenia registry date = 2005-09-05 pages = extension = .txt mime = text/plain words = 2917 sentences = 172 flesch = 51 summary = Our objective was to study the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for Shwachman-Diamond Syndrome (SDS). Our objective was to study the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for Shwachman-Diamond Syndrome (SDS). Polychemotherapy with an AML-like regimen, including high-dose cytarabine, mitoxantrone, VP16 and amsacrine, was administered to one of the five patients with MDS/ leukemia; it resulted in partial disease control and disappearance of the cytogenetic clone, but cytological bone marrow abnormalities persisted (about 5% blasts). We report the outcome of HSCT in 10 patients with SDS and severe hematological complications (bone marrow failure in five cases and myelodysplasia/AL in five cases). Successful allogeneic hematopoietic stem cell transplantation (HSCT) for Shwachman-Diamond syndrome Successful unrelated donor bone marrow transplantation for Shwachman-Diamond syndrome with leukemia Allogeneic bone marrow transplantation in Shwachman-Diamond syndrome with malignant myeloid transformation. Liver failure complicating non-alcoholic steatohepatitis following allogeneic bone marrow transplantation for Shwachman-Diamond syndrome cache = ./cache/cord-322606-cx6eh0ff.txt txt = ./txt/cord-322606-cx6eh0ff.txt === reduce.pl bib === id = cord-018243-hyvu9nuq author = Salman, Huda title = Fibrosing Alveolitis in Hematologic Malignancy Patients Undergoing Hematopoietic Cell Transplantation date = 2010-08-19 pages = extension = .txt mime = text/plain words = 6990 sentences = 357 flesch = 31 summary = This chapter will address the chronic lung complications that lead to pulmonary fibrosis and persistent organ dysfunction in each context with specific focus on hematologic malignancy patients treated using HSCT. Hematologic malignancy patients treated with chemotherapy or chest wall radiation therapy, or those who proceed to receive a HSCT may develop a wide variety inflammatory noninfectious lung disorders that ultimately may lead to pulmonary fibrosis. The diagnosis of drug-induced respiratory disease often is complex because: (1)1 patients may be exposed to several pneumo-toxic drugs concurrently or in sequence due to earlier treatment failure; (2)2 time to onset of pulmonary toxicity may be delayed, making it difficult to ascertain which agent is responsible for the pulmonary reaction; (3)3 the combination of drugs to treat malignant hematologic conditions may lead to unexpected drug interactions, producing enhanced toxicity compared with the toxicity of each agent considered separately; and (4)4 radiation therapy to the chest or TBI. cache = ./cache/cord-018243-hyvu9nuq.txt txt = ./txt/cord-018243-hyvu9nuq.txt === reduce.pl bib === id = cord-276952-nkaow79h author = Sim, Starling A. title = Viral Respiratory Tract Infections in Allogeneic Hematopoietic Stem Cell Transplantation Recipients in the Era of Molecular Testing date = 2018-03-09 pages = extension = .txt mime = text/plain words = 3687 sentences = 201 flesch = 46 summary = Viral respiratory tract infection (vRTI) is a significant cause of morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study aimed to assess the epidemiologic characteristics, risk factors, and outcomes of vRTI occurring in the period from conditioning to 100 days after allo-HSCT in the era of molecular testing. Demographic and clinical data were collected from hospital clinical records using a case report form and included age, sex, underlying disease, previous therapy, stem cell source, conditioning therapy, graft-versus-host disease (GVHD), and outcomes (ie intensive care unit [ICU] admission and death). For patients with RV infection, the number of vRTIs, type of RVs, clinical presentation, antiviral therapy, and outcomes (ie, ICU admission, death, use of mechanical ventilation, and progression to lower respiratory tract infection [LRTI]) were also obtained during the 100-day period. cache = ./cache/cord-276952-nkaow79h.txt txt = ./txt/cord-276952-nkaow79h.txt === reduce.pl bib === id = cord-280763-4bnv2t3f author = Piñana, José Luis title = Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study date = 2019-06-01 pages = extension = .txt mime = text/plain words = 4162 sentences = 190 flesch = 35 summary = METHODS: In this prospective, cross-sectional study, we retrospectively analyzed the effect of inactivated trivalent influenza vaccination on the prevalence of influenza RVI in a consecutive cohort of 136 allo-HSCT adult recipients who developed 161 RVI over 5 flu seasons (from 2013 to 2018). The influenza virus has a significant impact on morbidity and mortality in allogeneic hematopoietic stem cell transplantation patients (allo-HSCT), leading to complications ranging from self-limited upper-respiratory tract infections to life-threatening or fatal pneumonias [1] [2] [3] [4] . We conducted a prospective, cross-sectional, observational epidemiological study of community-acquired respiratory virus (CARV) respiratory tract disease (RTD) in allo-HSCT recipients who developed upper RTD (URTD) and/or lower RTD (LRTD) symptoms after transplant. In this study, we report the prevalence of influenza RTD according to the vaccination status over 5 consecutive influenza seasons in a consecutive series of allo-HSCT recipients with virologically-documented respiratory virus infections (RVIs). cache = ./cache/cord-280763-4bnv2t3f.txt txt = ./txt/cord-280763-4bnv2t3f.txt === reduce.pl bib === id = cord-259625-8lripsf7 author = Piñana, José Luis title = Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients date = 2019-09-03 pages = extension = .txt mime = text/plain words = 3574 sentences = 214 flesch = 48 summary = title: Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients BACKGROUND: There is growing evidence that community‐acquired respiratory virus (CARV) increases the risk of pulmonary invasive fungal disease (IFD) in the allogeneic hematopoietic stem cell transplantation (allo‐HSCT) setting. Generalized estimating equation model identified 4 risk factors for IFD: ATG‐based conditioning regimen [odds ratio (OR) 2.34, 95% confidence interval (CI) 1.05‐5.2, P = .038], CARV lower respiratory tract disease (OR 10.6, 95% CI 3.7‐30.8, P < .0001), CARV infection during the first year after transplant (OR 5.34, 95% CI 1.3‐21.8, P = .014), and corticosteroids during CARV (OR 2.6, 95% CI 1.1‐6.3, P = .03). Abbreviations: ALC, absolute lymphocyte count; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; ANC, absolute neutrophil count; ATG, antithymocyte globulin; CARV, communityacquired respiratory virus; GvHD, graft-versus-host disease; IFD, invasive pulmonary infectious fungal disease; IS, immunosuppressants; LRTD, lower respiratory tract disease. cache = ./cache/cord-259625-8lripsf7.txt txt = ./txt/cord-259625-8lripsf7.txt === reduce.pl bib === id = cord-017883-6a4fkd5v author = Dutta, Ankhi title = Infection Prevention in Pediatric Oncology and Hematopoietic Stem Cell Transplant Recipients date = 2018-07-16 pages = extension = .txt mime = text/plain words = 6243 sentences = 301 flesch = 35 summary = There are various factors which contribute to the increased susceptibility to infections in pediatric hematology/oncology (PHO) and HSCT patients, most prominent of them being disruption of cutaneous and mucosal barriers (oral, gastrointestinal, etc.), microbial gastrointestinal translocation, defects in cell-mediated immunity, and insufficient quantities and inadequate function of phagocytes. Based upon such data in adults, the IDSA Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer state that fluoroquinolone prophylaxis should be considered for high-risk patients with prolonged severe neutropenia [20] . Though some authors suggest that antibiotic prophylaxis should be considered in children undergoing induction chemotherapy for ALL, there is currently insufficient data to inform definitive guidelines for antibiotic prophylaxis to prevent bacterial infections in pediatric oncology patients [19] [20] [21] . cache = ./cache/cord-017883-6a4fkd5v.txt txt = ./txt/cord-017883-6a4fkd5v.txt === reduce.pl bib === id = cord-254183-98o0dssj author = Waggoner, Jesse J. title = Rare and Emerging Viral Infections in Transplant Recipients date = 2013-10-15 pages = extension = .txt mime = text/plain words = 3927 sentences = 236 flesch = 44 summary = In this review, we first discuss viral diagnostics and the developing field of viral discovery and then focus on rare and emerging viruses in the transplant population: human T-cell leukemia virus type 1; hepatitis E virus; bocavirus; KI and WU polyomaviruses; coronaviruses HKU1 and NL63; influenza, H1N1; measles; dengue; rabies; and lymphocytic choriomeningitis virus. Detection and reporting of such rare pathogens in transplant recipients is critical to patient care and improving our understanding of posttransplant infections. In a multicenter review of 85 cases of acute HEV infection, 65.9% of the solid organ transplant (SOT) recipients developed chronic hepatitis of whom 14.3% developed cirrhosis. Cases of lymphocytic choriomeningitis virus (LCMV) transmitted through organ transplantation (4 clusters, including 14 cases and 11 deaths) document the ability of this pathogen to cause severe disease in the immunocompromised host [10, [49] [50] [51] . Human T-cell leukemia virus type I-associated myelopathy following living-donor liver transplantation cache = ./cache/cord-254183-98o0dssj.txt txt = ./txt/cord-254183-98o0dssj.txt === reduce.pl bib === id = cord-272835-6nx4f8ss author = Paulsen, Grant C. title = Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation date = 2017-12-31 pages = extension = .txt mime = text/plain words = 10259 sentences = 553 flesch = 33 summary = Common respiratory viral infections (RVIs) are an important cause of morbidity and mortality following solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT). 18 Paulsen & Danziger-Isakov Published attributable mortality caused by LRTI in HSCT from a respiratory virus varies, up to 28% to 30% in some reports, most commonly involving influenza, RSV, adenovirus, and hMPV. Epidemiology, risk, and attributable mortality The impact of influenza infection in SOT patients can be particularly severe, especially in lung transplant recipients. 78 Reports of the most severe infections are largely based on outcomes following the 2009 H1N1 pandemic; however, a recent retrospective cohort study of Brazilian renal transplant recipients with influenza A between 2009 and 2014 reported a 14% incidence of both intensive care unit (ICU) admission and mortality, which is higher than expected. cache = ./cache/cord-272835-6nx4f8ss.txt txt = ./txt/cord-272835-6nx4f8ss.txt === reduce.pl bib === id = cord-268843-zml9lbve author = Cuvelier, Geoffrey D.E. title = Clinical presentation, immunologic features, and hematopoietic stem cell transplant outcomes for IKBKB immune deficiency date = 2018-10-31 pages = extension = .txt mime = text/plain words = 5812 sentences = 253 flesch = 39 summary = In the Canadian province of Manitoba, our group has periodically managed young infants of Northern Cree First Nations (Aboriginal) descent presenting with early-onset and life-threatening viral, bacterial, Mycobacterial, and fungal infections, clinically resembling severe combined immune deficiency (SCID). Herein we describe the clinical presentation, immunologic features, and HSCT outcomes for the largest cohort of infants with IKBKB immune deficiency resulting from complete loss of IKKβ expression published to date. Supporting a more profound immune deficiency are the other six reported patients with IKBKB mutations, who also presented with severe bacterial, fungal and viral infections as young infants. Like IKBKB immune deficiency, patients with hypermorphic NFKBIA mutations that result in reduced degradation of IκBα, present with multiple and severe bacterial, fungal and viral infections starting at an early age, typically before 3-months. cache = ./cache/cord-268843-zml9lbve.txt txt = ./txt/cord-268843-zml9lbve.txt === reduce.pl bib === id = cord-015389-vwgai4k9 author = nan title = Publication only date = 2009-03-25 pages = extension = .txt mime = text/plain words = 23868 sentences = 1465 flesch = 57 summary = This study evaluates the safety of this approach, in terms of infusion-related toxicity and hematopoietic reconstitution, in 385 consecutive autologous transplantations performed from 4/97 to 9/08 in 348 patients (median age 46; underlying disease: lymphoma in 178, myeloma in 131, acute leukaemia in 17, breast cancer in 22). Patients and methods: Eight pts after allogeneic hematopoetic stem cell transplantation (HSCT) underwent MSCs infusions (median age of pts was 11 years, male/female: 6/2) between 2006 and 2009. Akiyama Tokyo Metropolitan Komagome Hospital (Tokyo, JP) Acute graft-versus-host disease (GVHD) is one of the major factors that have infl uence on the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT). Material and methods: during a 8 years period we have performed 144 stem cells transplantation in 134 patients with different hematological malignancies(AML: 74; ALL: 6; CML: 7; CLL: 1, NHL: 13; Hodgkin Diseases: 16; Multiple myelomas: 24; Aplastic anaemia: 1;Myelofi brosis:1 Ewing Sarcoma: 1; Male:78 Female 66. cache = ./cache/cord-015389-vwgai4k9.txt txt = ./txt/cord-015389-vwgai4k9.txt === reduce.pl bib === id = cord-014712-5u4e00q6 author = nan title = Selected Abstracts from the 100th J Project Meeting, Antalya, Turkey, March 12-14, 2014 date = 2014-08-02 pages = extension = .txt mime = text/plain words = 36900 sentences = 2254 flesch = 49 summary = Ege University Faculty of Medicine, Dept of Pediatric Immunology, Izmir, Turkey Ig class switch recombination deficiencies are rare PIDs (1:500,000 births) with normal or elevated serum IgM and low IgG, IgA and IgE levels, defective or normal somatic hypermutation, defective T/B cooperation (50%), intrinsic B cell defect (50%), susceptibility to bacterial infections begining from the first year of age (impaired B cell immunity) and lack of germinal centres in secondary lymphoid organs. Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK Even following the introduction of biologic disease modifying antirheumatic drugs (DMARDs), a small number of children suffering from severe, refractory autoimmune (AI), rheumatic and/or autoinflammatory disorders will not get into clinical remission (CR) and will potentially further suffer from multiple side-effects of combined and long-term immunosuppressive and anti-inflammatory therapies, in particular severe infections (Marodi L, Casanova JL. cache = ./cache/cord-014712-5u4e00q6.txt txt = ./txt/cord-014712-5u4e00q6.txt === reduce.pl bib === id = cord-292645-5nplyyai author = Hawkinson, Dana title = Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults date = 2013-10-22 pages = extension = .txt mime = text/plain words = 3983 sentences = 212 flesch = 37 summary = In the immunocompromised populations, particularly those undergoing chemotherapy for malignancy and solid organ and hematopoeitic stem cell transplant patients, viral respiratory infections can cause high rates of morbidity and mortality. Several case reports of pediatric immunocompromised hosts, including those with HSCT, leukemia, and liver transplantation, appear in the literature, predominantly with oseltamivir-resistant pandemic influenza H1N1 viral isolates. Despite limited data on its efficacy in clearing RSV infection in solid organ transplant (SOT), ribavirin, especially in the aerosolized form, has additionally been evaluated in conjunction with other therapies, including steroids, IVIG, and palivizumab (see below), and remains a standard part of many local treatment protocols. The current antiviral armamentarium against respiratory viral infections aside from influenza therapies is limited, resulting in few options to impact the associated morbidity and mortality from these illnesses in immunocompromised hosts. Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: detection of extrapulmonary H1N1 RNA and use of intravenous peramivir cache = ./cache/cord-292645-5nplyyai.txt txt = ./txt/cord-292645-5nplyyai.txt === reduce.pl bib === id = cord-291966-5jm5c2lj author = Abandeh, Foad I. title = Outcomes of Hematopoietic Stem Cell Transplant Recipients with Rhinovirus Infection: A Matched, Case-Control Study date = 2013-07-22 pages = extension = .txt mime = text/plain words = 2481 sentences = 135 flesch = 45 summary = title: Outcomes of Hematopoietic Stem Cell Transplant Recipients with Rhinovirus Infection: A Matched, Case-Control Study The controls were defined as patients who underwent HSCT in the same study period, and who were never diagnosed with rhinovirus, whether they had PCR testing of the upper or lower respiratory tracts or not. 1 The following data were collected after reviewing the patients' medical records: age, gender, ethnicity, underlying malignancy, type of HSCT, medical comorbidities, conditioning regimen, immunosuppression and anti-infective prophylaxis at the time of rhinovirus diagnosis, laboratory findings at the time of rhinovirus diagnosis ( ± 7 days), other infections after rhinovirus diagnosis, CMV and EBV infection or disease after transplant, in addition to outcomes at the end of the follow-up period including mortality, hospitalizations and GVHD. Of these, other upper and lower respiratory tract infectious diseases were the cause of recurrent hospitalizations in seven cases and six controls (P ¼ 0.125). cache = ./cache/cord-291966-5jm5c2lj.txt txt = ./txt/cord-291966-5jm5c2lj.txt === reduce.pl bib === id = cord-339931-e2ylkonb author = Mo, Xiao-Dong title = Treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: the role of corticosteroids date = 2018-03-12 pages = extension = .txt mime = text/plain words = 5092 sentences = 247 flesch = 48 summary = We aimed to evaluate the treatments, particularly the role of corticosteroids, in patients with late-onset hemorrhagic cystitis (LOHC) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). There are several therapeutic methods for LOHC, including ensuring appropriate hydration, hematological homeostasis (maintaining high platelet counts, appropriate red cell counts, and levels of clotting factors), pain relief, catheterization for cystoscopic clot extraction, continuous bladder irrigation with normal saline for prevention of clots and bladder tamponade, anti-infection (particularly antiviral), hyperbaric oxygen, estrogen, clotting factors, and keratinocyte growth factor therapies [5] . However, for the patients having concurrent grade II to IV acute GVHD and refractory LOHC, systemic corticosteroid therapy should be added immediately with the use of empirical antiviral therapies or anti-CMV therapy (Fig. 1) . For patients showing unsatisfactory response to anti-infection therapies, additional corticosteroid therapy may help to achieve CR, particularly for those with severe LOHC. Hemorrhagic cystitis following hematopoietic stem cell transplantation: incidence, risk factors and association with CMV reactivation and graft-versushost disease cache = ./cache/cord-339931-e2ylkonb.txt txt = ./txt/cord-339931-e2ylkonb.txt === reduce.pl bib === id = cord-283141-dh8j7lyl author = Haskologlu, Sule title = Clinical, immunological features and follow up of 20 patients with dedicator of cytokinesis 8 (DOCK8) deficiency date = 2020-03-11 pages = extension = .txt mime = text/plain words = 2600 sentences = 172 flesch = 47 summary = [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Since the parental consanguinity rate is high (23.2%) in Turkey, DOCK8 deficiency has an important place among CIDs. Here, we retrospectively evaluated the clinical and immunologic features and treatment modalities of 20 patients with DOCK8 deficiency and follow-up results of hematopoietic stem cell transplant (HSCT) in 11 patients among them as a single-center experience. clinic, DOCK8 deficiency, follow-up, hematopoietic stem cell transplantation, immunological features Hematopoietic stem cell transplantation outcomes for 11 patients with dedicator of cytokinesis 8 (DOCK8) deficiency Successful engraftment of donor marrow after allogeneic hematopoietic cell transplantation in autosomal-recessive hyper-IgE syndrome caused by dedicator of cytokinesis 8 deficiency Clinical and immunological correction of DOCK8 deficiency by allogeneic hematopoietic stem cell transplantation following a reduced toxicity conditioning regimen Successful hematopoietic stem cell transplantation after myeloablative conditioning in three patients with dedicator of cytokinesis 8 deficiency (DOCK8) related Hyper IgE syndrome cache = ./cache/cord-283141-dh8j7lyl.txt txt = ./txt/cord-283141-dh8j7lyl.txt === reduce.pl bib === id = cord-016932-bej10xbf author = Lum, Lawrence G. title = Specific Adoptive T-Cell Therapy for Viral and Fungal Infections date = 2018-06-19 pages = extension = .txt mime = text/plain words = 8079 sentences = 352 flesch = 38 summary = Early adoptive T-cell immunotherapy studies showed that administration of allogeneic virus-specific cytotoxic T lymphocytes (vCTL) can prevent and control viral infections and reconstitute antiviral immunity to cytomegalovirus (CMV) and Epstein-Barr virus (EBV). High-affinity TCR genes can be cloned and transduced into polyclonal T cells to generate a large population of (1) Blood is obtained from donors (autologous, allogeneic, or umbilical cord blood) or is drawn or apheresis is performed to obtain a larger quantity of blood; (2) PBMCs are processed via: (a) cell selection panel using multimers with a pathogen-derived peptide associated with a type-I HLA molecule or column selection after in vitro stimulation of T cells with antigens followed by binding of IFNɣ or CD154-expressing T cells with antibody-coated immu-nomagnetic beads; (b) cell expansion by stimulating the PBMC with APCs produced by antigenic peptide pools, viral transduction, or nucleofection; (c) genetic modification that involves the transfer of high-affinity pathogenspecific TCRs or CARs to redirect the specificity of the T cells; and (d) polyclonal expansion of T cells for 8-14 days and arming with BiAbs directed at the pathogen of interest on one hand and the TCR on the other hand; (3) quality control and release testing; and (4) infusion into patients TCR pathogen-specific CTLs [45] . cache = ./cache/cord-016932-bej10xbf.txt txt = ./txt/cord-016932-bej10xbf.txt === reduce.pl bib === id = cord-005487-vac061r8 author = nan title = Physicians Abstracts: EBMT 2010 date = 2010-04-07 pages = extension = .txt mime = text/plain words = 58975 sentences = 3128 flesch = 58 summary = We retrospectively analyzed 1257 patients (pts), 755 children (age≤18) and 502 adults, receiving fi rst single (n = 1080) or double UCBT (n = 177) in EBMT centers, between 1995 and 2009 , for malignant and non-malignant diseases, who survived at least 100 days from transplantation with neutrophils recovery and without relapse or autologous reconstitution. Prochymal® improves response rates in patients with steroid-refractory acute graft-versus-host disease involving the liver and gut: results of a randomized, placebo-controlled, multicentre phase III trial in GvHD P.J. Martin (1) , J.P. Uberti (2) Background and methods: Steroid-refractory acute GVHD (SR-GVHD) remains a signifi cant and life-threatening complication of allogeneic hematopoietic cell transplantation (HCT). A. Nagler (1) Background: Allogeneic transplantation of hematopoietic stem cells (allo-SCT) from an HLA-matched related (MRD) or unrelated donor (URD) is a curative option for patients (pts) with high-risk hematological disease (HRHD). cache = ./cache/cord-005487-vac061r8.txt txt = ./txt/cord-005487-vac061r8.txt === reduce.pl bib === id = cord-322822-z0ehfrg0 author = Barton, Todd D. title = Viral Pneumonias Other Than Cytomegalovirus in Transplant Recipients date = 2005-11-01 pages = extension = .txt mime = text/plain words = 8012 sentences = 365 flesch = 37 summary = Although case reports of viral pneumonia complicating hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT) have been described for decades, it is only in recent years that larger case series and therapeutic trials have been conducted and reported, providing greater insight into the impact of CARV on these immunosuppressed hosts. After some general observations about CARV infections, this article focuses on this important recent literature and specifically on the four most common pathogens, respiratory syncytial virus (RSV), influenza virus, parainfluenza virus (PIV), and adenovirus. Because these series do not include patients who had asymptomatic infection, overall reported rates of CARV infection are predictably lower, ranging from 4% to 27% in HSCT recipients [1 -3,11 ] to 8% to 21% in lung transplant recipients [8, 12, 13] . cache = ./cache/cord-322822-z0ehfrg0.txt txt = ./txt/cord-322822-z0ehfrg0.txt === reduce.pl bib === id = cord-294906-1m4h116m author = Jarmoliński, Tomasz title = SARS‐CoV‐2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation – a case report date = 2020-09-18 pages = extension = .txt mime = text/plain words = 1482 sentences = 103 flesch = 50 summary = title: SARS‐CoV‐2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation – a case report Here, we report a unique case of a child with viral pneumonia caused by coinfection with human metapneumovirus (MPV), respiratory syncytial virus (RSV), and SARS‐CoV‐2 after HSCT. CONCLUSIONS: Posttransplant care in HSCT recipients with COVID‐19 infection is feasible in regular transplant units, provided the patient does not present with respiratory failure. Early and repeated testing for SARS‐CoV‐2 in posttransplant patients with concomitant infection mitigation strategies should be considered in children after HSCT who develop fever, respiratory symptoms and perhaps gastrointestinal symptoms to control the spread of COVID‐19 both in patients and healthcare workers in hospital environments. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation cache = ./cache/cord-294906-1m4h116m.txt txt = ./txt/cord-294906-1m4h116m.txt === reduce.pl bib === id = cord-347761-wgodcsav author = Cant, Andrew title = Infections in the Immunocompromised date = 2009-10-24 pages = extension = .txt mime = text/plain words = 5992 sentences = 331 flesch = 39 summary = Pneumocystis jiroveci pneumonia (PCP), CMV and Aspergillus are particularly important and well recognized sources of infection in the immunocompromised host; however, other significant pathogens have more recently been identified. Lung biopsy may be particularly important in the diagnosis of fungal infection, especially when there is a negative BAL in patients with persistent signs, symptoms or chest x-ray changes. PCP has historically been associated with HIV but is also a significant cause of morbidity in other groups of immunocompromised patients, particularly those with haematological malignancies, brain tumours requiring prolonged courses of steroids, prolonged neutropaenia or lymphopaenia, and those undergoing HSCT. Prophylaxis to prevent CMV and HSV reactivation is used for children undergoing HSCT and many SOTs. Surveillance in high-risk patients enables pre-emptive treatment to be given before damaging disease occurs. Adenovirus is usually responsible for relatively minor upper respiratory tract or gastrointestinal infection but can result in life-threatening pneumonia, meningitis, encephalitis and disseminated disease in the immunocompromised. cache = ./cache/cord-347761-wgodcsav.txt txt = ./txt/cord-347761-wgodcsav.txt === reduce.pl bib === id = cord-004675-n8mlxe7p author = nan title = 2019 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference date = 2019-02-26 pages = extension = .txt mime = text/plain words = 86427 sentences = 5050 flesch = 46 summary = However, the mean infusion rate per site was similar between patients aged <18 years ( XMEN disease (X-linked Immunodeficency with Magnesium defect, Epstein-Barr virus infection and Neoplasia) is a primary immune deficiency caused by mutations in MAGT1 and characterized by chronic infection with Epstein-Barr virus (EBV), EBV-driven lymphoma, CD4 T-cell lymphopenia, and dysgammaglobulinemia. We present the case of a 1-year old Hispanic infant with a pathogenic variant in MAGT1 gene that clinically manifested with early Pneumocystis jirovecii and cytomegalovirus (CMV) interstitial pneumonia, and EBV chronic infection with good response to intravenous immunoglobulins supplementation without hematopoietic stem cell transplantation or gene therapy. Chief, Laboratory of Clinical Immunology and Microbiology, IDGS, DIR, NIAID, NIH, Bethesda, MD, USA Hypomorphic Recombination Activating Gene 1 (RAG1) mutations result in residual T-and B-cell development in both humans and mice and have been found in patients presenting with delayed-onset combined immune deficiency with granulomas and/or autoimmunity (CID-G/AI). cache = ./cache/cord-004675-n8mlxe7p.txt txt = ./txt/cord-004675-n8mlxe7p.txt === reduce.pl bib === id = cord-014976-546zaoxn author = nan title = Publication only date = 2006-03-08 pages = extension = .txt mime = text/plain words = 51926 sentences = 2983 flesch = 53 summary = In order to evaluate if malignant and non malignant hematological diseases quantitatively and qualitatively affect BM derived MSCs, bone marrow from children with acute lymphoblastic leukemia (ALL diagnosis n=9, different phases of treatment n=29, end of therapy n=10), idiopathic thrombocytopenic purpura (n=16), autoimmune neutropenia (n=12) and control patients (solid tumors without BM involvement, n=30) was harvested and the mononuclear cell (MNC) fraction isolated. Case: In our hospital a total of 3 patients with relapsed Hodgkin's disease underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) from an HLA-identical sibling. We report a case of a young male patient of 19 years old with aggressive MS who was treated with a high-dose immunosuppressive regimen (HDIS) using myeloablation followed by autologous blood stem cell transplantation (ASCT) that has induced a dramatic and long-lasting remission of the disease. cache = ./cache/cord-014976-546zaoxn.txt txt = ./txt/cord-014976-546zaoxn.txt === reduce.pl bib === id = cord-348130-t9tysvr8 author = Cho, Sung-Yeon title = Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea date = 2018-02-27 pages = extension = .txt mime = text/plain words = 9707 sentences = 506 flesch = 34 summary = In addition, the types and risk factors of infectious complications differ according to the stem cell source, donor type, conditioning intensity, region, prophylaxis strategy, and comorbidities, such as graft-versushost disease and invasive fungal infection. Bacteria: consider fluoroquinolone a Fungus: consider prophylaxis during neutropenia, consider PCP prophylaxis Virus: during neutropenia or longer depending on risks HSCT, hematopoietic stem cell transplantation; PCP, Pneumocystis jirovecii pneumonia; GVHD, graft-versus-host disease; TNF-α, tumor necrosis factor-α. In a systematic review and meta-analysis of non-HIV immunocompromised hosts (patients with acute leukemia and recipients of HSCT and solid organ transplant), the incidence of PCP was reduced by 91% (relative risk [RR], 0.09) in trimethoprim/sulfamethoxazole prophylaxis group compared with placebo [69, 70] . Epidemiology and risk factors for invasive fungal diseases among allogeneic hematopoietic stem cell transplant recipients in Korea: results of cache = ./cache/cord-348130-t9tysvr8.txt txt = ./txt/cord-348130-t9tysvr8.txt === reduce.pl bib === id = cord-294150-eq2vkm4i author = Lee, Yoon‐Kyoung title = Late‐onset noninfectious interstitial lung disease following autologous haematopoietic stem cell transplantation in paediatric patients date = 2016-04-12 pages = extension = .txt mime = text/plain words = 3369 sentences = 186 flesch = 43 summary = BACKGROUND AND OBJECTIVE: High‐dose chemotherapy (HDCT) followed by autologous haematopoietic stem cell transplantation (HSCT) is widely used in paediatric cancer patients, but few data about noninfectious interstitial lung disease (ILD) following this treatment are available. High-dose chemotherapy (HDCT) followed by autologous haematopoietic stem cell transplantation (HSCT) is widely used as a treatment for advanced or refractory paediatric solid tumours. Twenty-five parameters were analysed as potential risk factors for noninfectious ILD, including age at HDCT; gender; underlying tumour diagnosis; use of each chemotherapy agent (cisplatin, etoposide, cyclophosphamide, carboplatin, vincristine, ifosfamide, doxorubicin, methotrexate, actinomycin D and bleomycin); use of each HDCT agent (carboplatin, thiotepa, melphalan, cyclophosphamide, etoposide, busulfan and ifosfamide); MIBG treatment; interleukin-2 usage; number of HDCT treatments; total body irradiation; and thoracic field radiation therapy. In this study, the incidence of noninfectious ILD following HDCT and autologous HSCT in paediatric Interstitial lung disease and transplant solid tumour patients was 2.4%. cache = ./cache/cord-294150-eq2vkm4i.txt txt = ./txt/cord-294150-eq2vkm4i.txt === reduce.pl bib === id = cord-005478-5iu38pr6 author = nan title = The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Oral Session date = 2019-07-03 pages = extension = .txt mime = text/plain words = 63350 sentences = 3869 flesch = 58 summary = There were some differences among groups: patients in group-1 were younger (median age 46 years, p< 0.02) were transplanted in more recent year (2015, p< 0.001), received more frequently a regimen based on TBF (thiotepa, fludarabine and busulfan) (83%, p< 0.001) and bone marrow (BM) as source of stem cells (77%, p< 0.001), with no ATG (100%, p< 0.001). Clinical Trial Registry: NCT01217723 Disclosure: None of the Authors have any conflicts of interest to declare O105 Immune reconstitution -based score at diagnosis of CGVHD predicts GVHD severity and overall-survival: A novel prognostication tool for GVHD treatment tailoring Background: Allogeneic stem cell transplantation (HSCT) survivors are at a relevant risk of developing chronic GvHD (cGvHD), which importantly affects quality of life and increases morbidity and mortality. cache = ./cache/cord-005478-5iu38pr6.txt txt = ./txt/cord-005478-5iu38pr6.txt === reduce.pl bib === id = cord-313474-1gux1gsi author = nan title = Physicians Abstracts date = 2015-03-20 pages = extension = .txt mime = text/plain words = 51420 sentences = 2890 flesch = 57 summary = Materials (or patients) and methods: We performed a multicenter, multinational, open-label, randomized study comparing anti-lymphocyte globulin (ATG-Fresenius s ) 10 mg/kg on day -3, -2 and -1 with no ATG in patients with AML (n ¼ 110) or ALL (n ¼ 45) in 1 st complete remission (CR; n ¼ 139) or 2 nd CR (n ¼ 16) who received peripheral blood stem cells from their HLA-identical sibling after standard TBI (12 Gy)/Ccclophosphamide (120 mg/kg) or busulfan (16 mg/ kg)/Cy (120 mg/kg) based myeloablative conditioning regimen. After allo-HSCT, detection of positive WT1 was followed by immunomodulatory therapeutic interventions according to the time from transplant, the presence of active graft-versus-host disease (GvHD) and the general clinical conditions: tapering and/or discontinuation of immunosuppressive drugs (IS), donor lymphocytes infusions (DLI), administration of hypomethylating agents. Introduction: Haploidentical hematopoietic stem cell transplantation(Haplo-HSCT)is feasible option for patients with acute leukemia(AL)at high risk of relapse who do not have HLA-matched related or unrelated donors. cache = ./cache/cord-313474-1gux1gsi.txt txt = ./txt/cord-313474-1gux1gsi.txt === reduce.pl bib === id = cord-005480-yg7salqt author = nan title = Oral Sessions and Working Party date = 2008-03-26 pages = extension = .txt mime = text/plain words = 72626 sentences = 3873 flesch = 55 summary = Standard NIH or Eurolupus cyclophosphamide (CY) protocols and mycophenolate Mofetil (MMF) as induction therapy in severe BILAG A SLE is still associated with 20 % failure, 50% relapse and 10% to 15 % death at 10 years In the absence of a single standard treatment worldwide for refractory SLE, phase I-II studies analysed the use of: a) rituximab (anti CD20 mAb) in more than 1 000 patients showing complete to partial early response around 100% with relapse in 50 to 60% of the cases; b) autologous Hematopoietic Stem Cell Transplantation (HSCT) since 1997 under the auspices of the joined EBMT-EULAR working party, reporting durable remission with reduced or no immunosuppressive drug requirement in 66%, one-third of whom later relapsed to some degree with a 74 ± 7% (n= 62/79) overall survival at 5 years for SLE among the 863 HSCT procedures registered: in 2007 in the EBMT data base. cache = ./cache/cord-005480-yg7salqt.txt txt = ./txt/cord-005480-yg7salqt.txt === reduce.pl bib === id = cord-006466-e1phpqes author = nan title = 2018 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference date = 2018-04-23 pages = extension = .txt mime = text/plain words = 92230 sentences = 5516 flesch = 46 summary = Whole exome sequencing revealed a heterozygous mutation, previously reported (c.1425+1G>T) Conclusions: In summary, this report emphasizes the suspicion of a combined immunodeficiency in the presence of multiple abscesses by Mycoplasma, the usefulness of rDNA 16s in order to achieve proper Objectives: We describe a 15-year-old male patient with novel heterozygous mutation of EP300 gene; his first manifestations were initially characterized by infections, cytopenia and hypogammaglobulinemia suggesting a Common Variable Immunodeficiency (CVID), but later on, persisting lymphopenia was suggestive of a combined immunodeficiency. Conclusions: Close monitoring of immune function in early life for patients with CHH and CID as well as the availability of suitable donors assists in determining management, including HSCT Introduction/Background: Leukocyte Adhesion Deficiency (LAD) represents a group of distinct inherited disorders, which inhibit the normal extravasation of neutrophils and their recruitment to sites of infection or inflammation. cache = ./cache/cord-006466-e1phpqes.txt txt = ./txt/cord-006466-e1phpqes.txt === reduce.pl bib === id = cord-024651-578c9ut5 author = nan title = 2020 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference date = 2020-05-11 pages = extension = .txt mime = text/plain words = 84560 sentences = 5089 flesch = 47 summary = Abstract/Case Report Text Introduction: Mutations in the gene encoding signal transducer and activator of transcription 3 (STAT3) cause autosomal dominant hyperimmunoglobulin E syndrome (AD-HIES) characterized by recurrent skin and sinopulmonary infections, atopic dermatitis, and elevated serum immunoglobulin E (IgE) levels. Objective: The purpose of this study is to increase awareness and improve diagnosis of primary immune deficiency (PID) in the heterogenous group of patients with autoimmune cytopenia (AIC) by identifying clinical characteristics and laboratory biomarkers that distinguish those with underlying PID, disease activity and guide mechanism-based targeted therapy. 7 Chief, Laboratory of Clinical Immunology and Microbiology/National Institute of Allergy and Infectious Diseases, NIAID/National Institutes of Health, NIH Abstract/Case Report Text We have previously used the artificial thymic organoid (ATO) system, based on the 3D aggregation and culture of a delta-like canonical Notch ligand 4-expressing stromal cell line (MS5-Dll4) with CD34+ cells, to study T cell differentiation from CD34+ cells obtained from patients carrying defects that are intrinsic to hematopoietic cells (RAG1-2, AK2, IL2RG) or that affect thymus development (DiGeorge syndrome). cache = ./cache/cord-024651-578c9ut5.txt txt = ./txt/cord-024651-578c9ut5.txt === reduce.pl bib === id = cord-009997-oecpqf1j author = nan title = 2018 ASPHO ABSTRACTS date = 2018-03-31 pages = extension = .txt mime = text/plain words = 182060 sentences = 10342 flesch = 48 summary = Completed cranial radiation and proceeded to allogeneic stem cell transplant with unrelated cord marrow donor and is disease free at approximately day +200.Case 2: 5 year-old female diagnosed with FLT3 and MLL negative AML and completed treatment per COG AAML1031 study on the low risk arm without Bortezomib. Design/Method: This study was a retrospective chart review that included patients 3 to 23 years old with sickle cell disease type SS and S 0 followed at St. Christopher's Hospital for Children. Background: Hydroxyurea, chronic blood transfusion, and bone marrow transplantation can reduce complications, and improve survival in sickle cell disease (SCD), but are associated with a significant decisional dilemma because of the inherent risk-benefit tradeoffs, and the lack of comparative studies. Brown University -Hasbro Children's Hospital, Providence, Rhode Island, United States Background: Despite clinical advances in the treatment of sickle cell disease (SCD) in pediatric and young adult patients, pain remains a significant source of disease-related morbidity. cache = ./cache/cord-009997-oecpqf1j.txt txt = ./txt/cord-009997-oecpqf1j.txt === reduce.pl bib === id = cord-005460-ezrn8cva author = nan title = Physicians – Poster Session date = 2017-07-28 pages = extension = .txt mime = text/plain words = 287105 sentences = 15681 flesch = 56 summary = Still the optimal combination of immunosuppressive agents with PTCy should be elucidated for different types of SCTs. We report the 2-year update of the prospective NCT02294552 single-center trial that evaluated risk-adapted graft-versushost disease (GVHD) prophylaxis with PTCy in related, unrelated and haploidentical SCTs. 200 adult patients (median age 32 y.o., range: 18-62) with hematologic malignancies, including AML (47.5%), ALL (26.5%), CML (10.5%), MDS (4%), and lymphomas (11.5%), were enrolled in the study. Long-term follow-up from the prospective randomized phase III multicenter trial comparing a standard GvHD prophylaxis with cyclosporine A and methotrexate with or without additional pretransplant ATLG (Grafalon, previously ATG-FRESENIUS S) (given 20 mg/kg/day, days − 3 to − 1) in unrelated donor hematopoietic cell transplantation after myeloablative conditioning resulted in a significant reduction of acute and chronic GvHD without compromising relapse rate and survival [1, 2, 3] . cache = ./cache/cord-005460-ezrn8cva.txt txt = ./txt/cord-005460-ezrn8cva.txt === reduce.pl bib === id = cord-005453-4057qib7 author = nan title = The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session date = 2019-07-03 pages = extension = .txt mime = text/plain words = 275771 sentences = 16876 flesch = 56 summary = To compare the safety and efficacy of prophylactic DLI for prevention of relapse after allogeneic peripheral blood stem cell transplantation from haploidentical donors (HID-SCT) and matched-sibling donors (MSD-SCT) in patients with very high-risk acute myeloid leukemia (AML), we performed a retrospective, observational cohort study enrolled in 21 HID-SCT and 13 MSD-SCT recipients. The aim of this study is to identify the prognostic impact of pre-transplant TIM3 levels on early and late transplant related complications as well as post-transplant relapse and survival Methods: A total of 177 hematopoietic stem cell transplantation (HSCT) recipients with an initial diagnosis of acute leukemia [median age: 36(16-66) years; male/ female: 111/66] were included in the study. cache = ./cache/cord-005453-4057qib7.txt txt = ./txt/cord-005453-4057qib7.txt ===== Reducing email addresses Creating transaction Updating adr table ===== Reducing keywords cord-005446-jr3yj4o2 cord-000121-duwfxeyt cord-010130-28bt3x25 cord-005448-5fznfp5p cord-006492-pc1vayyl cord-007791-nzjm6zyq cord-015922-5wwy0m2k cord-018319-tylkbh4h cord-006856-b1w25ob5 cord-005482-v5iayczy cord-003866-3gwbc7z9 cord-018906-03nynqtq cord-261827-uprv8a2k cord-017302-xez0zso3 cord-279638-jr1mbh7s cord-266359-uf1ao1x1 cord-018339-tyrlpl94 cord-007788-09t52zix cord-018302-lmly43rd cord-018209-v2crgj5w cord-030921-wydk9p93 cord-281026-2avisuge cord-322606-cx6eh0ff cord-276952-nkaow79h cord-280763-4bnv2t3f cord-254183-98o0dssj cord-259625-8lripsf7 cord-272835-6nx4f8ss cord-015389-vwgai4k9 cord-018243-hyvu9nuq cord-017883-6a4fkd5v cord-268843-zml9lbve cord-014712-5u4e00q6 cord-292645-5nplyyai cord-291966-5jm5c2lj cord-339931-e2ylkonb cord-016932-bej10xbf cord-283141-dh8j7lyl cord-005487-vac061r8 cord-322822-z0ehfrg0 cord-294906-1m4h116m cord-347761-wgodcsav cord-004675-n8mlxe7p cord-348130-t9tysvr8 cord-294150-eq2vkm4i cord-014976-546zaoxn cord-005478-5iu38pr6 cord-313474-1gux1gsi cord-005480-yg7salqt cord-006466-e1phpqes cord-009997-oecpqf1j cord-005460-ezrn8cva cord-024651-578c9ut5 cord-005453-4057qib7 Creating transaction Updating wrd table ===== Reducing urls cord-010130-28bt3x25 cord-007791-nzjm6zyq cord-018339-tyrlpl94 cord-007788-09t52zix cord-272835-6nx4f8ss cord-339931-e2ylkonb cord-283141-dh8j7lyl cord-348130-t9tysvr8 cord-005478-5iu38pr6 cord-005480-yg7salqt cord-009997-oecpqf1j cord-005460-ezrn8cva cord-005453-4057qib7 Creating transaction Updating url table ===== Reducing named entities cord-005446-jr3yj4o2 cord-000121-duwfxeyt cord-010130-28bt3x25 cord-005448-5fznfp5p cord-006492-pc1vayyl cord-007791-nzjm6zyq cord-015922-5wwy0m2k cord-018319-tylkbh4h cord-006856-b1w25ob5 cord-003866-3gwbc7z9 cord-018906-03nynqtq cord-005482-v5iayczy cord-017302-xez0zso3 cord-261827-uprv8a2k cord-279638-jr1mbh7s cord-266359-uf1ao1x1 cord-007788-09t52zix cord-018209-v2crgj5w cord-018302-lmly43rd cord-281026-2avisuge cord-030921-wydk9p93 cord-322606-cx6eh0ff cord-018243-hyvu9nuq cord-280763-4bnv2t3f cord-276952-nkaow79h cord-254183-98o0dssj cord-259625-8lripsf7 cord-272835-6nx4f8ss cord-017883-6a4fkd5v cord-018339-tyrlpl94 cord-268843-zml9lbve cord-292645-5nplyyai cord-015389-vwgai4k9 cord-014712-5u4e00q6 cord-339931-e2ylkonb cord-291966-5jm5c2lj cord-016932-bej10xbf cord-283141-dh8j7lyl cord-322822-z0ehfrg0 cord-294906-1m4h116m cord-347761-wgodcsav cord-348130-t9tysvr8 cord-005487-vac061r8 cord-294150-eq2vkm4i cord-004675-n8mlxe7p cord-014976-546zaoxn cord-005478-5iu38pr6 cord-005480-yg7salqt cord-313474-1gux1gsi cord-006466-e1phpqes cord-024651-578c9ut5 cord-009997-oecpqf1j cord-005460-ezrn8cva cord-005453-4057qib7 Creating transaction Updating ent table ===== Reducing parts of speech cord-000121-duwfxeyt cord-005446-jr3yj4o2 cord-010130-28bt3x25 cord-005448-5fznfp5p cord-007791-nzjm6zyq cord-006492-pc1vayyl cord-018906-03nynqtq cord-015922-5wwy0m2k cord-003866-3gwbc7z9 cord-018319-tylkbh4h cord-261827-uprv8a2k cord-017302-xez0zso3 cord-279638-jr1mbh7s cord-006856-b1w25ob5 cord-018339-tyrlpl94 cord-005482-v5iayczy cord-266359-uf1ao1x1 cord-007788-09t52zix cord-018302-lmly43rd cord-030921-wydk9p93 cord-281026-2avisuge cord-018209-v2crgj5w cord-322606-cx6eh0ff cord-018243-hyvu9nuq cord-280763-4bnv2t3f cord-254183-98o0dssj cord-276952-nkaow79h cord-259625-8lripsf7 cord-017883-6a4fkd5v cord-292645-5nplyyai cord-272835-6nx4f8ss cord-268843-zml9lbve cord-291966-5jm5c2lj cord-339931-e2ylkonb cord-283141-dh8j7lyl cord-016932-bej10xbf cord-322822-z0ehfrg0 cord-294906-1m4h116m cord-347761-wgodcsav cord-348130-t9tysvr8 cord-015389-vwgai4k9 cord-294150-eq2vkm4i cord-014712-5u4e00q6 cord-313474-1gux1gsi cord-005487-vac061r8 cord-014976-546zaoxn cord-005480-yg7salqt cord-024651-578c9ut5 cord-005478-5iu38pr6 cord-006466-e1phpqes cord-004675-n8mlxe7p cord-009997-oecpqf1j cord-005453-4057qib7 cord-005460-ezrn8cva Creating transaction Updating pos table Building ./etc/reader.txt cord-005453-4057qib7 cord-009997-oecpqf1j cord-005460-ezrn8cva cord-005453-4057qib7 cord-005460-ezrn8cva cord-005480-yg7salqt number of items: 54 sum of words: 1,633,704 average size in words: 30,253 average readability score: 44 nouns: patients; cell; cells; disease; treatment; transplantation; years; patient; transplant; stem; results; risk; donor; days; months; therapy; study; age; group; day; blood; time; infection; survival; infections; pts; conditioning; analysis; diagnosis; graft; cases; relapse; data; dose; response; incidence; recipients; methods; children; marrow; mortality; range; bone; levels; regimen; donors; prophylaxis; grade; case; use verbs: receiving; used; including; showed; associated; following; compare; developed; reported; increased; performed; treat; undergo; identify; based; related; presented; reduced; observed; evaluating; found; remaining; occurs; matched; diagnosed; improve; requiring; died; analyzed; given; suggests; achieved; described; demonstrated; considered; reveal; resulted; lead; decreased; assessing; cause; relapsed; according; transplanted; detected; starting; confirmed; determine; range; defined adjectives: median; clinical; high; acute; severe; significant; hematopoietic; chronic; first; immune; non; low; higher; respiratory; primary; overall; normal; autologous; unrelated; early; peripheral; positive; pediatric; post; specific; viral; lower; anti; different; complete; old; negative; second; common; free; multiple; refractory; pre; single; pulmonary; haploidentical; retrospective; total; long; recurrent; oral; patient; genetic; effective; secondary adverbs: respectively; also; however; well; significantly; prior; previously; still; often; even; therefore; especially; retrospectively; currently; later; statistically; recently; frequently; particularly; clinically; highly; successfully; alone; potentially; less; commonly; mainly; usually; least; early; subsequently; now; overall; finally; approximately; furthermore; initially; additionally; moreover; relatively; cyclophosphamide; typically; daily; generally; yet; fully; newly; already; almost; far pronouns: we; our; it; their; he; she; his; its; them; they; her; i; us; one; itself; themselves; him; you; my; itma; your; mg; il-12r1; igg4; himself; herself; ≥65; αat; İt; tdcs; s382; pt#3; prets; pcr)-positive; p078; p061; p029; ourselves; ours; o139; n=760; mrnas; mass).four; ly294002; low-(score; jak1-and; immunosuppression-0,26; il12rb1; il-7ra; il-15-driven proper nouns: HSCT; GVHD; T; mg; CMV; SCT; HLA; OS; AML; CD34; GvHD; NK; ATG; ASCT; CI; kg; IV; HCT; G; RIC; EBV; Hospital; CR; II; CD4; aGVHD; B; PCR; University; Background; MRD; BM; CD8; CD3; CSF; DLI; SCID; NRM; VOD; CT; MM; MDS; TBI; ECP; PFS; TRM; C; CVID; RSV; PBSC keywords: hsct; patient; cmv; cell; gvhd; aml; ric; infection; hla; ebv; day; cd8; cd34; result; nrm; hct; disease; asct; vod; transplantation; rsv; hospital; cd4; background; atg; university; tbi; scid; pid; pcr; pbsc; mrd; ivig; ips; hlh; ecp; ebmt; cvid; csf; cgd; year; trm; recipient; pulmonary; mutation; method; january; introduction; immunology; dna one topic; one dimension: patients file(s): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091773/ titles(s): Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study three topics; one dimension: patients; patients; patients file(s): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091844/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086569/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123147/ titles(s): Physicians – Poster Session | 2019 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference | Respiratory Syncytial Virus and Human Metapneumovirus Infection in Transplant Recipients five topics; three dimensions: patients cell hsct; patients patient cells; patients cell transplantation; patients infection respiratory; pulmonary hsct may file(s): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091844/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086569/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103192/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123147/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123073/ titles(s): Physicians – Poster Session | 2019 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference | 19th Meeting of the Austrian Society of Transplantation, Transfusion, and Genetics, October 26–28, 2005 | Respiratory Syncytial Virus and Human Metapneumovirus Infection in Transplant Recipients | Fibrosing Alveolitis in Hematologic Malignancy Patients Undergoing Hematopoietic Cell Transplantation Type: cord title: keyword-hsct-cord date: 2021-05-25 time: 00:26 username: emorgan patron: Eric Morgan email: emorgan@nd.edu input: keywords:hsct ==== make-pages.sh htm files ==== make-pages.sh complex files ==== make-pages.sh named enities ==== making bibliographics id: cord-291966-5jm5c2lj author: Abandeh, Foad I. title: Outcomes of Hematopoietic Stem Cell Transplant Recipients with Rhinovirus Infection: A Matched, Case-Control Study date: 2013-07-22 words: 2481 sentences: 135 pages: flesch: 45 cache: ./cache/cord-291966-5jm5c2lj.txt txt: ./txt/cord-291966-5jm5c2lj.txt summary: title: Outcomes of Hematopoietic Stem Cell Transplant Recipients with Rhinovirus Infection: A Matched, Case-Control Study The controls were defined as patients who underwent HSCT in the same study period, and who were never diagnosed with rhinovirus, whether they had PCR testing of the upper or lower respiratory tracts or not. 1 The following data were collected after reviewing the patients'' medical records: age, gender, ethnicity, underlying malignancy, type of HSCT, medical comorbidities, conditioning regimen, immunosuppression and anti-infective prophylaxis at the time of rhinovirus diagnosis, laboratory findings at the time of rhinovirus diagnosis ( ± 7 days), other infections after rhinovirus diagnosis, CMV and EBV infection or disease after transplant, in addition to outcomes at the end of the follow-up period including mortality, hospitalizations and GVHD. Of these, other upper and lower respiratory tract infectious diseases were the cause of recurrent hospitalizations in seven cases and six controls (P ¼ 0.125). abstract: The impact of rhinovirus in hematopoietic stem cell transplant (HSCT) recipients is not well defined. A retrospective, matched, case-control study of HSCT recipients with rhinovirus was conducted between 2009 and 2011. Controls were matched for timing relative to transplant, malignancy, and stem cell source. There were 47 cases and 94 controls. Cases and controls did not differ with respect to age, gender, ethnicity, donor source, malignancy, conditioning regimen, immunosuppression, antimicrobial prophylaxis, or significant comorbidities. There were no differences in need for ICU care, 100 day mortality, hospice discharge, relapse of disease, GVHD or development of disease or infection due to CMV or EBV. Other infectious complications after rhinovirus diagnosis were also equal. However, there was an increased number of recurrent hospitalizations from any cause among cases (46.8% vs. 24.5%, P=0.007). Recurrent hospitalizations due to any infection were also more common in cases (34% vs. 14.9%, P=0.015). For patients who were diagnosed with rhinovirus pre-transplant (n=13), there was no difference in outcomes compared to matched controls. HSCT recipients with rhinovirus have an increased risk of hospital readmission. However, there was no difference in outcomes compared to matched controls. Transplantation in patients with active rhinovirus infection appears to be safe. url: https://www.nature.com/articles/bmt2013100.pdf doi: 10.1038/bmt.2013.100 id: cord-322822-z0ehfrg0 author: Barton, Todd D. title: Viral Pneumonias Other Than Cytomegalovirus in Transplant Recipients date: 2005-11-01 words: 8012 sentences: 365 pages: flesch: 37 cache: ./cache/cord-322822-z0ehfrg0.txt txt: ./txt/cord-322822-z0ehfrg0.txt summary: Although case reports of viral pneumonia complicating hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT) have been described for decades, it is only in recent years that larger case series and therapeutic trials have been conducted and reported, providing greater insight into the impact of CARV on these immunosuppressed hosts. After some general observations about CARV infections, this article focuses on this important recent literature and specifically on the four most common pathogens, respiratory syncytial virus (RSV), influenza virus, parainfluenza virus (PIV), and adenovirus. Because these series do not include patients who had asymptomatic infection, overall reported rates of CARV infection are predictably lower, ranging from 4% to 27% in HSCT recipients [1 -3,11 ] to 8% to 21% in lung transplant recipients [8, 12, 13] . abstract: Community-acquired respiratory viruses (CARVs) are frequent causes of upper and lower respiratory tract infections in tranplant recipients. In most series, respiratory syncytial virus and parainfluenza are the most common CARVs, followed by influenza and adenovirus. Significant morbidity and mortality are associated with these infections, particularly when they progress to pneumonia or when they are associated with bacterial or fungal coinfections. Outcomes are also poor with adenovirus, frequently reflecting disseminated infection. Efforts to prevent morbidity and mortality from CARV infection should focus on prevention, because treatment options are limited with inconclusive data to support their efficacy. url: https://www.sciencedirect.com/science/article/pii/S0272523105000584 doi: 10.1016/j.ccm.2005.06.004 id: cord-261827-uprv8a2k author: Brodszki, Nicholas title: Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions date: 2016-01-15 words: 4395 sentences: 228 pages: flesch: 54 cache: ./cache/cord-261827-uprv8a2k.txt txt: ./txt/cord-261827-uprv8a2k.txt summary: title: Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment available for severe combined immunodeficiency (SCID); although, there is a high incidence of severe infections and an increased risk of graft-versus host-disease (GvHD) with HSCT. Haploidentical HSCT protocols utilizing extensively ex vivo T-cell depleted grafts (CliniMACs system) have proven efficient in preventing GvHD, but cause a delay in early T-cell recovery that increases the risk of viral infections. Here, we present a novel approach for treating SCID that combines selective depletion of GvHD-inducing alpha/beta (α/β) T-cells from the haploidentical HSCT graft with a subsequent donor lymphocyte infusion (DLI) enriched for CD45RO+ memory T-cells. Unselected donor lymphocyte infusions (DLIs), which are frequently used as a "tool" to boost anti-viral immunity post-transplant, harbor a significant risk of inducing severe GvHD in the haploidentical setting [6, 7] . abstract: BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment available for severe combined immunodeficiency (SCID); although, there is a high incidence of severe infections and an increased risk of graft-versus host-disease (GvHD) with HSCT. Early intervention is a crucial prognostic factor and a HLA-haploidentical parental donor is often available. Haploidentical HSCT protocols utilizing extensively ex vivo T-cell depleted grafts (CliniMACs system) have proven efficient in preventing GvHD, but cause a delay in early T-cell recovery that increases the risk of viral infections. Here, we present a novel approach for treating SCID that combines selective depletion of GvHD-inducing alpha/beta (α/β) T-cells from the haploidentical HSCT graft with a subsequent donor lymphocyte infusion (DLI) enriched for CD45RO+ memory T-cells. RESULTS: Our patient was diagnosed with SCID (T-B + NK+ phenotype). At 9 months of age, he received a T cell receptor(TCR)α/β-cell depleted graft from his haploidentical mother, following a reduced intensity conditioning regimen with no additional GvHD prophylaxis. Engraftment was rapid with complete donor chimerism and no signs of GvHD. However, at 12 weeks post HSCT, the patient was still T-cell lymphopenic with clinical symptoms of multiple severe viral infections. Consequently, therapeutic DLIs were initiated for enhanced anti-viral immunity. The patient was treated with CD45RA+ depleted haploidentical maternal donor lymphocytes enriched from unmobilized whole blood, and a total T-cell dose of no more than 25 x10(3) CD3+ cells/kg with >99.9 % purity of CD3 + CD45RO+ memory T-cells was transferred. Following the DLI, a prompt increase in CD3 + CD4+ and CD3 + CD8+ counts was observed with a subsequent clearance of viral infections. No acute or chronic GvHD was observed. CONCLUSIONS: Automated depletion of CD45RA+ naïve T-cells from unmobilized whole blood is a simple and rapid strategy to provide unmanipulated DLIs, with a potentially broad repertoire of pathogen specific memory T-cells. In the haploidentical setting, CD45RA+ depleted DLIs can be safely administered at low T-cell doses for efficient enhancement of viral immunity and limited risk of GvHD. We demonstrate the successful use of this approach following TCR-α/β-cell depleted HSCT for the treatment of SCID. url: https://doi.org/10.1186/s13023-016-0385-3 doi: 10.1186/s13023-016-0385-3 id: cord-279638-jr1mbh7s author: Calore, Elisabetta title: Treatment of Acute Graft-versus-Host Disease in Childhood with Extracorporeal Photochemotherapy/Photopheresis: The Padova Experience date: 2015-07-14 words: 5592 sentences: 279 pages: flesch: 57 cache: ./cache/cord-279638-jr1mbh7s.txt txt: ./txt/cord-279638-jr1mbh7s.txt summary: Acute graft-versus-host disease (aGVHD) is the major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Update on the mechanism of action and on clinical efficacy of extracorporeal photopheresis in the treatment of acute and chronic graft versus host disease in children Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies Role of extracorporeal photopheresis (ECP) in treatment of steroid-refractory acute graft-versus-host disease Extracorporeal Photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients abstract: Acute graft-versus-host disease (aGVHD) is the major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Systemic steroid treatment represents the first-line therapy for aGVHD and is associated with a response rate of 30% to 60%. Steroid-resistant patients have a poor prognosis with high transplantation-related mortality (TRM). Several second-line therapies have been proposed for the management of unresponsive aGVHD, without proven beneficial effects on patients' outcome or overall long-term survival. For these reasons, extracorporeal photochemotherapy/photopheresis (ECP), a cell-based approach to control GVHD that spares generalized immunosuppression, seems to be promising. In this study, we report the outcome of 72 consecutive pediatric patients treated with ECP between 1997 and 2013 for aGVHD. Among them, 21 patients had steroid-resistant aGVHD, 42 had steroid-dependent aGVHD, and 9 did not receive steroid as first-line therapy because of clinical contraindications. A complete response was obtained in 72% of patients, a partial response was observed in 11%, and there was no response in 17% of patients. At day +180, TRM was 4% in the whole cohort; TRM was 3% and 20% among responders and nonresponders to ECP, respectively (P < .0001). The 5-year overall survival was 71%, showing a difference between responders and nonresponders of 78% and 30%, respectively (P = .0004). The 5-year time to progression of primary disease was 81%, without any significant difference between the 2 groups. Moreover, the 5-year progression-free survival of primary disease was 72%, with a significant difference (P = .0007) between responders (79%) and nonresponders (30%) to ECP. In conclusion, this study demonstrates that ECP is highly effective in aGVHD without a negative impact on primary disease. url: https://doi.org/10.1016/j.bbmt.2015.07.007 doi: 10.1016/j.bbmt.2015.07.007 id: cord-347761-wgodcsav author: Cant, Andrew title: Infections in the Immunocompromised date: 2009-10-24 words: 5992 sentences: 331 pages: flesch: 39 cache: ./cache/cord-347761-wgodcsav.txt txt: ./txt/cord-347761-wgodcsav.txt summary: Pneumocystis jiroveci pneumonia (PCP), CMV and Aspergillus are particularly important and well recognized sources of infection in the immunocompromised host; however, other significant pathogens have more recently been identified. Lung biopsy may be particularly important in the diagnosis of fungal infection, especially when there is a negative BAL in patients with persistent signs, symptoms or chest x-ray changes. PCP has historically been associated with HIV but is also a significant cause of morbidity in other groups of immunocompromised patients, particularly those with haematological malignancies, brain tumours requiring prolonged courses of steroids, prolonged neutropaenia or lymphopaenia, and those undergoing HSCT. Prophylaxis to prevent CMV and HSV reactivation is used for children undergoing HSCT and many SOTs. Surveillance in high-risk patients enables pre-emptive treatment to be given before damaging disease occurs. Adenovirus is usually responsible for relatively minor upper respiratory tract or gastrointestinal infection but can result in life-threatening pneumonia, meningitis, encephalitis and disseminated disease in the immunocompromised. abstract: Infections in the immunocompromised differ significantly from those in the immunocompetent. They can be more serious, more often life threatening, more difficult to diagnose and are caused by more unusual organisms. Children can be immunocompromised for a variety of reasons and the numbers, worldwide, are growing. url: https://www.ncbi.nlm.nih.gov/pubmed/20204751/ doi: 10.1007/978-1-4419-0981-7_1 id: cord-007791-nzjm6zyq author: Carreras, Enric title: Noninfectious Pulmonary Complications date: 2018-09-12 words: 2611 sentences: 185 pages: flesch: 46 cache: ./cache/cord-007791-nzjm6zyq.txt txt: ./txt/cord-007791-nzjm6zyq.txt summary: These distinct but related pathways of inflammation culminate in the recruitment of immune cells to the lung leading to tissue damage and dysfunction (Cooke and Yanik 2016) Incidence -The strict methodology required to establish IPS diagnosis and the increased use of RIC have reduced its incidence of 20% to 25% observed 20 years ago (at that time IPS was called idiopathic pneumonia) -This reduction runs in parallel of the improvement in the diagnostic methodologies to detect infectious pathogens. A recent prospective study showed that among 198 patients included after day +100, the cumulative incidence of LONIPC is 20%, and that of BOS is 11% at 3 years among allo-HSCT recipients (Bergeron et al. Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation abstract: Lung injury occurs frequently following HSCT and significantly contributes to morbidity and mortality in the immediate post transplant period and in the months and years that follow. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123376/ doi: 10.1007/978-3-030-02278-5_52 id: cord-018319-tylkbh4h author: Chemaly, Roy F. title: Respiratory Viruses date: 2011-01-04 words: 8852 sentences: 467 pages: flesch: 37 cache: ./cache/cord-018319-tylkbh4h.txt txt: ./txt/cord-018319-tylkbh4h.txt summary: Historically, the most common causes of respiratory infections in cancer patients were thought to be opportunistic bacteria and fungi, but newer diagnostic methods have revealed that respiratory viruses can cause serious morbidity and mortality in such patients, including leukemia patients and hematopoietic stem cell transplant (HSCT) recipients. Many viruses are known to cause respiratory tract infections, but the most common in hospitalized cancer patients are influenza viruses, respiratory syncytial virus (RSV), and parainfluenza viruses (PIV) [1, 2] . Although the combination of ribavirin and intravenous immunoglobulin (IVIG) or palivizumab has not been evaluated in a randomized trial, it is sometimes used in severely ill patients with RSV pneumonia, especially HSCT recipients, given that they have high mortality rates from this infection [3, 11, 14] . However, because other viruses can produce the same syndrome and influenza infection can produce other respiratory syndromes, a confirmatory test detecting the virus or viral antigens in nasal washes, throat swabs, respiratory tract secretions, or bronchoalveolar lavage specimens is needed in sporadic cases and in immunocompromised patients. abstract: The respiratory viruses as a group are the most common cause of an acute infectious illness in developed societies. The immunocompromised state of many cancer patients constitutes the basis for the frequent failure of the host to promote a normal and rapid recovery from an acute respiratory viral infection and results in a more severe and prolonged infection that causes significant morbidity and mortality in these patients. Those respiratory viruses that are most prevalent and most prone to produce lower respiratory illnesses and pneumonia in healthy hosts, RSV, influenza viruses, and parainfluenza viruses, are those most likely to cause severe illness and pneumonia leading to hospitalization in immunocompromised persons. However, viruses less prone to produce a lower respiratory illness but that are highly prevalent, such as rhinoviruses, may frequently be associated with severe illness. The limited availability of antivirals and vaccines for the acute respiratory viruses means that these infections will continue to be important for many years and dictate a need for utilizing infection control procedures as much as possible, particularly in hospitals and institutions, so as to minimize spread. Efforts to develop specific vaccines are important as their use could prevent as well as reduce exposure of cancer patients to these viruses. Development of specific antivirals is important for use in immunocompromised patients as normal recovery mechanisms may be seriously impaired. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123165/ doi: 10.1007/978-1-60761-644-3_32 id: cord-348130-t9tysvr8 author: Cho, Sung-Yeon title: Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea date: 2018-02-27 words: 9707 sentences: 506 pages: flesch: 34 cache: ./cache/cord-348130-t9tysvr8.txt txt: ./txt/cord-348130-t9tysvr8.txt summary: In addition, the types and risk factors of infectious complications differ according to the stem cell source, donor type, conditioning intensity, region, prophylaxis strategy, and comorbidities, such as graft-versushost disease and invasive fungal infection. Bacteria: consider fluoroquinolone a Fungus: consider prophylaxis during neutropenia, consider PCP prophylaxis Virus: during neutropenia or longer depending on risks HSCT, hematopoietic stem cell transplantation; PCP, Pneumocystis jirovecii pneumonia; GVHD, graft-versus-host disease; TNF-α, tumor necrosis factor-α. In a systematic review and meta-analysis of non-HIV immunocompromised hosts (patients with acute leukemia and recipients of HSCT and solid organ transplant), the incidence of PCP was reduced by 91% (relative risk [RR], 0.09) in trimethoprim/sulfamethoxazole prophylaxis group compared with placebo [69, 70] . Epidemiology and risk factors for invasive fungal diseases among allogeneic hematopoietic stem cell transplant recipients in Korea: results of abstract: Hematopoietic stem cell transplantation (HSCT) is a treatment for hematologic malignancies, immune deficiencies, or genetic diseases, ect. Recently, the number of HSCTs performed in Korea has increased and the outcomes have improved. However, infectious complications account for most of the morbidity and mortality after HSCT. Post-HSCT infectious complications are usually classified according to the time after HSCT: pre-engraftment, immediate post-engraftment, and late post-engraftment period. In addition, the types and risk factors of infectious complications differ according to the stem cell source, donor type, conditioning intensity, region, prophylaxis strategy, and comorbidities, such as graft-versushost disease and invasive fungal infection. In this review, we summarize infectious complications after HSCT, focusing on the Korean perspectives. url: https://doi.org/10.3904/kjim.2018.036 doi: 10.3904/kjim.2018.036 id: cord-010130-28bt3x25 author: Crocchiolo, R. title: Infections after T‐replete haploidentical transplantation and high‐dose cyclophosphamide as graft‐versus‐host disease prophylaxis date: 2015-03-26 words: 3519 sentences: 175 pages: flesch: 46 cache: ./cache/cord-010130-28bt3x25.txt txt: ./txt/cord-010130-28bt3x25.txt summary: RESULTS: After a median follow‐up of 23 months, cumulative incidence of viral infections was 70% (95% confidence interval [CI] 59–81) at 100 days and 77% (95% CI 67–87) at 1 year; 35 of 65 patients at risk had CMV reactivation (54%) and the rate of polyomavirus‐virus‐associated cystitis was 19% (13/70). In the present analysis, we described infectious complications after unmanipulated, T-cell replete haplo-HSCT using post-transplant Cy in 70 consecutive patients and found, aside from a high incidence of viral infections/reactivations, especially in the early posttransplant period, a quite low incidence of late bacterial infections, together with a very low incidence of IFIs after day +180 (2 events in the overall 11 observed). In conclusion, the present single-center data on 70 consecutive patients receiving T-cell replete haplo-HSCT with post-transplant Cy confirm a high rate of viral infections before day +100 and a lower incidence of infections afterward, suggesting a satisfactory although non-optimal immune reconstitution after this type of transplantation. abstract: BACKGROUND: Recently, a platform of T‐cell replete haploidentical hematopoietic stem cell transplantation (haplo‐HSCT) using post‐transplant cyclophosphamide (Cy) has shown high reproducibility and acceptable safety profile. METHOD: This prospective cohort analysis allowed us to collect data on infections among 70 consecutive recipients of haplo‐HSCT affected by various hematologic malignancies. RESULTS: After a median follow‐up of 23 months, cumulative incidence of viral infections was 70% (95% confidence interval [CI] 59–81) at 100 days and 77% (95% CI 67–87) at 1 year; 35 of 65 patients at risk had CMV reactivation (54%) and the rate of polyomavirus‐virus‐associated cystitis was 19% (13/70). Cumulative incidence of bacterial and fungal infections at 1 year were 63% (95% CI 51–75) and 12% (95% CI 4–19), respectively. Of note, only 1 invasive fungal infection occurred beyond 1 year after transplant (day +739). CONCLUSION: In conclusion, despite a high rate of viral infections in the early period, present data suggest a satisfactory infectious profile after T‐cell replete haplo‐HSCT using post‐transplant Cy. These results may help clinicians to improve both prophylactic and therapeutic antimicrobial strategies in this emerging haploidentical setting. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169814/ doi: 10.1111/tid.12365 id: cord-268843-zml9lbve author: Cuvelier, Geoffrey D.E. title: Clinical presentation, immunologic features, and hematopoietic stem cell transplant outcomes for IKBKB immune deficiency date: 2018-10-31 words: 5812 sentences: 253 pages: flesch: 39 cache: ./cache/cord-268843-zml9lbve.txt txt: ./txt/cord-268843-zml9lbve.txt summary: In the Canadian province of Manitoba, our group has periodically managed young infants of Northern Cree First Nations (Aboriginal) descent presenting with early-onset and life-threatening viral, bacterial, Mycobacterial, and fungal infections, clinically resembling severe combined immune deficiency (SCID). Herein we describe the clinical presentation, immunologic features, and HSCT outcomes for the largest cohort of infants with IKBKB immune deficiency resulting from complete loss of IKKβ expression published to date. Supporting a more profound immune deficiency are the other six reported patients with IKBKB mutations, who also presented with severe bacterial, fungal and viral infections as young infants. Like IKBKB immune deficiency, patients with hypermorphic NFKBIA mutations that result in reduced degradation of IκBα, present with multiple and severe bacterial, fungal and viral infections starting at an early age, typically before 3-months. abstract: IKBKB immune deficiency is a rare but life-threatening primary immunodeficiency disorder, involving activation defects in adaptive and innate immunity. We present sixteen cases of a homozygous IKBKB mutation (c.1292dupG) in infants characterized by early-onset bacterial, viral, fungal and Mycobacterial infections. In most cases, T- and B-cells were quantitatively normal, but phenotypically naïve, with severe hypogammaglobulinemia. T-cell receptor excision circles were normal, meaning newborn screening by TREC analysis would miss IKBKB cases. Although IKBKB immune deficiency does not meet traditional laboratory based definitions for SCID, this combined immune deficiency appears to be at least as profound. Urgent HSCT, performed in eight patients, remains the only known curative therapy, although only three patients are survivors. Ongoing infections after transplant remain a concern, and may be due to combinations of poor social determinants of health, secondary graft failure, and failure of HSCT to replace non-hematopoietic cells important in immune function and dependent upon IKK/NF-κB pathways. url: https://doi.org/10.1016/j.clim.2018.10.019 doi: 10.1016/j.clim.2018.10.019 id: cord-322606-cx6eh0ff author: Donadieu, J title: Hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: experience of the French neutropenia registry date: 2005-09-05 words: 2917 sentences: 172 pages: flesch: 51 cache: ./cache/cord-322606-cx6eh0ff.txt txt: ./txt/cord-322606-cx6eh0ff.txt summary: Our objective was to study the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for Shwachman-Diamond Syndrome (SDS). Our objective was to study the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for Shwachman-Diamond Syndrome (SDS). Polychemotherapy with an AML-like regimen, including high-dose cytarabine, mitoxantrone, VP16 and amsacrine, was administered to one of the five patients with MDS/ leukemia; it resulted in partial disease control and disappearance of the cytogenetic clone, but cytological bone marrow abnormalities persisted (about 5% blasts). We report the outcome of HSCT in 10 patients with SDS and severe hematological complications (bone marrow failure in five cases and myelodysplasia/AL in five cases). Successful allogeneic hematopoietic stem cell transplantation (HSCT) for Shwachman-Diamond syndrome Successful unrelated donor bone marrow transplantation for Shwachman-Diamond syndrome with leukemia Allogeneic bone marrow transplantation in Shwachman-Diamond syndrome with malignant myeloid transformation. Liver failure complicating non-alcoholic steatohepatitis following allogeneic bone marrow transplantation for Shwachman-Diamond syndrome abstract: Our objective was to study the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for Shwachman-Diamond Syndrome (SDS). Among 71 SDS patients included in the French Severe Chronic Neutropenia Registry, 10 received HSCT between 1987 and 2004 in five institutions. The indications were bone marrow failure in five cases, and myelodysplastic syndrome (MDS) or leukemia in five cases. The median follow-up of patients who survived without relapse is 6.9 years (3.1–16.8 years). The conditioning regimen consisted of a busulfan–cyclophosphamide combination (n=6) or total body irradiation plus chemotherapy (n=4). Six patients received stem cells from unrelated donors and four from identical siblings. Engraftment was complete in eight patients and unassessable in two patients. These latter two patients died of infections 32 and 36 days after HSCT, with grade IV graft-versus-host disease and multiorgan dysfunction. A third patient died from an acute respiratory distress syndrome 17 months after HSCT with progressive granulocytic sarcoma. One patient had an MDS relapse 4 months after HSCT and died 10 months later. The overall 5-year event-free survival rate is 60±15%. We conclude that HSCT is feasible for patients with SDS who develop bone marrow failure or malignant transformation. url: https://www.ncbi.nlm.nih.gov/pubmed/16151425/ doi: 10.1038/sj.bmt.1705141 id: cord-018339-tyrlpl94 author: Dsouza, Kevin title: Late Noninfectious Pulmonary Complications in Hematopoietic Stem Cell Transplantation date: 2019-07-09 words: 5734 sentences: 316 pages: flesch: 30 cache: ./cache/cord-018339-tyrlpl94.txt txt: ./txt/cord-018339-tyrlpl94.txt summary: A recent prospective study to evaluate the epidemiology of late non onset noninfectious complications after allogenic stem cell transplant reported a cumulative incidence of BOS 36 months posttransplant at 10.7% [9] . In a study of 9550 patients of post-allogenic HCST recipients, HLA disparity, female-to-male HSCT, and peripheral blood stem cell transplant (PBSCT) were associated with an increased risk of developing OP. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants Concurrent treatment with a tumor necrosis factor-alpha inhibitor and veno-venous extracorporeal membrane oxygenation in a post-hematopoietic stem cell transplant patient with idiopathic pneumonia syndrome: a case report Incidence, clinical features, and risk factors of idiopathic pneumonia syndrome following hematopoietic stem cell transplantation in children Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation abstract: Hematopoietic stem cell transplantation (HSCT) is an established therapeutic modality for a number of malignant and nonmalignant conditions. Pulmonary complications following HSCT are associated with increased mortality and morbidity. These complications may be classified into infectious versus noninfectious, and early versus late based on the time of occurrence post-transplant. Thus, exclusion of infectious etiologies is the first step in the diagnoses of pulmonary complications. Late onset noninfectious pulmonary complications typically occur 3 months post-transplant. Bronchiolitis obliterans is the major contributor to late-onset pulmonary complications, and its clinical presentation, pathogenesis, and current therapeutic approaches are discussed. Idiopathic pneumonia syndrome is another important complication which usually occurs early, although its onset may be delayed. Organizing pneumonia is important to recognize due to its responsiveness to corticosteroids. Other late onset noninfectious pulmonary complications discussed here include pulmonary venoocclusive disease, pulmonary cytolytic thrombi, pleuroparenchymal fibroelastosis, thoracic air leak syndrome, and posttransplant lymphoproliferative disorders. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123191/ doi: 10.1007/978-3-319-74588-6_51 id: cord-017883-6a4fkd5v author: Dutta, Ankhi title: Infection Prevention in Pediatric Oncology and Hematopoietic Stem Cell Transplant Recipients date: 2018-07-16 words: 6243 sentences: 301 pages: flesch: 35 cache: ./cache/cord-017883-6a4fkd5v.txt txt: ./txt/cord-017883-6a4fkd5v.txt summary: There are various factors which contribute to the increased susceptibility to infections in pediatric hematology/oncology (PHO) and HSCT patients, most prominent of them being disruption of cutaneous and mucosal barriers (oral, gastrointestinal, etc.), microbial gastrointestinal translocation, defects in cell-mediated immunity, and insufficient quantities and inadequate function of phagocytes. Based upon such data in adults, the IDSA Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer state that fluoroquinolone prophylaxis should be considered for high-risk patients with prolonged severe neutropenia [20] . Though some authors suggest that antibiotic prophylaxis should be considered in children undergoing induction chemotherapy for ALL, there is currently insufficient data to inform definitive guidelines for antibiotic prophylaxis to prevent bacterial infections in pediatric oncology patients [19] [20] [21] . abstract: Pediatric patients with malignancies and transplant recipients are at high risk of infection-related morbidity and mortality. Children at the highest risk for infections are those with acute myeloid leukemia (AML), relapsed acute lymphoblastic leukemia (ALL), and hematopoietic stem cell transplant recipients (HSCT). These patients are at high risk for life-threatening bacterial, viral, and fungal infections which are associated with prolonged hospital stay, poor quality of life, and increased healthcare cost and death. Recognition of risk factors which predisposes them to infections, early identification of signs and symptoms of infections, prompt diagnosis, and empiric/definitive treatment are the mainstay in reducing infection-related morbidity and mortality. Infection control and prevention programs also play a crucial role in preventing hospital-acquired infections in these immunosuppressed hosts. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122566/ doi: 10.1007/978-3-319-98122-2_16 id: cord-000121-duwfxeyt author: Dzieciątkowski, Tomasz title: Prevalence of human herpesvirus 6 antibodies and DNA in allogeneic stem cell transplant patients: two-year single centre experience date: 2008-05-30 words: 2549 sentences: 137 pages: flesch: 49 cache: ./cache/cord-000121-duwfxeyt.txt txt: ./txt/cord-000121-duwfxeyt.txt summary: title: Prevalence of human herpesvirus 6 antibodies and DNA in allogeneic stem cell transplant patients: two-year single centre experience INTRODUCTION: Human herpesvirus 6 (HHV-6) has been recognized as a potentially significant pathogen in hemopoietic stem cell transplant (HSCT) recipients. In a recent study we summarized retrospective results of the determination of HHV infection status in allogeneic stem cell transplant recipients. As infections with HHV-6 are rarely accompanied by clinical symptoms, our first aim was to compare HHV-6 infection status, measured as viral DNA presence in the blood in the post-transplantation period and patients'' anti-HHV-6 serological status by detection of IgG and IgM antibodies. In the two patients who had a single HHV-6-positive blood sample, viral DNA was detected at a later time. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients abstract: INTRODUCTION: Human herpesvirus 6 (HHV-6) has been recognized as a potentially significant pathogen in hemopoietic stem cell transplant (HSCT) recipients. Different clinical manifestations have been described, including fever, skin rash, bone marrow suppression, and encephalitis. MATERIALS AND METHODS: A retrospective review of a group of 26 adult recipients of allogeneic HSCTs was conducted. Serum samples taken before transplant were examined for the presence of specific anti-HHV-6 IgM and IgG antibodies. After transplantation, quantitative real-time PCR was used to determine viral load in plasma samples from days 0–80 post-transplant. RESULTS: HHV-6 DNA was detected in plasma samples in 8 (30%) of the 26 recipients between days 18 and 40 after transplantation. All of them developed fever of unknown origin and over 50% had graft-versus-host disease features. Three individuals from this group died during detectable HHV-6 viremia. Another two recipients showed a single positive PCR result at a later time. Infection with HHV-6 was thus confirmed in 10 (38.5%) of the 26 graft recipients. CONCLUSIONS: There is a high frequency of detectable HHV-6 viral load in stem cell transplant recipients in Poland. Further investigation to monitor HHV-6 reactivation in graft recipients will be important to improve outcome for these patients. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766496/ doi: 10.1007/s00005-008-0021-6 id: cord-030921-wydk9p93 author: Even-Or, Ehud title: Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases date: 2020-08-27 words: 3715 sentences: 182 pages: flesch: 43 cache: ./cache/cord-030921-wydk9p93.txt txt: ./txt/cord-030921-wydk9p93.txt summary: We report our experience with nine pediatric patients with nonmalignant diseases who were transplanted from a haploidentical donor with PT-Cy. From 2015 to 2019, nine children with nonmalignant diseases underwent haploidentical HSCT with PT-Cy, two as a second transplant and seven as primary grafts after upfront serotherapy and busulfan-based myeloablative conditioning. Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment option for children with a variety of genetic nonmalignant disorders including osteopetrosis, bone marrow failure, and immune deficiencies [1] [2] [3] . Haploidentical HSCT is a readily available alternative option for patients who do not have a matched donor, but engraftment failure, high rates of graft-versus-host disease (GvHD), delayed immune reconstitution and other posttransplant complications are of significant concern. recently reported 27 haploidentical HSCT with PT-Cy for pediatric nonmalignant diseases using a busulfan-based myeloablative conditioning regimen with upfront alemtuzumab showing a high engraftment rate (24 of 27 patients engrafted) and a 2 years overall survival rate of 77.7% [6] . abstract: Allogeneic hematopoietic stem cell transplantation (HSCT) is curative for a variety of nonmalignant disorders including osteopetrosis, bone marrow failures, and immune deficiencies. Haploidentical HSCT is a readily available option in the absence of a matched donor, but engraftment failure and other post-transplant complications are a concern. Post-transplant cyclophosphamide (PT-Cy) regimens are gaining popularity and recent reports show promising results. We report our experience with nine pediatric patients with nonmalignant diseases who were transplanted from a haploidentical donor with PT-Cy. From 2015 to 2019, nine children with nonmalignant diseases underwent haploidentical HSCT with PT-Cy, two as a second transplant and seven as primary grafts after upfront serotherapy and busulfan-based myeloablative conditioning. Patient’s diseases included osteopetrosis (n = 5), congenital amegakaryocytic thrombocytopenia (n = 2), hemophagocytic lymphohistiocytosis (n = 1), and Wiskott Aldrich syndrome (n = 1). Two patients failed to engraft following upfront PT-Cy transplants, one was salvaged with a second PT-Cy transplant, and the other with a CD34+ selected graft. None of the patients suffered from graft-versus-host disease. Three patients died from early posttransplant infectious complications and six patients are alive and well. In conclusion, haploidentical HSCT with PT-Cy is a feasible option for pediatric patients with nonmalignant diseases lacking a matched donor. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450679/ doi: 10.1038/s41409-020-01040-9 id: cord-005446-jr3yj4o2 author: Forrest, D L title: Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study date: 2003-06-10 words: 4931 sentences: 278 pages: flesch: 46 cache: ./cache/cord-005446-jr3yj4o2.txt txt: ./txt/cord-005446-jr3yj4o2.txt summary: title: Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study We evaluated 40 patients undergoing high-dose chemo/ radiotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) (allogeneic (22) , autologous (18) ) to determine the safety and feasibility of administering low molecular weight heparin (LMWH) as hepatic veno-occlusive disease (VOD) prophylaxis. We evaluated 40 patients undergoing high-dose chemo/ radiotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) (allogeneic (22) , autologous (18) ) to determine the safety and feasibility of administering low molecular weight heparin (LMWH) as hepatic veno-occlusive disease (VOD) prophylaxis. Daily patient evaluation while receiving dalteparin included patient weight, oxygen saturation, liver size, presence of right upper quadrant (RUQ) abdominal pain, ascites or pleural effusions, complete blood count (CBC), serum creatinine, assessment of bleeding and GVHD; adverse events, grading of RRT and the number of red cell and platelet transfusions were recorded; liver function tests (bilirubin, AST, ALT, alkaline phosphatase), INR, PTT and fibrinogen were measured twice weekly. abstract: We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) (allogeneic (22), autologous (18)) to determine the safety and feasibility of administering low molecular weight heparin (LMWH) as hepatic veno-occlusive disease (VOD) prophylaxis. Patients received a once daily subcutaneous injection of dalteparin 2500 anti-Xa i.u. commencing the day prior to starting HDCT, and continuing until day +30 post HSCT or hospital discharge, whichever came first. Dosage adjustments were made for patients developing renal failure. All bleeding episodes were recorded and graded and VOD was diagnosed and graded according to Seattle criteria. At 100 days of follow-up, the overall survival and probability of regimen-related mortality were 85 and 15%, respectively. Nine patients developed VOD. The probability of developing VOD post allogeneic and autologous HSCT was 28% (95% CI, 6–45) and 17% (95% CI, 0–32), respectively. VOD was graded as moderate (n=8) and severe (n=1). VOD resolved in all cases except for one patient who died secondary to severe VOD and multiorgan failure. Clinically significant bleeding episodes occurred in three patients; 24 patients developed minor bleeding not requiring specific therapy. All bleeding episodes resolved. These results suggest that LMWH for VOD prophylaxis is safe with a low incidence of serious bleeding events. Whether it is superior to unfractionated heparin, however, is unknown and should be addressed within the context of a randomized controlled trial. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091773/ doi: 10.1038/sj.bmt.1704087 id: cord-266359-uf1ao1x1 author: Hakki, Morgan title: The clinical impact of coronavirus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients date: 2015-04-15 words: 3261 sentences: 157 pages: flesch: 38 cache: ./cache/cord-266359-uf1ao1x1.txt txt: ./txt/cord-266359-uf1ao1x1.txt summary: BACKGROUND: Compared to other respiratory viruses, relatively little is known about the clinical impact of coronavirus (CoV) infection after hematopoietic stem cell transplant (HSCT) or in patients with hematologic malignancies. CONCLUSIONS: CoV is frequently detected in HSCT and hematologic malignancy patients in whom suspicion for a respiratory viral infection exists, but is less likely to progress to lower respiratory tract disease than most other respiratory viruses. The clinical significance of respiratory viruses such as influenza, respiratory syncytial virus (RSV), parainfluenza viruses (PIVs), human metapneumovirus (hMPV), rhinovirus (RhV), and adenovirus (AdV) in patients with hematologic malignancies or recipients of autologous or allogeneic hematopoietic stem cell transplant (HSCT) is well described [1] [2] [3] [4] [5] [6] [7] [8] . In conclusion, we found that CoV is detected frequently in patients with hematologic malignancies and HSCT recipients in whom suspicion for a respiratory viral infection exists, but is associated with less LRTD than other respiratory viruses except RhV/EnV. abstract: BACKGROUND: Compared to other respiratory viruses, relatively little is known about the clinical impact of coronavirus (CoV) infection after hematopoietic stem cell transplant (HSCT) or in patients with hematologic malignancies. OBJECTIVES: To characterize the role of CoV in respiratory tract infections among HSCT and hematologic malignancy patients. STUDY DESIGN: We conducted a retrospective review of all cases of CoV infection documented by polymerase chain reaction, (PCR)-based testing on nasopharyngeal and bronchoalveolar lavage fluid samples between June 2010 and 2013. Cases of CoV infection occurring in HSCT and hematologic malignancy patients were identified and the clinical characteristics of these cases were compared to other respiratory viruses. RESULTS: CoV was identified in 2.6% (n = 43) of all samples analyzed (n = 1661) and in 6.8% of all samples testing positive for a respiratory virus (n = 631). 33 of 38 (86.8%) of patients in whom CoV was identified were HSCT and hematologic malignancy patients. Among these patients, CoV was detected in 9.7% of unique infection episodes, with only rhinovirus/enterovirus (RhV/EnV) infection being more common. Group I CoV subtypes accounted for 76.3% of cases, and 57% of infections were diagnosed between December and March. CoV infection was associated with upper respiratory tract symptoms in most patients, similar to other respiratory viruses. Possible and proven lower respiratory tract disease was less common compared to other respiratory viruses except RhV/EnV. CONCLUSIONS: CoV is frequently detected in HSCT and hematologic malignancy patients in whom suspicion for a respiratory viral infection exists, but is less likely to progress to lower respiratory tract disease than most other respiratory viruses. url: https://www.ncbi.nlm.nih.gov/pubmed/26071326/ doi: 10.1016/j.jcv.2015.04.012 id: cord-283141-dh8j7lyl author: Haskologlu, Sule title: Clinical, immunological features and follow up of 20 patients with dedicator of cytokinesis 8 (DOCK8) deficiency date: 2020-03-11 words: 2600 sentences: 172 pages: flesch: 47 cache: ./cache/cord-283141-dh8j7lyl.txt txt: ./txt/cord-283141-dh8j7lyl.txt summary: [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Since the parental consanguinity rate is high (23.2%) in Turkey, DOCK8 deficiency has an important place among CIDs. Here, we retrospectively evaluated the clinical and immunologic features and treatment modalities of 20 patients with DOCK8 deficiency and follow-up results of hematopoietic stem cell transplant (HSCT) in 11 patients among them as a single-center experience. clinic, DOCK8 deficiency, follow-up, hematopoietic stem cell transplantation, immunological features Hematopoietic stem cell transplantation outcomes for 11 patients with dedicator of cytokinesis 8 (DOCK8) deficiency Successful engraftment of donor marrow after allogeneic hematopoietic cell transplantation in autosomal-recessive hyper-IgE syndrome caused by dedicator of cytokinesis 8 deficiency Clinical and immunological correction of DOCK8 deficiency by allogeneic hematopoietic stem cell transplantation following a reduced toxicity conditioning regimen Successful hematopoietic stem cell transplantation after myeloablative conditioning in three patients with dedicator of cytokinesis 8 deficiency (DOCK8) related Hyper IgE syndrome abstract: Biallelic mutations in the dedicator of cytokinesis 8 gene (DOCK8) cause a progressive combined immunodeficiency (CID) characterized by susceptibility to severe viral skin infections, atopic diseases, recurrent respiratory infections, and malignancy. Hematopoietic stem cell transplantation (HSCT) is only curative treatment for the disease. However, there is limited information about long‐term outcome of HSCT and its effect to protect against cancer development in DOCK8‐deficient patients. In this study, we retrospectively evaluated clinical and immunologic characteristics of 20 DOCK8‐deficient patients and outcome of 11 patients who underwent HSCT. We aimed to report the experience of our center and the result of the largest transplantation series of DOCK8 deficiency in our country. Median follow‐up time is 71 months (min‐max: 16‐172) in all patients and 48 months (min‐max: 5‐84) in transplanted patients. Atopic dermatitis (18/20), recurrent respiratory tract infections (17/20), and food allergy (14/20) were the most frequent clinical manifestations. Failure to thrive (13/20), liver problems (12/20), bronchiectasis (11/20), chronic diarrhea (10/21), and autism spectrum disorders (3/20) were remarkable findings in our series. Elevated IgE level (20/20) and eosinophilia (17/20), low IgM level (15/20), and decreased CD3+ T (10/20) and CD4+ T (11/20) cell count were prominent laboratory findings. HSCT was performed in 11 patients. All patients achieved adequate engraftment and showed improvement in their clinical and immunologic findings. Atopic dermatitis and food allergies improved in all patients, and their dietary restriction was stopped except one patient who was transplanted recently. The frequency of infections was decreased. The overall survival is 91% in HSCT‐received patients and 80% in all. HSCT at the earliest possible period with most suitable donor‐ and patient‐specific appropriate conditioning regimen and GvHD prophylaxis is lifesaving for DOCK8 deficiency cases. url: https://doi.org/10.1111/pai.13236 doi: 10.1111/pai.13236 id: cord-292645-5nplyyai author: Hawkinson, Dana title: Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults date: 2013-10-22 words: 3983 sentences: 212 pages: flesch: 37 cache: ./cache/cord-292645-5nplyyai.txt txt: ./txt/cord-292645-5nplyyai.txt summary: In the immunocompromised populations, particularly those undergoing chemotherapy for malignancy and solid organ and hematopoeitic stem cell transplant patients, viral respiratory infections can cause high rates of morbidity and mortality. Several case reports of pediatric immunocompromised hosts, including those with HSCT, leukemia, and liver transplantation, appear in the literature, predominantly with oseltamivir-resistant pandemic influenza H1N1 viral isolates. Despite limited data on its efficacy in clearing RSV infection in solid organ transplant (SOT), ribavirin, especially in the aerosolized form, has additionally been evaluated in conjunction with other therapies, including steroids, IVIG, and palivizumab (see below), and remains a standard part of many local treatment protocols. The current antiviral armamentarium against respiratory viral infections aside from influenza therapies is limited, resulting in few options to impact the associated morbidity and mortality from these illnesses in immunocompromised hosts. Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: detection of extrapulmonary H1N1 RNA and use of intravenous peramivir abstract: Respiratory viruses cause significant morbidity and mortality in immunocompromised populations such as stem cell transplant and solid organ transplant patients. Few viruses causing respiratory tract infection have an approved therapy, and many of the viruses have no therapeutic options at all. In this article, we describe novel agents under development for treatment options against several respiratory viruses. url: https://www.ncbi.nlm.nih.gov/pubmed/24146257/ doi: 10.1007/s11908-013-0370-0 id: cord-005448-5fznfp5p author: Holtan, S G title: CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies date: 2010-03-08 words: 2589 sentences: 120 pages: flesch: 39 cache: ./cache/cord-005448-5fznfp5p.txt txt: ./txt/cord-005448-5fznfp5p.txt summary: title: CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies The combination of fludarabine and melphalan as a reduced-intensity conditioning (RIC) regimen extends allogeneic hematopoietic SCT (HSCT) as a therapeutic option for elderly or frail patients with relapsed, refractory or other high-risk hematologic malignancies. Factors analyzed for association with survival included demographic and disease factors (age at transplant, sex, lymphoid vs myeloid disease, karyotype and blast percentage in those with MDS and leukemia, disease status at transplant, previous HSCT, and previous chemotherapy for solid tumors), donor/graft factors (CD34 þ cell dose, graft source, related vs unrelated graft, degree of HLA match, CMV serostatus and ABO match), and post transplant factors (time to neutrophil, lymphocyte and platelet engraftment, day þ 100 chimerism status, development of and severity of acute GVHD, development of and severity of chronic GVHD). abstract: The combination of fludarabine and melphalan as a reduced-intensity conditioning (RIC) regimen extends allogeneic hematopoietic SCT (HSCT) as a therapeutic option for elderly or frail patients with relapsed, refractory or other high-risk hematologic malignancies. Whether any modifiable factors exist that could improve survival before or immediately after HSCT is unknown. We reviewed the medical records of the first 50 patients at our institution to undergo fludarabine/melphalan RIC from September 2000 to September 2007 to determine factors associated with survival. A total of 25 (50%) patients had undergone prior HSCT and as such was a high-risk group of patients. On multivariate analysis, CD34(+) cell dose greater than 5.5 × 10(6) per kg (risk ratio (RR) 0.44, 95% CI 0.19–0.98, P=0.02) and full donor chimerism at day +100 (RR 0.17, 95% CI 0.06–0.64, P=0.002) remained independent prognostic factors. In our series, achievement of full donor chimerism at day +100 was associated with an approximately 70% 2-year survival, a favorable outcome in this high-risk group of patients. Although the infused CD34(+) cell dose is a modifiable variable, whether donor lymphocyte infusions or other immunologic interventions should be performed to promote the establishment of full chimerism early post transplant remains unknown. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091776/ doi: 10.1038/bmt.2010.49 id: cord-294906-1m4h116m author: Jarmoliński, Tomasz title: SARS‐CoV‐2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation – a case report date: 2020-09-18 words: 1482 sentences: 103 pages: flesch: 50 cache: ./cache/cord-294906-1m4h116m.txt txt: ./txt/cord-294906-1m4h116m.txt summary: title: SARS‐CoV‐2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation – a case report Here, we report a unique case of a child with viral pneumonia caused by coinfection with human metapneumovirus (MPV), respiratory syncytial virus (RSV), and SARS‐CoV‐2 after HSCT. CONCLUSIONS: Posttransplant care in HSCT recipients with COVID‐19 infection is feasible in regular transplant units, provided the patient does not present with respiratory failure. Early and repeated testing for SARS‐CoV‐2 in posttransplant patients with concomitant infection mitigation strategies should be considered in children after HSCT who develop fever, respiratory symptoms and perhaps gastrointestinal symptoms to control the spread of COVID‐19 both in patients and healthcare workers in hospital environments. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation abstract: BACKGROUND: Respiratory viral infections are known causes of mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Here, we report a unique case of a child with viral pneumonia caused by coinfection with human metapneumovirus (MPV), respiratory syncytial virus (RSV), and SARS‐CoV‐2 after HSCT. CASE REPORT: A 9‐year‐old girl with acute lymphoblastic leukemia underwent allogeneic HSCT from a matched, unrelated donor. During the posttransplant period, in profound leukopenia (below 10 leukocytes/µL), she was diagnosed with SARS‐CoV‐2, MPV and RSV pneumonia and was treated with ribavirin and chloroquine. Before leukocyte recovery, the girl became asymptomatic, and SARS‐CoV‐2 and RSV clearance was achieved. The shedding of SARS‐CoV‐2 stopped before immune system recovery, and one may hypothesize that the lack of an inflammatory response might have been a contributing factor to the mild clinical course. CONCLUSIONS: Posttransplant care in HSCT recipients with COVID‐19 infection is feasible in regular transplant units, provided the patient does not present with respiratory failure. Early and repeated testing for SARS‐CoV‐2 in posttransplant patients with concomitant infection mitigation strategies should be considered in children after HSCT who develop fever, respiratory symptoms and perhaps gastrointestinal symptoms to control the spread of COVID‐19 both in patients and healthcare workers in hospital environments. Training of staff and the availability of personal protective equipment are crucial for containing SARS‐CoV‐2 infection. url: https://doi.org/10.1111/petr.13875 doi: 10.1111/petr.13875 id: cord-294150-eq2vkm4i author: Lee, Yoon‐Kyoung title: Late‐onset noninfectious interstitial lung disease following autologous haematopoietic stem cell transplantation in paediatric patients date: 2016-04-12 words: 3369 sentences: 186 pages: flesch: 43 cache: ./cache/cord-294150-eq2vkm4i.txt txt: ./txt/cord-294150-eq2vkm4i.txt summary: BACKGROUND AND OBJECTIVE: High‐dose chemotherapy (HDCT) followed by autologous haematopoietic stem cell transplantation (HSCT) is widely used in paediatric cancer patients, but few data about noninfectious interstitial lung disease (ILD) following this treatment are available. High-dose chemotherapy (HDCT) followed by autologous haematopoietic stem cell transplantation (HSCT) is widely used as a treatment for advanced or refractory paediatric solid tumours. Twenty-five parameters were analysed as potential risk factors for noninfectious ILD, including age at HDCT; gender; underlying tumour diagnosis; use of each chemotherapy agent (cisplatin, etoposide, cyclophosphamide, carboplatin, vincristine, ifosfamide, doxorubicin, methotrexate, actinomycin D and bleomycin); use of each HDCT agent (carboplatin, thiotepa, melphalan, cyclophosphamide, etoposide, busulfan and ifosfamide); MIBG treatment; interleukin-2 usage; number of HDCT treatments; total body irradiation; and thoracic field radiation therapy. In this study, the incidence of noninfectious ILD following HDCT and autologous HSCT in paediatric Interstitial lung disease and transplant solid tumour patients was 2.4%. abstract: BACKGROUND AND OBJECTIVE: High‐dose chemotherapy (HDCT) followed by autologous haematopoietic stem cell transplantation (HSCT) is widely used in paediatric cancer patients, but few data about noninfectious interstitial lung disease (ILD) following this treatment are available. Therefore, we aimed to evaluate the incidence, clinical features and risk factors of noninfectious ILD after HDCT in paediatric patients. METHODS: This was a retrospective cohort study of paediatric solid tumour patients who underwent HDCT and autologous HSCT between 1997 and 2012. ILD was diagnosed using clinical symptoms and radiography after excluding cardiac, renal and infectious causes. Risk factors were analysed using a Cox proportional hazard regression model. RESULTS: Three hundred and forty patients were enrolled, and the median age was 3 years (interquartile range 1–7). Eight patients (2.4%) were diagnosed with noninfectious ILD. The median duration of symptom onset was 30 months (range 7–74). Six (75%) of eight ILD patients died during the study period, even though steroids were administered for treatment. High‐dose cyclophosphamide use (hazard ratio = 11.37, 95% confidence interval = 1.38–93.32, P = 0.023) and sex (hazard ratio = 0.10, 95% confidence interval = 0.01–0.84, P = 0.034) were associated with late‐onset, noninfectious ILD upon multivariate analysis. CONCLUSION: The incidence of noninfectious ILD after HDCT and autologous HSCT was not negligible, and the clinical features of ILD showed late onset and a poor prognosis. Female gender and high‐dose cyclophosphamide treatment may be risk factors for noninfectious ILD, but further studies with a larger number of ILD patients are suggested. url: https://www.ncbi.nlm.nih.gov/pubmed/27072744/ doi: 10.1111/resp.12787 id: cord-016932-bej10xbf author: Lum, Lawrence G. title: Specific Adoptive T-Cell Therapy for Viral and Fungal Infections date: 2018-06-19 words: 8079 sentences: 352 pages: flesch: 38 cache: ./cache/cord-016932-bej10xbf.txt txt: ./txt/cord-016932-bej10xbf.txt summary: Early adoptive T-cell immunotherapy studies showed that administration of allogeneic virus-specific cytotoxic T lymphocytes (vCTL) can prevent and control viral infections and reconstitute antiviral immunity to cytomegalovirus (CMV) and Epstein-Barr virus (EBV). High-affinity TCR genes can be cloned and transduced into polyclonal T cells to generate a large population of (1) Blood is obtained from donors (autologous, allogeneic, or umbilical cord blood) or is drawn or apheresis is performed to obtain a larger quantity of blood; (2) PBMCs are processed via: (a) cell selection panel using multimers with a pathogen-derived peptide associated with a type-I HLA molecule or column selection after in vitro stimulation of T cells with antigens followed by binding of IFNɣ or CD154-expressing T cells with antibody-coated immu-nomagnetic beads; (b) cell expansion by stimulating the PBMC with APCs produced by antigenic peptide pools, viral transduction, or nucleofection; (c) genetic modification that involves the transfer of high-affinity pathogenspecific TCRs or CARs to redirect the specificity of the T cells; and (d) polyclonal expansion of T cells for 8-14 days and arming with BiAbs directed at the pathogen of interest on one hand and the TCR on the other hand; (3) quality control and release testing; and (4) infusion into patients TCR pathogen-specific CTLs [45] . abstract: Despite advances in anti-infective agents, viral and fungal infections after hematopoietic stem cell transplantation (HSCT) continue to cause life-threatening complications that limit the success of HSCT. Early adoptive T-cell immunotherapy studies showed that administration of allogeneic virus-specific cytotoxic T lymphocytes (vCTL) can prevent and control viral infections and reconstitute antiviral immunity to cytomegalovirus (CMV) and Epstein-Barr virus (EBV). Advances in immunobiology, in vitro culture technology, and current good manufacturing practice (cGMP) have provided opportunities for advancing adoptive cell therapy for viral infections: (1) T cells have been expanded targeting multiple pathogens; (2) vCTL production no longer requires viral infection or viral vector transduction of antigen-presenting cells (APCs); (3) the source of lymphocytes is no longer restricted to donors who are immune to the pathogens; (4) naive T cells have been redirected with chimeric antigen receptor T cells (CARTs) or armed with bispecific antibody-armed T cells (BATs) to mediate vCTL activity; (5) these technologies could be combined to targeted multiple viral or fungal pathogens; and (6) pathogen-specific T-cell products manufactured from third parties and banked for “off-the-shelf” use post-HSCT may soon become a reality. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121368/ doi: 10.1007/978-3-319-77674-3_20 id: cord-015922-5wwy0m2k author: Marty, Francisco M. title: Infection in the Hematopoietic Stem Cell Transplant Recipient date: 2008 words: 10254 sentences: 489 pages: flesch: 33 cache: ./cache/cord-015922-5wwy0m2k.txt txt: ./txt/cord-015922-5wwy0m2k.txt summary: Other prophylactic strategies commonly utilized in HSCT patients include acyclovir to prevent herpes simplex virus (HSV) and VZV reactivation, fluoroquinolones [5] to prevent gram-negative sepsis and fluconazole to prevent yeast infection. It has been suggested that EBV viral load surveillance in peripheral blood be carried out in high risk patients (those with primary EBV infection, anti-T cell antibody therapy for GVHD, HLA-mismatched or T cell-depleted HSCT recipients), with decreased immunosuppression +/− antiviral therapy (acyclovir or ganciclovir) carried out in the setting of high viral loads [1, 4, 41, 42] . Infliximab use in patients with severe graftversus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120030/ doi: 10.1007/978-1-59745-438-4_19 id: cord-339931-e2ylkonb author: Mo, Xiao-Dong title: Treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: the role of corticosteroids date: 2018-03-12 words: 5092 sentences: 247 pages: flesch: 48 cache: ./cache/cord-339931-e2ylkonb.txt txt: ./txt/cord-339931-e2ylkonb.txt summary: We aimed to evaluate the treatments, particularly the role of corticosteroids, in patients with late-onset hemorrhagic cystitis (LOHC) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). There are several therapeutic methods for LOHC, including ensuring appropriate hydration, hematological homeostasis (maintaining high platelet counts, appropriate red cell counts, and levels of clotting factors), pain relief, catheterization for cystoscopic clot extraction, continuous bladder irrigation with normal saline for prevention of clots and bladder tamponade, anti-infection (particularly antiviral), hyperbaric oxygen, estrogen, clotting factors, and keratinocyte growth factor therapies [5] . However, for the patients having concurrent grade II to IV acute GVHD and refractory LOHC, systemic corticosteroid therapy should be added immediately with the use of empirical antiviral therapies or anti-CMV therapy (Fig. 1) . For patients showing unsatisfactory response to anti-infection therapies, additional corticosteroid therapy may help to achieve CR, particularly for those with severe LOHC. Hemorrhagic cystitis following hematopoietic stem cell transplantation: incidence, risk factors and association with CMV reactivation and graft-versushost disease abstract: We aimed to evaluate the treatments, particularly the role of corticosteroids, in patients with late-onset hemorrhagic cystitis (LOHC) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). One hundred and sixty-three consecutive patients who underwent non-T-cell-depleted allo-HSCT and met the criterion of LOHC after allo-HSCT were enrolled in this study. The median time from allo-HSCT to the occurrence of LOHC was 29 (range, 4–155) days. Pathogens identified in blood and/or urine samples from 143 patients were mostly viruses. All of the patients with LOHC received intravenous fluid hydration, alkalization, and forced diuresis, of which 2 patients achieved complete remission (CR) after these treatments. The remaining 161 patients received anti-infection therapies and 71 achieved CR after the therapies. Corticosteroids were additionally applied to 83 out of 90 patients who did not achieve CR after anti-infection therapies, and 88.0% (n = 73) of them showed a grade 3 to 4 LOHC at the beginning of corticosteroid therapy. Thirty-five patients showed an immediate response (CR or downgraded at least one grade) within 1 week after the beginning of the corticosteroid therapy. Sixty-four patients (77.1%) achieved CR after corticosteroid therapy, and the median period from the beginning of corticosteroid therapy to CR was 17 days. Thus, we observed that viruses were the most common pathogens in LOHC after allo-HSCT and that anti-infection therapies were critical. For patients not showing a satisfactory response to anti-infection therapies, additional corticosteroid therapy may help to achieve CR. url: https://www.ncbi.nlm.nih.gov/pubmed/29532160/ doi: 10.1007/s00277-018-3290-0 id: cord-018906-03nynqtq author: Moulton, Bart title: Pulmonary Complications date: 2014-11-25 words: 2864 sentences: 217 pages: flesch: 45 cache: ./cache/cord-018906-03nynqtq.txt txt: ./txt/cord-018906-03nynqtq.txt summary: After hematopoietic stem cell transplant (HSCT), up to 60 % of patients develop pulmonary complications. In spite of antibacterial, antiviral, and antifungal prophylaxis, reduced host defenses render the HSCT patient vulnerable to pulmonary and other infections in the early weeks and even months post-transplantation. This chapter suggests an integrative approach followed by a description of the most common pulmonary syndromes seen in HSCT patients, including diffuse alveolar hemorrhage (DAH), idiopathic pneumonia syndrome (IPS), bronchiolitis obliterans syndrome (BOS), and cryptogenic organizing pneumonia (COP). Two-year mortality after hematopoietic stem cell transplant (HSCT) has been estimated using a pre-transplantation assessment of mortality (PAM) score which incorporates spirometry and diffusing capacity variables in combination with the presence of renal and hepatic dysfunction, conditioning regimen, and disease risk. Diffuse alveolar hemorrhage (DAH) is a subset of pulmonary hemorrhage that can develop in up to 5 % of all post-HSCT recipients with mortality rates ranging between 50 and 80 % based on the two largest case series. abstract: After hematopoietic stem cell transplant (HSCT), up to 60 % of patients develop pulmonary complications. In spite of antibacterial, antiviral, and antifungal prophylaxis, reduced host defenses render the HSCT patient vulnerable to pulmonary and other infections in the early weeks and even months post-transplantation. This chapter suggests an integrative approach followed by a description of the most common pulmonary syndromes seen in HSCT patients, including diffuse alveolar hemorrhage (DAH), idiopathic pneumonia syndrome (IPS), bronchiolitis obliterans syndrome (BOS), and cryptogenic organizing pneumonia (COP). The high risk of developing pulmonary complications after HSCT necessitates a pre-transplant pulmonary workup. Pulmonary function tests (PFTs) are done prior to HSCT and include spirometry and diffusion capacity of carbon monoxide (DLCO). Low DLCO and alveolar–arterial oxygen gradient on PFTs carry increased mortality post-HSCT. Decreased DLCO and forced expiratory volume in one second (FEV1) < 80 % are indicators of developing respiratory failure post-HSCT. Investigating new pulmonary complaints is challenging. All patients should undergo an extensive workup of new pulmonary findings, including dyspnea, cough, fever, and hypoxia. In the first 4–6 weeks post-HSCT, immunocompromised patients can develop bacterial pneumonia. Pathogens include gram-negative rods (Pseudomonas or Klebsiella), Staphylococcus aureus, and Nocardia. While chest X-rays could show typical lobar or multilobar opacities, computed tomography (CT) scan of the chest (noncontrast CT scans are adequate for workup of infectious processes) may yield additional characteristic findings (nodules, ground glass opacities, etc.). Fungal pneumonias, primarily aspergillus, can also develop in this early period. There is a very strong association between invasive Aspergillus pneumonia and neutropenia lasting more than 10 days. Viral pneumonia may develop as well in this patient population; however, it tends to occur later. Cytomegalovirus (CMV) is the most common viral pathogen, but with monitoring and preemptive therapy, the incidence has declined. Other viruses have emerged as pathogens, including respiratory syncytial virus (RSV), influenza, parainfluenza, and human metapneumovirus (see Chap. 17). url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123908/ doi: 10.1007/978-3-319-13832-9_22 id: cord-006492-pc1vayyl author: Ono, Shintaro title: Hematopoietic Stem Cell Transplantation for XIAP Deficiency in Japan date: 2016-11-04 words: 3178 sentences: 170 pages: flesch: 45 cache: ./cache/cord-006492-pc1vayyl.txt txt: ./txt/cord-006492-pc1vayyl.txt summary: BACKGROUND: X-linked inhibitor of apoptosis protein (XIAP) deficiency is a rare immunodeficiency that is characterized by recurrent hemophagocytic lymphohistiocytosis (HLH) and splenomegaly and sometimes associated with refractory inflammatory bowel disease (IBD). Although hematopoietic stem cell transplantation (HSCT) is the only curative therapy, the outcomes of HSCT for XIAP deficiency remain unsatisfactory compared with those for SLAM-associated protein deficiency and familial HLH. CONCLUSION: The RIC regimen and HLH control might be important factors for successful HSCT outcomes, with improved IBD, in patients with XIAP deficiency. The transplantations were performed in different institutions, but all conditioning regimens were RIC, except that for patient 1, who was given an intermediate intensity regimen, but died of HLH and acute respiratory distress syndrome on day 27 post-HSCT, in which virus infection or reactivation might not be involved. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAMassociated protein deficiency/X-linked lymphoproliferative Disease type 1 abstract: BACKGROUND: X-linked inhibitor of apoptosis protein (XIAP) deficiency is a rare immunodeficiency that is characterized by recurrent hemophagocytic lymphohistiocytosis (HLH) and splenomegaly and sometimes associated with refractory inflammatory bowel disease (IBD). Although hematopoietic stem cell transplantation (HSCT) is the only curative therapy, the outcomes of HSCT for XIAP deficiency remain unsatisfactory compared with those for SLAM-associated protein deficiency and familial HLH. AIM: To investigate the outcomes and adverse events of HSCT for patients with XIAP deficiency, a national survey was conducted. METHODS: A spreadsheet questionnaire was sent to physicians who had provided HSCT treatment for patients with XIAP deficiency in Japan. RESULTS: Up to the end of September 2016, 10 patients with XIAP deficiency had undergone HSCT in Japan, 9 of whom (90%) had survived. All surviving patients had received a fludarabine-based reduced intensity conditioning (RIC) regimen. Although 5 patients developed post-HSCT HLH, 4 of them survived after etoposide administration. In addition, the IBD associated with XIAP deficiency improved remarkably after HSCT in all affected cases. CONCLUSION: The RIC regimen and HLH control might be important factors for successful HSCT outcomes, with improved IBD, in patients with XIAP deficiency. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10875-016-0348-4) contains supplementary material, which is available to authorized users. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101905/ doi: 10.1007/s10875-016-0348-4 id: cord-018209-v2crgj5w author: Pastores, Stephen M. title: What Has Been Learned from Postmortem Studies? date: 2010-08-19 words: 5270 sentences: 327 pages: flesch: 31 cache: ./cache/cord-018209-v2crgj5w.txt txt: ./txt/cord-018209-v2crgj5w.txt summary: Infectious and noninfectious pulmonary complications occur in 30-60% of patients with hematological malignancy and recipients of hematopoietic stem cell transplantation (HSCT) and are associated with signifi cant morbidity and mortality [1] . This chapter will review the infectious and noninfectious pulmonary findings that have been described at autopsy in patients with hematological malignancies, including blood and bone marrow transplant recipients. Table 20 .1 lists the infectious and non-infectious pulmonary disorders reported in autopsy studies of patients with hematologic malignancy, including HSCT recipients. Several autopsy series have reported diagnostic discrepancies between premortem clinical diagnosis and postmortem autopsy findings ranging from 5% to 64% in patients with hematologic malignancy and HSCT recipients (Table 20. Infectious and noninfectious pulmonary diseases are commonly found on postmortem autopsy studies in patients with hematological malignancy and HSCT recipients. Major diagnostic discrepancies between clinical premortem diagnoses and postmortem autopsy findings have been reported in patients with hematologic malignancy. abstract: Infectious and noninfectious pulmonary diseases are commonly found on postmortem autopsy studies in patients with hematological malignancy. Despite the technological advances in diagnostic testing and imaging modalities, obtaining an accurate clinical diagnosis remains difficult and often not possible until autopsy. Major diagnostic discrepancies between clinical premortem diagnoses and postmortem autopsy findings have been reported in these patients. The most common missed diagnoses are due to opportunistic infections and cardiopulmonary complications. These findings underscore the importance of enhanced surveillance, monitoring and treatment of infections and cardiopulmonary disorders in these patients. Autopsies remain important in determining an accurate cause of death and for improved understanding of diagnostic deficiencies, as well as for medical education and quality assurance. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123032/ doi: 10.1007/978-3-642-15742-4_20 id: cord-272835-6nx4f8ss author: Paulsen, Grant C. title: Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation date: 2017-12-31 words: 10259 sentences: 553 pages: flesch: 33 cache: ./cache/cord-272835-6nx4f8ss.txt txt: ./txt/cord-272835-6nx4f8ss.txt summary: Common respiratory viral infections (RVIs) are an important cause of morbidity and mortality following solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT). 18 Paulsen & Danziger-Isakov Published attributable mortality caused by LRTI in HSCT from a respiratory virus varies, up to 28% to 30% in some reports, most commonly involving influenza, RSV, adenovirus, and hMPV. Epidemiology, risk, and attributable mortality The impact of influenza infection in SOT patients can be particularly severe, especially in lung transplant recipients. 78 Reports of the most severe infections are largely based on outcomes following the 2009 H1N1 pandemic; however, a recent retrospective cohort study of Brazilian renal transplant recipients with influenza A between 2009 and 2014 reported a 14% incidence of both intensive care unit (ICU) admission and mortality, which is higher than expected. abstract: Respiratory viruses are common in solid organ and hematopoietic stem cell transplant recipients and a recognized cause of significant morbidity and mortality. Epidemiology, risk factors, and attributable mortality in both populations are reviewed. In addition, virus-specific prevention and treatment options, including emerging investigational therapies, are discussed for respiratory syncytial virus, influenza, adenovirus, parainfluenza, and other respiratory viruses. url: https://www.sciencedirect.com/science/article/pii/S0272523117300783 doi: 10.1016/j.ccm.2017.07.012 id: cord-259625-8lripsf7 author: Piñana, José Luis title: Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients date: 2019-09-03 words: 3574 sentences: 214 pages: flesch: 48 cache: ./cache/cord-259625-8lripsf7.txt txt: ./txt/cord-259625-8lripsf7.txt summary: title: Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients BACKGROUND: There is growing evidence that community‐acquired respiratory virus (CARV) increases the risk of pulmonary invasive fungal disease (IFD) in the allogeneic hematopoietic stem cell transplantation (allo‐HSCT) setting. Generalized estimating equation model identified 4 risk factors for IFD: ATG‐based conditioning regimen [odds ratio (OR) 2.34, 95% confidence interval (CI) 1.05‐5.2, P = .038], CARV lower respiratory tract disease (OR 10.6, 95% CI 3.7‐30.8, P < .0001), CARV infection during the first year after transplant (OR 5.34, 95% CI 1.3‐21.8, P = .014), and corticosteroids during CARV (OR 2.6, 95% CI 1.1‐6.3, P = .03). Abbreviations: ALC, absolute lymphocyte count; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; ANC, absolute neutrophil count; ATG, antithymocyte globulin; CARV, communityacquired respiratory virus; GvHD, graft-versus-host disease; IFD, invasive pulmonary infectious fungal disease; IS, immunosuppressants; LRTD, lower respiratory tract disease. abstract: BACKGROUND: There is growing evidence that community‐acquired respiratory virus (CARV) increases the risk of pulmonary invasive fungal disease (IFD) in the allogeneic hematopoietic stem cell transplantation (allo‐HSCT) setting. To date, there is a lack of knowledge regarding the risk factors (RFs), as well as the most critical period for subsequent onset of IFD after CARV infections in allo‐HSCT recipients. METHODS: In this prospective longitudinal observational CARV survey, we analyzed the effect of CARV on subsequent IFD development in 287 adult allo‐HSCT recipients diagnosed with 597 CARV episodes from December 2013 to December 2018. Multiplex PCR panel assays were used to test CARVs in respiratory specimens. FINDINGS: Twenty‐nine out of 287 allo‐HSCT recipients (10%) developed IFD after a CARV episode. The median time of IFD onset was 21 days (range, 0‐158 days) from day of the first CARV detection. Generalized estimating equation model identified 4 risk factors for IFD: ATG‐based conditioning regimen [odds ratio (OR) 2.34, 95% confidence interval (CI) 1.05‐5.2, P = .038], CARV lower respiratory tract disease (OR 10.6, 95% CI 3.7‐30.8, P < .0001), CARV infection during the first year after transplant (OR 5.34, 95% CI 1.3‐21.8, P = .014), and corticosteroids during CARV (OR 2.6, 95% CI 1.1‐6.3, P = .03). CONCLUSION: Allo‐HSCT recipients conditioned with ATG and under corticosteroid therapy at the time of CARV LRTD during the first year after transplant may require close monitoring for subsequent IFD. url: https://doi.org/10.1111/tid.13158 doi: 10.1111/tid.13158 id: cord-280763-4bnv2t3f author: Piñana, José Luis title: Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study date: 2019-06-01 words: 4162 sentences: 190 pages: flesch: 35 cache: ./cache/cord-280763-4bnv2t3f.txt txt: ./txt/cord-280763-4bnv2t3f.txt summary: METHODS: In this prospective, cross-sectional study, we retrospectively analyzed the effect of inactivated trivalent influenza vaccination on the prevalence of influenza RVI in a consecutive cohort of 136 allo-HSCT adult recipients who developed 161 RVI over 5 flu seasons (from 2013 to 2018). The influenza virus has a significant impact on morbidity and mortality in allogeneic hematopoietic stem cell transplantation patients (allo-HSCT), leading to complications ranging from self-limited upper-respiratory tract infections to life-threatening or fatal pneumonias [1] [2] [3] [4] . We conducted a prospective, cross-sectional, observational epidemiological study of community-acquired respiratory virus (CARV) respiratory tract disease (RTD) in allo-HSCT recipients who developed upper RTD (URTD) and/or lower RTD (LRTD) symptoms after transplant. In this study, we report the prevalence of influenza RTD according to the vaccination status over 5 consecutive influenza seasons in a consecutive series of allo-HSCT recipients with virologically-documented respiratory virus infections (RVIs). abstract: BACKGROUND: Vaccination is the primary method for preventing influenza respiratory virus infection (RVI). Although the influenza vaccine is able to achieve serological responses in some allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, its clinical benefits are still uncertain. METHODS: In this prospective, cross-sectional study, we retrospectively analyzed the effect of inactivated trivalent influenza vaccination on the prevalence of influenza RVI in a consecutive cohort of 136 allo-HSCT adult recipients who developed 161 RVI over 5 flu seasons (from 2013 to 2018). Respiratory viruses in upper– and/or lower–respiratory tract specimens were tested using multiplex polymerase chain reaction panel assays. RESULTS: Overall, we diagnosed 74 episodes (46%) of influenza RVI in 70 allo-HSCT recipients. Influenza RVI occurred in 51% of the non-vaccinated compared to 36% of the vaccinated recipients (P = .036). A multivariate analysis showed that influenza vaccination was associated with a lower prevalence of influenza RVI (odds ratio [OR] 0.39, P = .01). A multivariate risk factor analysis of lower–respiratory tract disease (LRTD) identified 2 conditions associated with the probability of influenza RVI progression: influenza vaccination (OR 0.12, 95% confidence interval [CI] 0.014–1, P = .05) and a high-risk immunodeficiency score (OR 36, 95% CI 2.26–575, P = .011). Influenza vaccination was also associated with a lower likelihood of an influenza-related hospital admission (14% vs 2%, P = .04). CONCLUSIONS: This study shows that influenza vaccination may have a clinical benefit in allo-HSCT recipients with virologically-confirmed RVI, in terms of a lower influenza RVI prevalence, slower LRTD progression, and lower likelihood of hospital admission. url: https://doi.org/10.1093/cid/ciy792 doi: 10.1093/cid/ciy792 id: cord-018302-lmly43rd author: Renaud, Christian title: Respiratory Syncytial Virus and Human Metapneumovirus Infection in Transplant Recipients date: 2016-02-15 words: 10500 sentences: 459 pages: flesch: 30 cache: ./cache/cord-018302-lmly43rd.txt txt: ./txt/cord-018302-lmly43rd.txt summary: Respiratory viral infections due to respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) cause infections in immunocompromised transplant patients ranging from mild upper respiratory infections to severe lower respiratory tract disease with respiratory failure. Surveillance studies of respiratory viruses from transplant centers have established the high frequency and the signifi cant clinical impact of respiratory viral infections in HSCT recipients overall [ 8 -15 , 46 , 47 ] as well as the relative importance of RSV in terms of morbidity and mortality (Table 31 -2 ). A retrospective MDACC study of confi rmed RSV infections in 280 allogeneic HSCT recipients from 1996 to 2009 utilized multivariable logistic regression to demonstrate that lack of ribavirin aerosol therapy at the upper respiratory tract disease stage was an important risk factor associated with RSV LRTI and all-cause mortality [ 99 ] . abstract: Respiratory viral infections due to respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) cause infections in immunocompromised transplant patients ranging from mild upper respiratory infections to severe lower respiratory tract disease with respiratory failure. These viruses are more readily diagnosed due to improvements in sensitive molecular diagnostic methods. The epidemiology of RSV and hMPV is similarly becoming more readily appreciated in hematopoietic stem cell transplant (HSCT) patients of all ages as well as solid organ transplant (SOT) patients, with lung transplant recipients having evidence of more frequent and severe complications related to these viruses. RSV and hMPV infection typically but not always present with upper respiratory signs and symptoms that progress to lower respiratory tract disease. Treatment options for RSV are limited, with aerosolized, intravenous, and oral ribavirin all studied in HSCT and lung transplant patients. No antiviral therapy for the treatment of hMPV is available, although ribavirin has shown some effectiveness in vitro. New antiviral agents including RSV fusion inhibitors and nucleoside analogs are being developed, with some under clinical evaluation. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123147/ doi: 10.1007/978-3-319-28797-3_31 id: cord-018243-hyvu9nuq author: Salman, Huda title: Fibrosing Alveolitis in Hematologic Malignancy Patients Undergoing Hematopoietic Cell Transplantation date: 2010-08-19 words: 6990 sentences: 357 pages: flesch: 31 cache: ./cache/cord-018243-hyvu9nuq.txt txt: ./txt/cord-018243-hyvu9nuq.txt summary: This chapter will address the chronic lung complications that lead to pulmonary fibrosis and persistent organ dysfunction in each context with specific focus on hematologic malignancy patients treated using HSCT. Hematologic malignancy patients treated with chemotherapy or chest wall radiation therapy, or those who proceed to receive a HSCT may develop a wide variety inflammatory noninfectious lung disorders that ultimately may lead to pulmonary fibrosis. The diagnosis of drug-induced respiratory disease often is complex because: (1)1 patients may be exposed to several pneumo-toxic drugs concurrently or in sequence due to earlier treatment failure; (2)2 time to onset of pulmonary toxicity may be delayed, making it difficult to ascertain which agent is responsible for the pulmonary reaction; (3)3 the combination of drugs to treat malignant hematologic conditions may lead to unexpected drug interactions, producing enhanced toxicity compared with the toxicity of each agent considered separately; and (4)4 radiation therapy to the chest or TBI. abstract: Although advances in antineoplastic therapy have considerably improved the survival of patients with hematological malignancies, current treatment modalities increase the risk of late complications. Several forms of chronic pulmonary dysfunction due to infectious or noninfectious causes commonly occur in the months to years after chemo-radiotherapy and can be fatal or result in long-term morbidity. The judicious use of prophylactic antimicrobial agents has tipped the balance toward noninfectious etiologies. Hence, while opportunistic infections still contribute to chronic lung disease, late sequelae resulting from antineoplastic therapy have been identified and reported. Patients who proceed to receive hematopoietic cell transplantation (HSCT) are particularly prone to developing lung complications. Pulmonary dysfunction occurring after HSCT may manifest with obstructive or restrictive pulmonary mechanics and may range in severity from subtle, subclinical functional changes to frank respiratory failure. Insights generated using animal models suggest that the immunologic mechanisms contributing to lung inflammation after HSCT may be similar to those responsible for graft-versus host disease. In sum, chronic fibrotic pulmonary dysfunction is a frequent and significant complication facing survivors of hematologic malignancies and their practitioners. The high incidence and suboptimal response to current support care and immunosuppressive therapy underscore the need for heightened awareness and continued research in this area. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123073/ doi: 10.1007/978-3-642-15742-4_42 id: cord-276952-nkaow79h author: Sim, Starling A. title: Viral Respiratory Tract Infections in Allogeneic Hematopoietic Stem Cell Transplantation Recipients in the Era of Molecular Testing date: 2018-03-09 words: 3687 sentences: 201 pages: flesch: 46 cache: ./cache/cord-276952-nkaow79h.txt txt: ./txt/cord-276952-nkaow79h.txt summary: Viral respiratory tract infection (vRTI) is a significant cause of morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study aimed to assess the epidemiologic characteristics, risk factors, and outcomes of vRTI occurring in the period from conditioning to 100 days after allo-HSCT in the era of molecular testing. Demographic and clinical data were collected from hospital clinical records using a case report form and included age, sex, underlying disease, previous therapy, stem cell source, conditioning therapy, graft-versus-host disease (GVHD), and outcomes (ie intensive care unit [ICU] admission and death). For patients with RV infection, the number of vRTIs, type of RVs, clinical presentation, antiviral therapy, and outcomes (ie, ICU admission, death, use of mechanical ventilation, and progression to lower respiratory tract infection [LRTI]) were also obtained during the 100-day period. abstract: Viral respiratory tract infection (vRTI) is a significant cause of morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study aimed to assess the epidemiologic characteristics, risk factors, and outcomes of vRTI occurring in the period from conditioning to 100 days after allo-HSCT in the era of molecular testing. This study was a retrospective record review of patients who underwent allo-HSCT at Royal Melbourne Hospital between January 2010 and December 2015. Symptomatic patients were tested using respiratory multiplex polymerase chain reaction (PCR). Logistic regression and Kaplan-Meier analysis were used to identify risk factors for vRTI and the risk of death or intensive care unit (ICU) admission, respectively. A total of 382 patients were reviewed, and 65 episodes of vRTI were identified in 56 patients (14.7%). Rhinovirus accounted for the majority of infections (69.2%). The majority of episodes presented initially with upper respiratory tract infection (58.5%), with 28.9% of them progressing to lower respiratory tract infection. Eleven episodes (16.9%) were associated with ICU admission. There were no deaths directly due to vRTI. Previous autologous HSCT was associated with an increased risk of vRTI (odds ratio, 2.1; 95% confidence interval, 1.0 to 4.1). The risks of death (P = .47) or ICU admission (P = .65) were not significantly different by vRTI status. vRTI is common in the first 100 days after allo-HSCT and is associated with ICU admission. url: https://www.ncbi.nlm.nih.gov/pubmed/29530766/ doi: 10.1016/j.bbmt.2018.03.004 id: cord-017302-xez0zso3 author: Stephens, R. Scott title: ICU Complications of Hematopoietic Stem Cell Transplant, Including Graft vs Host Disease date: 2019-07-24 words: 5226 sentences: 289 pages: flesch: 33 cache: ./cache/cord-017302-xez0zso3.txt txt: ./txt/cord-017302-xez0zso3.txt summary: Hematopoietic stem cell transplant (HSCT) has become an essential therapeutic modality in the treatment of malignant and non-malignant hematologic disease. Allogeneic transplants are associated with more morbidity and mortality than autologous transplants, and are further categorized based on conditioning regimen (myeloablative [MA] vs non-myeloablative [NMA]), donor-recipient relation (related vs unrelated), HLA matching (full match vs haploidentical vs mismatched), and stem cell source (bone marrow, peripheral blood, umbilical cord blood). Refinement of transplant techniques over the last 2 decades has dramatically decreased transplant-related mortality, but approximately 15% of HSCT patients require critical care [10] and earlier ICU admission has been associated with improved survival rates [11, 12] . Outcomes of stem cell transplant patients with acute respiratory failure requiring mechanical ventilation in the United States Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease abstract: Hematopoietic stem cell transplant (HSCT) is an essential treatment modality for many malignant and non-malignant hematologic diseases. Advances in HSCT techniques have dramatically decreased peri-transplant morbidity and mortality, but it remains a high-risk procedure, and a significant number of patients will require critical care during the transplant process. Complications of HSCT are both infectious and non-infectious, and the intensivist must be familiar with common infections, the management of neutropenic sepsis and septic shock, the management of respiratory failure in the immunocompromised host, and a plethora of HSCT-specific complications. Survival from critical illness after HSCT is improving, but the mortality rate remains unacceptably high. Continued research and optimization of critical care provision in this population should continue to improve outcomes. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121823/ doi: 10.1007/978-3-030-26710-0_80 id: cord-281026-2avisuge author: Versluys, A.Birgitta title: Strong Association between Respiratory Viral Infection Early after Hematopoietic Stem Cell Transplantation and the Development of Life-Threatening Acute and Chronic Alloimmune Lung Syndromes date: 2010-01-06 words: 5971 sentences: 316 pages: flesch: 49 cache: ./cache/cord-281026-2avisuge.txt txt: ./txt/cord-281026-2avisuge.txt summary: title: Strong Association between Respiratory Viral Infection Early after Hematopoietic Stem Cell Transplantation and the Development of Life-Threatening Acute and Chronic Alloimmune Lung Syndromes Alloimmune lung syndromes (allo-LS), including idiopathic pneumonia syndrome, bronchiolitis obliterans syndrome, and bronchiolitis obliterans organizing pneumonia, are severe complications after hematopoietic stem cell transplantation (HSCT). Multivariate analysis showed that respiratory viral infection early after HSCT is an important predictor for the development of allo-LS (P <.0001). To analyze risk factors for outcomes, we considered variables associated with the recipient (age at transplantation, sex, CMV serology, RV positivity, single/multiple viruses), the disease (malignant vs nonmalignant), the donor/transplantation technique (cell source, HLA disparity, donor relationship, conditioning regimen), HSCT complications (allo-LS, acute GVHD [aGVHD], CMV and adenovirus plasma DNA positivity, venoocclusive disease), and relapse. Prospective study of respiratory viral infections in pediatric hemopoietic stem cell transplantation patients abstract: Alloimmune lung syndromes (allo-LS), including idiopathic pneumonia syndrome, bronchiolitis obliterans syndrome, and bronchiolitis obliterans organizing pneumonia, are severe complications after hematopoietic stem cell transplantation (HSCT). In our cohort of 110 pediatric patients, 30 had allo-LS (27.3%), 18 with ideopathic pneumonia syndrome and 12 with bronchiolitis obliterans syndrome. Multivariate analysis showed that respiratory viral infection early after HSCT is an important predictor for the development of allo-LS (P <.0001). This was true for all viruses tested. In multivariate analysis, allo-LS was the only predictor for higher mortality (P = .04). Paradoxically, prolonged administration of immunosuppressive agents because of acute graft-versus-host disease had a protective effect on the development of allo-LS (P = .004). We hypothesize that early infection of the respiratory tract with a common cold virus makes the lungs a target for alloimmunity. url: https://www.ncbi.nlm.nih.gov/pubmed/20060053/ doi: 10.1016/j.bbmt.2009.12.534 id: cord-254183-98o0dssj author: Waggoner, Jesse J. title: Rare and Emerging Viral Infections in Transplant Recipients date: 2013-10-15 words: 3927 sentences: 236 pages: flesch: 44 cache: ./cache/cord-254183-98o0dssj.txt txt: ./txt/cord-254183-98o0dssj.txt summary: In this review, we first discuss viral diagnostics and the developing field of viral discovery and then focus on rare and emerging viruses in the transplant population: human T-cell leukemia virus type 1; hepatitis E virus; bocavirus; KI and WU polyomaviruses; coronaviruses HKU1 and NL63; influenza, H1N1; measles; dengue; rabies; and lymphocytic choriomeningitis virus. Detection and reporting of such rare pathogens in transplant recipients is critical to patient care and improving our understanding of posttransplant infections. In a multicenter review of 85 cases of acute HEV infection, 65.9% of the solid organ transplant (SOT) recipients developed chronic hepatitis of whom 14.3% developed cirrhosis. Cases of lymphocytic choriomeningitis virus (LCMV) transmitted through organ transplantation (4 clusters, including 14 cases and 11 deaths) document the ability of this pathogen to cause severe disease in the immunocompromised host [10, [49] [50] [51] . Human T-cell leukemia virus type I-associated myelopathy following living-donor liver transplantation abstract: Emerging viral pathogens include newly discovered viruses as well as previously known viruses that are either increasing, or threatening to increase in incidence. While often first identified in the general population, they may affect transplant recipients, in whom their manifestations may be atypical or more severe. Enhanced molecular methods have increased the rate of viral discovery but have not overcome the problem of demonstrating pathogenicity. At the same time, improved clinical diagnostic methods have increased the detection of reemerging viruses in immunocompromised patients. In this review, we first discuss viral diagnostics and the developing field of viral discovery and then focus on rare and emerging viruses in the transplant population: human T-cell leukemia virus type 1; hepatitis E virus; bocavirus; KI and WU polyomaviruses; coronaviruses HKU1 and NL63; influenza, H1N1; measles; dengue; rabies; and lymphocytic choriomeningitis virus. Detection and reporting of such rare pathogens in transplant recipients is critical to patient care and improving our understanding of posttransplant infections. url: https://www.ncbi.nlm.nih.gov/pubmed/23839998/ doi: 10.1093/cid/cit456 id: cord-007788-09t52zix author: Wallhult, Elisabeth title: Early and Acute Complications and the Principles of HSCT Nursing Care date: 2017-11-22 words: 13962 sentences: 766 pages: flesch: 46 cache: ./cache/cord-007788-09t52zix.txt txt: ./txt/cord-007788-09t52zix.txt summary: Some other relatively rare complications are also covered here: haemorrhagic cystitis (HC), endothelial damage (ED) syndromes including engraftment syndrome (ES), idiopathic pneumonia syndrome (IPS), diffuse alveolar haemorrhage (DAH), transplant-associated microangiopathy (TAM) and sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). Oral damage may be a hallmark of graft versus host disease (GvHD) in patients following allogeneic stem cell transplantation, and the presence of lichenoid hyperkeratotic plaques (diagnostic sign), gingivitis, mucositis, erythema, pain, xerostomia and ulcers may indicate GvHD. The increased risk of infections in patients undergoing haematopoietic stem cell transplantation (HSCT) is well known, and infection is a leading cause of morbidity and mortality. Differential diagnoses will need to be excluded by assessing risk factors, symptoms and lab tests since liver dysfunction can also be seen in sepsis, viral infection, graft versus host disease (GvHD) and iron overload and as a side effect from many of the drugs used in the HSCT setting. abstract: Haematopoietic stem cell transplantation (HSCT) generally includes preparative or conditioning regimes containing chemotherapy and/or radiotherapy in high doses. These regimens, as well as other treatments before and after HSCT such as immunosuppressive drugs to prevent graft versus host disease (GvHD) (see Chap. 11), may affect the patient’s organs and tissues and may cause both acute and long-term complications. In the evolving field of stem cell therapies, some complications that traditionally have been regarded as early complications are now, due to changes in preparative regimens and choice of stem cell source, sometimes seen later in the post-transplant out-patient setting. The complications covered in this chapter generally occur within 100 days post HSCT and are thus classified as early complications. Two of the most common early complications are oral complications/mucositis and sepsis. Some other relatively rare complications are also covered here: haemorrhagic cystitis (HC), endothelial damage (ED) syndromes including engraftment syndrome (ES), idiopathic pneumonia syndrome (IPS), diffuse alveolar haemorrhage (DAH), transplant-associated microangiopathy (TAM) and sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). For all complications, recommendations for prevention and principles for nursing care are presented since careful nursing monitoring, prompt intervention and care may have an influence on patients’ morbidity and mortality. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123335/ doi: 10.1007/978-3-319-50026-3_9 id: cord-003866-3gwbc7z9 author: Zecha, Judith A. E. M. title: The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy date: 2019-06-20 words: 6120 sentences: 332 pages: flesch: 29 cache: ./cache/cord-003866-3gwbc7z9.txt txt: ./txt/cord-003866-3gwbc7z9.txt summary: [38] MRSA was detected in the oral cavity following HSCT, especially during OM peak severity HSCT CT chemotherapy, CONS coagulase-negative staphylococci, HSCT hematopoietic stem cell transplantation, MRSA methicillin-resistant staphylococcus spp., OM oral mucositis When pattern recognition receptors (PRRs) expressed by cells of the innate immune system within the mucosa (e.g., macrophages, neutrophils, and dendritic cells) are exposed to CRAMPS, this results in the release of cytokines that act locally, and also may have distant effects by activating intracellular and intercellular signaling loops [64] . [70] Treatment of dental pathologies and reducing oral microbial load resulted in shorter duration of OM HSCT Khan and Wingard [54] Presence of oropharyngeal mucositis is an independent risk factor for bacteremia in neutropenic patients HSCT, non-Hodgkin lymphoma, leukemia Head and neck cancer FN febrile neutropenia, HSCT hematopoietic stem cell transplantation infrequent conversion of chronic dental disease to an acute state during CT and conclude that there is no need for the treatment of "asymptomatic" chronic dental infections prior to CT or conditioning therapy for HSCT [62, 108] . abstract: Febrile neutropenia (FN) is an inflammatory response causing fever that may develop during cancer therapy-induced neutropenia. FN may herald life-threatening infectious complications and should therefore be considered a medical emergency. Patients presenting with FN are routinely subjected to careful history taking and physical examination including X-rays and microbiological evaluations. Nevertheless, an infection is documented clinically in only 20–30% of cases, whereas a causative microbial pathogen is not identified in over 70% of FN cases. The oral cavity is generally only visually inspected. Although it is recognized that ulcerative oral mucositis may be involved in the development of FN, the contribution of infections of the periodontium, the dentition, and salivary glands may be underestimated. These infections can be easily overlooked, as symptoms and signs of inflammation may be limited or absent during neutropenia. This narrative review is aimed to inform the clinician on the potential role of the oral cavity as a potential source in the development of FN. Areas for future research directed to advancing optimal management strategies are discussed. url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726710/ doi: 10.1007/s00520-019-04925-8 id: cord-004675-n8mlxe7p author: nan title: 2019 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference date: 2019-02-26 words: 86427 sentences: 5050 pages: flesch: 46 cache: ./cache/cord-004675-n8mlxe7p.txt txt: ./txt/cord-004675-n8mlxe7p.txt summary: However, the mean infusion rate per site was similar between patients aged <18 years ( XMEN disease (X-linked Immunodeficency with Magnesium defect, Epstein-Barr virus infection and Neoplasia) is a primary immune deficiency caused by mutations in MAGT1 and characterized by chronic infection with Epstein-Barr virus (EBV), EBV-driven lymphoma, CD4 T-cell lymphopenia, and dysgammaglobulinemia. We present the case of a 1-year old Hispanic infant with a pathogenic variant in MAGT1 gene that clinically manifested with early Pneumocystis jirovecii and cytomegalovirus (CMV) interstitial pneumonia, and EBV chronic infection with good response to intravenous immunoglobulins supplementation without hematopoietic stem cell transplantation or gene therapy. Chief, Laboratory of Clinical Immunology and Microbiology, IDGS, DIR, NIAID, NIH, Bethesda, MD, USA Hypomorphic Recombination Activating Gene 1 (RAG1) mutations result in residual T-and B-cell development in both humans and mice and have been found in patients presenting with delayed-onset combined immune deficiency with granulomas and/or autoimmunity (CID-G/AI). abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086569/ doi: 10.1007/s10875-019-00597-5 id: cord-005453-4057qib7 author: nan title: The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session date: 2019-07-03 words: 275771 sentences: 16876 pages: flesch: 56 cache: ./cache/cord-005453-4057qib7.txt txt: ./txt/cord-005453-4057qib7.txt summary: To compare the safety and efficacy of prophylactic DLI for prevention of relapse after allogeneic peripheral blood stem cell transplantation from haploidentical donors (HID-SCT) and matched-sibling donors (MSD-SCT) in patients with very high-risk acute myeloid leukemia (AML), we performed a retrospective, observational cohort study enrolled in 21 HID-SCT and 13 MSD-SCT recipients. The aim of this study is to identify the prognostic impact of pre-transplant TIM3 levels on early and late transplant related complications as well as post-transplant relapse and survival Methods: A total of 177 hematopoietic stem cell transplantation (HSCT) recipients with an initial diagnosis of acute leukemia [median age: 36(16-66) years; male/ female: 111/66] were included in the study. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091813/ doi: 10.1038/s41409-019-0559-4 id: cord-005460-ezrn8cva author: nan title: Physicians – Poster Session date: 2017-07-28 words: 287105 sentences: 15681 pages: flesch: 56 cache: ./cache/cord-005460-ezrn8cva.txt txt: ./txt/cord-005460-ezrn8cva.txt summary: Still the optimal combination of immunosuppressive agents with PTCy should be elucidated for different types of SCTs. We report the 2-year update of the prospective NCT02294552 single-center trial that evaluated risk-adapted graft-versushost disease (GVHD) prophylaxis with PTCy in related, unrelated and haploidentical SCTs. 200 adult patients (median age 32 y.o., range: 18-62) with hematologic malignancies, including AML (47.5%), ALL (26.5%), CML (10.5%), MDS (4%), and lymphomas (11.5%), were enrolled in the study. Long-term follow-up from the prospective randomized phase III multicenter trial comparing a standard GvHD prophylaxis with cyclosporine A and methotrexate with or without additional pretransplant ATLG (Grafalon, previously ATG-FRESENIUS S) (given 20 mg/kg/day, days − 3 to − 1) in unrelated donor hematopoietic cell transplantation after myeloablative conditioning resulted in a significant reduction of acute and chronic GvHD without compromising relapse rate and survival [1, 2, 3] . abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091844/ doi: 10.1038/bmt.2017.134 id: cord-005478-5iu38pr6 author: nan title: The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Oral Session date: 2019-07-03 words: 63350 sentences: 3869 pages: flesch: 58 cache: ./cache/cord-005478-5iu38pr6.txt txt: ./txt/cord-005478-5iu38pr6.txt summary: There were some differences among groups: patients in group-1 were younger (median age 46 years, p< 0.02) were transplanted in more recent year (2015, p< 0.001), received more frequently a regimen based on TBF (thiotepa, fludarabine and busulfan) (83%, p< 0.001) and bone marrow (BM) as source of stem cells (77%, p< 0.001), with no ATG (100%, p< 0.001). Clinical Trial Registry: NCT01217723 Disclosure: None of the Authors have any conflicts of interest to declare O105 Immune reconstitution -based score at diagnosis of CGVHD predicts GVHD severity and overall-survival: A novel prognostication tool for GVHD treatment tailoring Background: Allogeneic stem cell transplantation (HSCT) survivors are at a relevant risk of developing chronic GvHD (cGvHD), which importantly affects quality of life and increases morbidity and mortality. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092200/ doi: 10.1038/s41409-019-0562-9 id: cord-005480-yg7salqt author: nan title: Oral Sessions and Working Party date: 2008-03-26 words: 72626 sentences: 3873 pages: flesch: 55 cache: ./cache/cord-005480-yg7salqt.txt txt: ./txt/cord-005480-yg7salqt.txt summary: Standard NIH or Eurolupus cyclophosphamide (CY) protocols and mycophenolate Mofetil (MMF) as induction therapy in severe BILAG A SLE is still associated with 20 % failure, 50% relapse and 10% to 15 % death at 10 years In the absence of a single standard treatment worldwide for refractory SLE, phase I-II studies analysed the use of: a) rituximab (anti CD20 mAb) in more than 1 000 patients showing complete to partial early response around 100% with relapse in 50 to 60% of the cases; b) autologous Hematopoietic Stem Cell Transplantation (HSCT) since 1997 under the auspices of the joined EBMT-EULAR working party, reporting durable remission with reduced or no immunosuppressive drug requirement in 66%, one-third of whom later relapsed to some degree with a 74 ± 7% (n= 62/79) overall survival at 5 years for SLE among the 863 HSCT procedures registered: in 2007 in the EBMT data base. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092258/ doi: 10.1038/bmt.2008.30 id: cord-005482-v5iayczy author: nan title: Publication Only date: 2016-03-21 words: 27400 sentences: 1715 pages: flesch: 54 cache: ./cache/cord-005482-v5iayczy.txt txt: ./txt/cord-005482-v5iayczy.txt summary: Material (or patients) and methods: Case Report 23-year-old male patient who underwent allogeneic hematopoietic stem cell tranplantation sixteen months ago, admitted to bone marrow transplantation clinic for shortness of breath. Material (or patients) and methods: Data sets of 436 consecutive patients who underwent allogeneic HSCT at a single center (University of Rostock) from 1998 to 10/2015 were analysed regarding their early mortality rates (d+30, d+60 Introduction: Mobilization and collection of CD34-positive stem cells for subsequent high-dose chemotherapy constitutes a standard approach in myeloma patients achieving a good remission after induction chemotherapy. Outcomes of high grade gastrointestinal gvhd post-hsct in children Material (or patients) and methods: This is a retrospective analysis of 28 pediatric patients presented with a clinical diagnosis of stage 3 and 4 acute GVHD of the GIS who were selected from allogeneic hematopoetic stem cell transplantation (HSCT) performed. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092319/ doi: 10.1038/bmt.2016.56 id: cord-005487-vac061r8 author: nan title: Physicians Abstracts: EBMT 2010 date: 2010-04-07 words: 58975 sentences: 3128 pages: flesch: 58 cache: ./cache/cord-005487-vac061r8.txt txt: ./txt/cord-005487-vac061r8.txt summary: We retrospectively analyzed 1257 patients (pts), 755 children (age≤18) and 502 adults, receiving fi rst single (n = 1080) or double UCBT (n = 177) in EBMT centers, between 1995 and 2009 , for malignant and non-malignant diseases, who survived at least 100 days from transplantation with neutrophils recovery and without relapse or autologous reconstitution. Prochymal® improves response rates in patients with steroid-refractory acute graft-versus-host disease involving the liver and gut: results of a randomized, placebo-controlled, multicentre phase III trial in GvHD P.J. Martin (1) , J.P. Uberti (2) Background and methods: Steroid-refractory acute GVHD (SR-GVHD) remains a signifi cant and life-threatening complication of allogeneic hematopoietic cell transplantation (HCT). A. Nagler (1) Background: Allogeneic transplantation of hematopoietic stem cells (allo-SCT) from an HLA-matched related (MRD) or unrelated donor (URD) is a curative option for patients (pts) with high-risk hematological disease (HRHD). abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092333/ doi: 10.1038/bmt.2010.40 id: cord-006466-e1phpqes author: nan title: 2018 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference date: 2018-04-23 words: 92230 sentences: 5516 pages: flesch: 46 cache: ./cache/cord-006466-e1phpqes.txt txt: ./txt/cord-006466-e1phpqes.txt summary: Whole exome sequencing revealed a heterozygous mutation, previously reported (c.1425+1G>T) Conclusions: In summary, this report emphasizes the suspicion of a combined immunodeficiency in the presence of multiple abscesses by Mycoplasma, the usefulness of rDNA 16s in order to achieve proper Objectives: We describe a 15-year-old male patient with novel heterozygous mutation of EP300 gene; his first manifestations were initially characterized by infections, cytopenia and hypogammaglobulinemia suggesting a Common Variable Immunodeficiency (CVID), but later on, persisting lymphopenia was suggestive of a combined immunodeficiency. Conclusions: Close monitoring of immune function in early life for patients with CHH and CID as well as the availability of suitable donors assists in determining management, including HSCT Introduction/Background: Leukocyte Adhesion Deficiency (LAD) represents a group of distinct inherited disorders, which inhibit the normal extravasation of neutrophils and their recruitment to sites of infection or inflammation. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101862/ doi: 10.1007/s10875-018-0485-z id: cord-006856-b1w25ob5 author: nan title: 19th Meeting of the Austrian Society of Transplantation, Transfusion, and Genetics, October 26–28, 2005 date: 2005 words: 29625 sentences: 1983 pages: flesch: 52 cache: ./cache/cord-006856-b1w25ob5.txt txt: ./txt/cord-006856-b1w25ob5.txt summary: Egr-1 and hypoxia-inducible factor-1 (HIF-1) gene expression was examined in left ventricular biopsies of explanted failing hearts in 28 ICM and 42 DCM patients, as well as in 12 donor grafts before reperfusion (control), at 10, 30, 60 minutes after reperfusion, and at 1, 2, 3, 4, 6, 12 posttransplant weeks, using real-time RT-PCR. The risk of transplant-related mortality (TRM) due to graft-versushost disease (GvHD) is higher in male recipients of female stem cells compared with female patients receiving a graft from a female donor. We therefore analyzed a single-center cohort of 72 high-risk patients transplanted with a related or unrelated stem cell graft after nonmyeloablative conditioning for outcome (acute and chronic GvHD, TRM, relapse, and survival). Four patients between the age of 34 and 44 years underwent allogeneic peripheral blood stem cell (PBSC) transplantation (SCT) from HLA-identical sibling or unrelated donors at our institution. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103192/ doi: 10.1007/s10353-005-0216-6 id: cord-009997-oecpqf1j author: nan title: 2018 ASPHO ABSTRACTS date: 2018-03-31 words: 182060 sentences: 10342 pages: flesch: 48 cache: ./cache/cord-009997-oecpqf1j.txt txt: ./txt/cord-009997-oecpqf1j.txt summary: Completed cranial radiation and proceeded to allogeneic stem cell transplant with unrelated cord marrow donor and is disease free at approximately day +200.Case 2: 5 year-old female diagnosed with FLT3 and MLL negative AML and completed treatment per COG AAML1031 study on the low risk arm without Bortezomib. Design/Method: This study was a retrospective chart review that included patients 3 to 23 years old with sickle cell disease type SS and S 0 followed at St. Christopher''s Hospital for Children. Background: Hydroxyurea, chronic blood transfusion, and bone marrow transplantation can reduce complications, and improve survival in sickle cell disease (SCD), but are associated with a significant decisional dilemma because of the inherent risk-benefit tradeoffs, and the lack of comparative studies. Brown University -Hasbro Children''s Hospital, Providence, Rhode Island, United States Background: Despite clinical advances in the treatment of sickle cell disease (SCD) in pediatric and young adult patients, pain remains a significant source of disease-related morbidity. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167873/ doi: 10.1002/pbc.27057 id: cord-014712-5u4e00q6 author: nan title: Selected Abstracts from the 100th J Project Meeting, Antalya, Turkey, March 12-14, 2014 date: 2014-08-02 words: 36900 sentences: 2254 pages: flesch: 49 cache: ./cache/cord-014712-5u4e00q6.txt txt: ./txt/cord-014712-5u4e00q6.txt summary: Ege University Faculty of Medicine, Dept of Pediatric Immunology, Izmir, Turkey Ig class switch recombination deficiencies are rare PIDs (1:500,000 births) with normal or elevated serum IgM and low IgG, IgA and IgE levels, defective or normal somatic hypermutation, defective T/B cooperation (50%), intrinsic B cell defect (50%), susceptibility to bacterial infections begining from the first year of age (impaired B cell immunity) and lack of germinal centres in secondary lymphoid organs. Great North Children''s Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK Even following the introduction of biologic disease modifying antirheumatic drugs (DMARDs), a small number of children suffering from severe, refractory autoimmune (AI), rheumatic and/or autoinflammatory disorders will not get into clinical remission (CR) and will potentially further suffer from multiple side-effects of combined and long-term immunosuppressive and anti-inflammatory therapies, in particular severe infections (Marodi L, Casanova JL. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086544/ doi: 10.1007/s10875-014-0065-9 id: cord-014976-546zaoxn author: nan title: Publication only date: 2006-03-08 words: 51926 sentences: 2983 pages: flesch: 53 cache: ./cache/cord-014976-546zaoxn.txt txt: ./txt/cord-014976-546zaoxn.txt summary: In order to evaluate if malignant and non malignant hematological diseases quantitatively and qualitatively affect BM derived MSCs, bone marrow from children with acute lymphoblastic leukemia (ALL diagnosis n=9, different phases of treatment n=29, end of therapy n=10), idiopathic thrombocytopenic purpura (n=16), autoimmune neutropenia (n=12) and control patients (solid tumors without BM involvement, n=30) was harvested and the mononuclear cell (MNC) fraction isolated. Case: In our hospital a total of 3 patients with relapsed Hodgkin''s disease underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) from an HLA-identical sibling. We report a case of a young male patient of 19 years old with aggressive MS who was treated with a high-dose immunosuppressive regimen (HDIS) using myeloablation followed by autologous blood stem cell transplantation (ASCT) that has induced a dramatic and long-lasting remission of the disease. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092326/ doi: 10.1038/sj.bmt.1705327 id: cord-015389-vwgai4k9 author: nan title: Publication only date: 2009-03-25 words: 23868 sentences: 1465 pages: flesch: 57 cache: ./cache/cord-015389-vwgai4k9.txt txt: ./txt/cord-015389-vwgai4k9.txt summary: This study evaluates the safety of this approach, in terms of infusion-related toxicity and hematopoietic reconstitution, in 385 consecutive autologous transplantations performed from 4/97 to 9/08 in 348 patients (median age 46; underlying disease: lymphoma in 178, myeloma in 131, acute leukaemia in 17, breast cancer in 22). Patients and methods: Eight pts after allogeneic hematopoetic stem cell transplantation (HSCT) underwent MSCs infusions (median age of pts was 11 years, male/female: 6/2) between 2006 and 2009. Akiyama Tokyo Metropolitan Komagome Hospital (Tokyo, JP) Acute graft-versus-host disease (GVHD) is one of the major factors that have infl uence on the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT). Material and methods: during a 8 years period we have performed 144 stem cells transplantation in 134 patients with different hematological malignancies(AML: 74; ALL: 6; CML: 7; CLL: 1, NHL: 13; Hodgkin Diseases: 16; Multiple myelomas: 24; Aplastic anaemia: 1;Myelofi brosis:1 Ewing Sarcoma: 1; Male:78 Female 66. abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104434/ doi: 10.1038/bmt.2009.50 id: cord-024651-578c9ut5 author: nan title: 2020 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference date: 2020-05-11 words: 84560 sentences: 5089 pages: flesch: 47 cache: ./cache/cord-024651-578c9ut5.txt txt: ./txt/cord-024651-578c9ut5.txt summary: Abstract/Case Report Text Introduction: Mutations in the gene encoding signal transducer and activator of transcription 3 (STAT3) cause autosomal dominant hyperimmunoglobulin E syndrome (AD-HIES) characterized by recurrent skin and sinopulmonary infections, atopic dermatitis, and elevated serum immunoglobulin E (IgE) levels. Objective: The purpose of this study is to increase awareness and improve diagnosis of primary immune deficiency (PID) in the heterogenous group of patients with autoimmune cytopenia (AIC) by identifying clinical characteristics and laboratory biomarkers that distinguish those with underlying PID, disease activity and guide mechanism-based targeted therapy. 7 Chief, Laboratory of Clinical Immunology and Microbiology/National Institute of Allergy and Infectious Diseases, NIAID/National Institutes of Health, NIH Abstract/Case Report Text We have previously used the artificial thymic organoid (ATO) system, based on the 3D aggregation and culture of a delta-like canonical Notch ligand 4-expressing stromal cell line (MS5-Dll4) with CD34+ cells, to study T cell differentiation from CD34+ cells obtained from patients carrying defects that are intrinsic to hematopoietic cells (RAG1-2, AK2, IL2RG) or that affect thymus development (DiGeorge syndrome). abstract: nan url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212516/ doi: 10.1007/s10875-020-00764-z id: cord-313474-1gux1gsi author: nan title: Physicians Abstracts date: 2015-03-20 words: 51420 sentences: 2890 pages: flesch: 57 cache: ./cache/cord-313474-1gux1gsi.txt txt: ./txt/cord-313474-1gux1gsi.txt summary: Materials (or patients) and methods: We performed a multicenter, multinational, open-label, randomized study comparing anti-lymphocyte globulin (ATG-Fresenius s ) 10 mg/kg on day -3, -2 and -1 with no ATG in patients with AML (n ¼ 110) or ALL (n ¼ 45) in 1 st complete remission (CR; n ¼ 139) or 2 nd CR (n ¼ 16) who received peripheral blood stem cells from their HLA-identical sibling after standard TBI (12 Gy)/Ccclophosphamide (120 mg/kg) or busulfan (16 mg/ kg)/Cy (120 mg/kg) based myeloablative conditioning regimen. After allo-HSCT, detection of positive WT1 was followed by immunomodulatory therapeutic interventions according to the time from transplant, the presence of active graft-versus-host disease (GvHD) and the general clinical conditions: tapering and/or discontinuation of immunosuppressive drugs (IS), donor lymphocytes infusions (DLI), administration of hypomethylating agents. Introduction: Haploidentical hematopoietic stem cell transplantation(Haplo-HSCT)is feasible option for patients with acute leukemia(AL)at high risk of relapse who do not have HLA-matched related or unrelated donors. abstract: nan url: https://www.ncbi.nlm.nih.gov/pubmed/25794251/ doi: 10.1038/bmt.2015.27 ==== make-pages.sh questions [ERIC WAS HERE] ==== make-pages.sh search /data-disk/reader-compute/reader-cord/bin/make-pages.sh: line 77: /data-disk/reader-compute/reader-cord/tmp/search.htm: No such file or directory Traceback (most recent call last): File "/data-disk/reader-compute/reader-cord/bin/tsv2htm-search.py", line 51, in with open( TEMPLATE, 'r' ) as handle : htm = handle.read() FileNotFoundError: [Errno 2] No such file or directory: '/data-disk/reader-compute/reader-cord/tmp/search.htm' ==== make-pages.sh topic modeling corpus Zipping study carrel